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Preface 
 
It is my great pleasure and honor to present this interesting book Pancreatitis – 
Treatment and Complications, written by an international group of experts, doctors, 
university professors and researchers with great experience in this field. 
Pancreatitis may be acute or chronic. Although they can be caused by similar 
aetiologies, they tend to follow distinct natural histories. Around 80% of acute 
pancreatitis diagnoses occur as secondary to gallstone disease and alcohol misuse. 
This disease is commonly associated with the sudden onset of upper abdominal pain 
radiating to the back that is usually severe enough to warrant the patient seeking 
urgent medical attention. The onset of pain may be related to a recent alcohol binge or 
a rich, fatty meal intake. The patient may appear unwell, be tachycardic and have 
significant tenderness in the upper abdomen.  
Overall, 10 to 25% of acute pancreatitis (AP) episodes are classified as severe, leading 
to an associated mortality rate, of 7 to 30%. Disease severity is best predicted from a 
number of clinical scoring systems which can be applied at diagnosis in association 
with repeated clinical assessment, measurement of acute inflammatory markers, and 
CT. All patients with suspected AP should be referred urgently. 
Establishing a biliary etiology in acute pancreatitis is clinically important because of 
the potential need for invasive treatment, such as endoscopic retrograde 
cholangiopancreatography. The etiology of acute biliary pancreatitis (ABP) is 
multifactorial and complex. The passing of small gallbladder stones or biliary sludge 
through the ampulla of Vater seems to be important in the pathogenesis of ABP. 
Infectious complications in severe acute pancreatitis are associated with considerable 
morbidity and mortality. The course of the disease is often protracted, and patients 
often stay in hospital for several weeks. Diagnosis of infected pancreatic necrosis is 
difficult, and the treatment consists of source control and antibiotic treatment. 
Antibiotic use should be rational in terms of a proper indication, a wide pancreatic 
penetration and long duration.  
Prophylactic antibiotics are ineffective in reducing the incidence of peri-pancreatic 
infection in patients with severe disease, or even documented necrotizing pancreatitis. 
X Preface 
 
The only rational indication for antibiotics is documented infection. Pancreatitis is one 
of the most frequent complications of endoscopic retrograde cholangiopancreatography 
(ERCP). The placement of a prophylactic pancreatic stent after ERCP can help prevent 
post-ERCP pancreatitis (PEP). 
Recurrent acute pancreatitis is a common clinical problem. Most cases of pancreatitis 
are identified by a careful history and physical examination. Despite advanced 
evaluation, the cause is not apparent in about 10% of cases. 
Increased intra-abdominal pressure (IAP), also referred to as intra-abdominal 
hypertension (IAH), affects organ function in critically ill patients and may lead to 
abdominal compartment syndrome (ACS). Its diagnosis and treatment are clearly 
described in this book. 
Although most cases of acute pancreatitis are uncomplicated and resolve 
spontaneously, the presence of complications has significant prognostic importance. 
Necrosis, hemorrhage, and infection convey rates of up to 25%, 50%, and 80% 
mortality, respectively. Other complications such as pseudocyst formation, 
pseudoaneurysm formation, or venous thrombosis increase morbidity and mortality to 
a lesser degree. The presence of ascites and pleural effusion and emphysematous 
pancreatitis, are less commonly found. We have reviewed in several chapters the 
computed tomographic findings of complications associated with acute pancreatitis 
with emphasis on their prognostic significance and impact on clinical management, for 
their early detection and proper follow-up. 
Inflammation of the pancreas has many presentations in children and adolescents. The 
etiology is often elusive, with a great number of cases being idiopathic. However, 
there have been a number of recent advances in the areas of cell biology, genetics and 
imaging technology, which should be highlighted. This book provides the reader with  
a review, with particular emphasis on some of these newer advances. 
I want to thank all of the authors for their excellent contributions and to the InTech 
editorial team, especially to Mr Vedran Greblo, for his continuous support and superb 
and ongoing help when it was needed. 
 
Prof. Luis Rodrigo Saez 
 Head of Gastroenterology Service, University Hospital Central of Asturias,  
Full Professor of Medicine, Oviedo University, 
 Spain 
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Acute Pancreatitis – The Current  
Concept in Ethiopathogenesis, 
Morphology and Complications 
 B. Suresh Kumar Shetty1, Ramdas Naik2 , Adithi S. Shetty3,  
Sharadha Rai4, Ritesh G. Menezes5 and Tanuj Kanchan1  
1Department of Forensic Medicine and Toxicology Kasturba Medical College,  
Mangalore, Manipal University, 
2Department of Pathology, Kasturba Medical College, Mangalore, Manipal University, 
3Department of Obstetrics & Gynaecology, K. S. Hegde Medical Academy,  
Mangalore, Nitte University, 
4Department of Pathology, Kasturba Medical College, Mangalore, Manipal University, 
5Department of Forensic Medicine and Toxicology, Srinivas Institute of 
Medical Sciences & Research Centre, Mangalore,  
India 
1. Introduction 
This chapter is a comprehensive approach on etiology, patho-phyosiological and 
complications of acute pancreatitis and its review will aid in evaluation of acute pancreatitis 
in-toto. Pancreatitis is the inflammation of the exocrine pancreas which results from injury 
to the acinar cells. It may be classified as either acute or chronic. Acute pancreatitis is the 
reversible injury to the pancreatic parenchyma associated with inflammation and is 
characterized by a recurrent episode of abdominal pain and elevated serum amylase and 
lipase levels. 
2. Etiopathogenesis of acute pancreatitis 
2.1 Etiology 
Acute pancreatitis is relatively common. Among the numerous causes, two factors which 
account for about 70 -80% of cases of acute pancreatitis are biliary tract disease and 
alcoholism. The male-to-female ratio is 1: 3 in the group with biliary tract disease and 6: 1 in 
those with alcoholism. 
2.1.1 Important causes are 
Alcohol and pancreatitis: Alcohol-induced acute pancreatitis usually develops in patients 
who consume large quantities of alcohol for 5-10 years before the first attack. However, it 
may occur with the consumption of a small quantity of alcohol also (two drinks/day). 
Environmental factors like smoking and high-fat diet may also contribute to the 
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development of acute pancreatitis in alcoholics. There are three possible different 
mechanisms of alcoholic pancreatitis.  
 Obstruction of small ductules by proteinaceous plugs: Chronic alcohol ingestion 
results in the secretion of protein-rich pancreatic fluid, which may result in 
inspissated protein plugs and obstruction of small pancreatic ducts.  
 Abnormal spasm sphincter of Oddi: Alcohol transiently increases pancreatic exocrine 
secretion and abnormal contraction of the sphincter of Oddi (the muscle at the 
ampulla of Vater),  
 Direct toxic effects: Metabolic byproducts of alcohol have direct toxic effects on the 
acinar cells. 
 
METABOLIC FACTORS 
 Alcoholism  
 Hyperlipoproteinemia/hypertriglyceridemia  
 Hyperparathyroidism  
 Hypercalcemia  
 Drugs (e.g., furosemide, azathioprine, cyclosporine, tacrolimus) 
GENETIC 
Mutations in the cationic trypsinogen (PRSS1) and trypsin inhibitor (SPINK1) genes 
MECHANICAL 
 Gallstones 
 Trauma and injury 
 Blunt abdominal trauma 
 Iatrogenic injury  
 Operative injury: Endoscopic procedures with dye injection(retrograde 
cholangiopancreatography) 
 Obstruction of the pancreatic duct 
 Periampullary neoplasms (e.g., carcinoma of pancreas)  
 Parasites (e.g., ascaris lumbricoides and clonorchis sinensis) 
VASCULAR/ISCHEMIC INJURY 
 Shock  
 Atheroembolism 
 Vasculitis 
INFECTIONS  
 Mumps 
Table 1. Etiologic Factors in Acute Pancreatitis 
Gallstones and pancreatitis 
 The frequency of acute pancreatitis is inversely proportional to the size of gallstones. 
Persistence of stones in the bile duct or the ampulla of vater is associated with more 
severe disease. An impacted gallstone may allow the reflux of bile into the pancreatic 
duct or occlude the duct's orifice. 
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Pancreatic Obstruction  
 It is a less common cause of acute pancreatitis. Sphincter of Oddi dysfunction and 
carcinoma of the pancreas are associated with acute pancreatitis and is usually of the 
mild type. 
Genetic Factors  
 About 10% to 20% of patients with acute pancreatitis have no known associated 
etiological processes. Though these are termed idiopathic, the evidence suggests that 
some may have a genetic basis.  
 Hereditary pancreatitis is characterized by recurrent attacks of severe pancreatitis 
usually developing in childhood. Most of these are caused by germline (inherited) 
mutations in the cationic trypsinogen gene (also known as PRSS1). In patients with 
these mutations, tryspin is inappropriately activated in the pancreas, which in turn 
activates other digestive proenzymes. 
 The serine protease inhibitor Kazal type 1 (SPINK1) gene codes for a pancreatic 
secretory trypsin inhibitor. This inhibits trypsin activity and prevents autodigestion of 
the pancreas by activated trypsin. Mutation in the SPINK1 gene leads to loss of function 
of the inhibitor gene and causes pancreatitis. 
The other etiological factors for acute pancreatitis are shown in the Table.1.  
2.2 Pathogenesis 
The changes of acute pancreatitis are due to autodigestion of the pancreatic substance by 
inappropriately activated pancreatic enzymes.  
2.2.1 Mechanism of activation of pancreatic enzymes (Figure.1)  
 Pancreatic duct obstruction: Any lesion which narrows the lumen of pancreatic ducts or 
impairs the flow of exocrine secretions can increase intraductal pressure and cause
back-diffusion. This results in the accumulation of enzyme-rich fluid in the interstitium 
and inappropriate activation of proenzymes. Gallstones is one of the main cause of 
pancreatic duct obstruction.  
 Defective intracellular transport of proenzymes within acinar cells: In normal acinar cells, the 
proenzymes and lysosomal hydrolases are transported in separate pathways.
Inappropriate delivery of pancreatic proenzymes to the intracellular compartment
containing lysosomal hydrolases may activate proenzymes. This mechanism may be
responsible for injury due to alcohol or duct obstruction. 
 Primary acinar cell injury: Acinar cells may be directly damaged by certain viruses (e.g., 
mumps), drugs, alcohol, trauma to the pancreas, ischemia and shock. 
 Hyperstimulation of pancreas: This may be seen in association with consumption of
alcohol or fat diet.  
 Reflux of bile: Infected bile or duodenal content may regurgitate into the pancreatic duct 
due to disruption of sphincter Oddi (e.g., gallstones). 
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Fig. 1. Diagram Of Mechanism Of Activation Of Pancreatic Enzymes 
2.2.2 Pancreatitis evolves in three phases 
 Initial phase: It is characterised by premature activation of zymogen granules releasing 
active enzymes which cause acinar cell injury, digestion of the pancreas and 
surrounding tissue. The hyperstimulation of the pancreas may result in the fusion of 
lysosome and zymogens within large vacuoles. Lysosomal hydrolase namely cathepsin 
B, is capable of activating trypsinogen to trypsin.  
 Inappropriate activation of trypsinogen: The inappropriate activation of trypsinogen is 
an important triggering event in acute pancreatitis. Pancreatic enzymes (including 
trypsin) are synthesized in an inactive proenzyme form. When trypsin is 
inappropriately activated, it in turn activates other proenzymes like 
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prophospholipase and proelastase into active forms. The actived enzyme lipase 
degrade fat cells and elastase damage the elastic fibers of blood vessels. Trypsin 
also activates kinin system, Hageman factor (factor XII), coagulation and 
complement systems.  
 Second phase: It involves the activation, chemoattraction and sequestration of 
neutrophils into the pancreas, resulting in an intrapancreatic inflammatory reaction of 
variable severity. Leukocyte release cytokines which is responsible for local 
inflammation and interstitial edema. Edema may decrease the local blood flow and 
cause further ischemic damage to acinar cells 
 Third phase: It is due to the effects of activated proteolytic enzymes and cytokines, 
released by the inflamed pancreas, on distant organs. Activated proteolytic enzymes, 
especially trypsin, not only digest pancreatic and peripancreatic tissues but also activate 
other enzymes such as elastase and phospholipase. The active enzymes protease digest 
cellular membranes and cause parenchymal cell necrosis. The activated lipase cause fat 
necrosis and the elastase disrupt the vessel wall leading to hemorrhage. Cell injury and 
death result in the liberation of bradykinin, vasoactive substances and histamine which 
produce vasodilation, increased vascular permeability, and edema with effects on many 
organs. Thus it may lead to systemic inflammatory response syndrome (SIRS) and acute 
respiratory distress syndrome (ARDS) as well as multiorgan failure. 
2.2.3 Safety mechanism 
The pancreas has many safety mechanisms to prevent autoactivation of zymogens. One of 
the known mechanism is the pancreatic secretory trypsin inhibitor (PSTI), which is found in 
secretory granules. It inhibits trypsin activity.  
2.3 Morphology 
The normal pancreas has a poorly developed capsule and lies close to adjacent structures, 
which includes the common bile duct, duodenum, splenic vein and transverse colon. Due to 
this, in acute pancreatitis these are also commonly involved in the inflammatory process. 
The morphological feature of acute pancreatitis varies from minimal inflammation and 
edema to severe extensive necrosis and hemorrhage. [Figure.2] 
2.3.1 Microscopic features: Important features of acute pancreatitis are 
 Leakage of blood vessels causing edema: Microvascular leakage results in leakage of 
plasma into the interstitum of pancreas resulting in edema.  
 Acute inflammation: Leukocytes are seen in the interstitial connective tissue of 
pancreas along with inflammatory fluid exudates. 
 Enzymatic fat necrosis: It is produced due to action of lipolytic enzymes-lipase.  
 Proteolytic destruction of pancreatic parenchyma: It is brought out by the action of 
protease.  
 Destruction of blood vessels: The elastase causes destruction of blood vessels and 
subsequent interstitial hemorrhage.  
Depending on the extent of severity of inflammatory reaction, acute pancreatitis - 
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Fig. 2. The Morphological Feature Of Acute Pancreatitis  
2.3.2 They are classified into three types 
2.3.2.1 Acute interstitial or edematous pancreatitis: 
It is a mild and reversible form of acute pancreatitis. It is usually managed medically. 
Microscopy: It shows interstitial edema and mild infiltratation of polymorphonuclear 
leukocytes, without any necrosis or hemorrhage. There may be focal areas of fat necrosis in 
the substance of the pancreas and in peripancreatic fat. Fat necrosis is due to the action of 
lipase on triglycerides which releases fatty acids from the fat cells. These fatty acids combine 
with calcium and form insoluble salts and this process is known as saponification. The 
insoluble salts impart a granular blue appearance to the involved fat cells.  
2.3.2.2 Acute necrotizing pancreatitis 
It is the severe form of acute pancreatitis in which the acinar, ductal tissues and islets of 
Langerhans show necrotic changes [Figure.2.] 
Hemorrhage:Vascular injury due to the enzyme elastase can lead to hemorrhage into the 
parenchyma of the pancreas, which shows areas of red-black areas of hemorrhage in the 
substance of pancreas.  
Fat necrosis: Foci of fat necrosis is seen both in the pancreatic and extra-pancreatic fat. The 
extra pancreatic tissue which may show fat necrosis includes: omentum, mesentery of the 
bowel and outside the abdominal cavity (subcutaneous fat). As a result of deposition of 
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calcium in the area of fat necrosis (saponification), the blood calcium level may be 
decreased, sometimes to the level of causing neuromuscular irritability. 
Peritoneal cavity: In majority of cases, the peritoneal cavity contains a serous, slightly 
turbid, brown-tinged fluid in which globules of fat (derived from the action of enzymes on 
adipose tissue) can be seen [Figure.3]. 
 
Fig. 3. Peritoneal Cavity In Acute Pancreatitis 
 Microscopy: 
 Edema: It is due to leakage through microvasculature. 
 Acute inflammation  
 Enzymatic fat necrosis: It appears granular blue with ghost outlines.  
 Proteolytic destruction of pancreatic parenchyma: Acinar and ductal tissues as well 
as the islets of Langerhans are necrotic. 
 Destruction of blood vessels (elastase) and subsequent interstitial hemorrhage.  
2.3.2.3 Acute hemorrhagic pancreatitis  
It is the most severe form of acute pancreatitis. It usually occurs in the middle aged and is 
associated with high morbidity and mortality. Microscopically, it shows extensive 
parenchymal necrosis accompanied by hemorrhage within the pancreas.  
The above features linked with the clinical features, laboratory findings and recent 
investigative procedures help in diagnosing acute pancreatitis with ease. The effective 
treatment modalities in recent years will insist on efficient interpretation of patho-
physiology in acute pancreatitis so as to ensure a speedy recovery from the cause. 
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2.4 Clinical features  
Abdominal pain is the major manifestation of acute pancreatitis. The pain may vary from mild 
and tolerable to severe, constant and incapacitating distress. Characteristically, the pain is 
steady and intense, located in the epigastrium and periumbilical region. It often radiates to 
the upper back as well as to the chest, flanks, and lower abdomen . Anorexia, nausea, 
vomiting and abdominal distention due to gastric and intestinal hypomotility and chemical 
peritonitis also frequently accompany the pain.  
Full-blown acute pancreatitis usually present with sudden calamitous onset of an “acute 
abdomen” and is a medical emergency. Many of the systemic features of severe acute 
pancreatitis are due to release of toxic enzymes, cytokines, and other mediators into the 
circulation and activation of the systemic inflammatory response. These mediators result in 
leukocytosis, hemolysis, disseminated intravascular coagulation, fluid sequestration, acute 
respiratory distress syndrome, and diffuse fat necrosis. Peripheral vascular collapse and 
shock with acute renal tubular necrosis may also occur. 
2.5 Laboratory findings 
Marked elevation of serum amylase levels during the first 24 hours, followed within 72 to 96 
hours by a rising serum lipase level.  
Hyperglycemia is common and is due to multiple factors, including decreased insulin 
release, increased glucagon release, and an increased output of adrenal glucocorticoids and 
catecholamines. Glycosuria occurs in 10% of cases.  
Hypocalcemia may result from precipitation of calcium soaps in necrotic fat; if persistent, it 
is a poor prognostic sign.  
Hypertriglyceridemia occurs in 15 to 20% of patients, and serum amylase and lipase levels 
in these individuals are often spuriously normal. 
Direct visualization of the enlarged inflamed pancreas by radiography is useful in the 
diagnosis of pancreatitis. 
2.6 Complications of pancreatitis  
Complication Mechanism 
Local pancreatic complications 
Necrosis Inflammation 
Abscess Localised collection of necrotic material 
Pseudocyst Disruption of pancreatic ducts 
Pancreatic ascites Disruption of pancreatic ducts 
Systemic complications 
Acute respiratory distress syndrome (ARDS) Hypoxia due to microthrombi in the pulmonary vessels.  
Hypocalcemia Sequestration of calcium in fat necrosis 
Hyperglycemia Disruption of islets of Langerhans with altered 
insulin/glucagon release 
Gastrointestinal complications 
Upper GI bleeding Gastric /duodenal erosions 
Duodenal obstruction Compression by pancreatic mass/pseudocyst 
Obstructive jaundice Compression by pancreatic mass/pseudocyst 
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2.7 Treatment 
In the majority of patients (85–90%) acute pancreatitis is self-limited and subsides 
spontaneously, usually within 3–7 days after treatment is started. About 5% with severe 
acute pancreatitis die from shock during the first week. Acute respiratory distress syndrome 
and acute renal failure are dangerous complications 
The key to the management of acute pancreatitis is “resting” the pancreas by total restriction 
of oral intake and by supportive therapy. Conventional mode of treatment include  
1. Analgesics for pain,  
2. Intravenous fluids and colloids to maintain normal intravascular volume, and  
3. No oral alimentation.  
The nasogastric suction has no clear-cut advantages in the treatment of mild to moderately 
severe acute pancreatitis. Therefore, it must be considered elective rather than mandatory. 
The drugs which block pancreatic secretion have not found to be of any benefit. For this and 
other reasons, anticholinergic drugs are not indicated in acute pancreatitis. 
Role of antibiotics: The benefit of antibiotic prophylaxis in the treatment of necrotizing 
acute pancreatitis remains controversial. It was observed that there is no benefit of antibiotic 
prophylaxis with regard to the risk of developing infected pancreatic necrosis. 
3. Conclusion 
These features linked with the clinical features, laboratory findings and recent investigative 
procedures will help in diagnosing acute pancreatitis with ease. The effective treatment 
modalities in recent years will insist on efficient interpretation of patho-physiology in acute 
pancreatitis so as to ensure a speedy recovery from the cause. 
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1. Introduction 
More than 220,000 patients are admitted to hospital each year with acute pancreatitis in the 
United States alone.1 The most common etiology of acute pancreatitis is gallstones. This 
chapter will focus on diagnostic and management issues related to acute biliary pancreatitis 
(ABP). Differentiating gallstone-induced acute pancreatitis from other etiologies (alcohol, 
medication induced, hypertriglyceridemia) should be prioritized in the initial investigation 
of acute pancreatitis as ABP has its own specific management considerations. 
2. Epidemiology 
Cholelithiasis, or gallstones, are present in up to 10% of the general population. Risk factors 
for developing gallstones include female sex, advancing age, ethnicity and genetics, obesity 
and the metabolic syndrome, rapid weight loss, high fat low fiber diet, pregnancy, and 
certain disease states such as cirrhosis and Crohn’s disease.2 Gallstones are present in 35-
75% of all patients with acute pancreatitis in developed nations.3,4 Up to 8% of patients with 
symptomatic gallstones will develop biliary pancreatitis due to migration into the bile duct, 
and ABP may be the initial presentation of gallstones in up to 40% of previously 
asymptomatic patients.5 The yearly incidence of ABP is estimated at 4.9-80.0 cases per 
100,000 population in the United States. Although most cases of ABP are mild and self-
limited, case fatality rates as high as 15% have been reported in severe cases.6 Risk factors 
for ABP include female gender with a ratio of 2:1 over males, age, with an incidence of ABP 
                                                 
1 Whitcomb DC. Clinical practice. Acute pancreatitis. NEJM. 2006;354:2142-2150. 
2 Shaffer SA. Epidemiology of gallbladder stone disease. Best Practice and Research Clinical 
Gastroenterology 2006;20:981-996. 
3 van Geenen EJM, van der Preet DL, Bhagirath R, et al. Etiology and diagnosis of acute biliary 
pancreatitis. Gastroenterology & Hepatology. 2010;7:495-502.  
4 Agrawal S, Jonnalagadda S. Gallstones, from gallbladder to gut. Management options for diverse 
complications. Postgraduate Medicine. 2000;108:143-153. 
5 van Erpecum KJ. Complications of bile-duct stones: acute cholangitis and pancreatitis. Best Practice & 
Research Clinical Gastroenterology. 2006;20:1139-1152.  
6 Kaw M, Al-Antably Y, Kaw P. Management of of gallstone pancreatitis: cholecystectomy or ERCP and 
endoscopic sphincterotomy. Gastrointestinal Endoscopy.2002;56:61-65. 
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over 3 times higher at age 75 compared with age 20, and ethnicity, with increased incidence 
in those of white and Hispanic backgrounds.7 
3. Pathogenesis 
The exact pathogenesis of acute biliary pancreatitis is unclear. Several structural and genetic 
explanations are supported in the current literature.  
3.1 Structural 
One mechanism involves obstruction of the common bile and pancreatic ducts as gallstones 
migrate down and become impacted in the ampulla of Vater. Classic observational studies 
revealed gallstones may be retrieved from the stool of patients with biliary pancreatitis in 
>90% of cases as compared to approximately 10% of patients with symptomatic gallstones in 
the absence of pancreatitis, and in no patients with alcohol induced pancreatitis.8,9 The 
precise mechanism of how the gallstones passing through the ampulla initiate and sustain 
pancreatic inflammation is unknown. It seems just the passage of material through the 
ampulla of Vater without overt obstruction may be enough to initiate pancreatitis as in the 
case of sludge containing microlithiasis. In this situation, passage of material through the 
ampulla may lead to spasm or local edema of the sphincter of Oddi resulting in temporary 
obstruction. Episodes of recurrent acute pancreatitis caused by microlithiasis may be 
significantly reduced by cholecystectomy or endoscopic sphincterotomy (ES). 
A second mechanism involves reflux of infected bile into the pancreatic duct. The 
inflammation associated with cholangitis may extend as far as the pancreas initiating the 
episode of acute pancreatitis. Normal pressures in the pancreatic duct are well above 
pressures in the common bile duct (CBD), preventing reflux of bile into the pancreatic duct 
under physiologic conditions. With ampullary obstruction secondary to passing gallstones, 
pressure gradients may shift, allowing flow of bile and pancreatic juice back into the 
pancreatic duct. Studies have shown sterile refluxate does not cause acute pancreatitis, 
however infected bile (especially with Escherichia coli) or mixtures of bile and pancreatic 
juice can lead to acute pancreatitis.10 
Gallstone-related factors have also been implicated as they relate to the number and 
frequency of gallstones that pass into the common bile duct and through the ampulla of 
Vater as well as the likelihood of obstruction. These factors include small size (<2-5mm), 
higher number (>20) of gallstones in the gallbladder, irregular surface of the gallstones, 
good emptying of the gallbladder with meals, and cystic duct width over 5mm. Next, bile 
duct anatomy including an enlarged CBD (>1.3mm), a wide angle between the CBD and 
pancreatic duct, and a common pancreaticobiliary channel may also predispose to acute 
                                                 
7 van Geenen EJM, van der Preet DL, Bhagirath R, et al. Etiology and diagnosis of acute biliary 
pancreatitis. Gastroenterology & Hepatology. 2010;7:495-502. 
8 Acosta JM, Ledesma CL. Gallstone migration as a cause of acute pancreatitis. NEJM. 1974;290:484-487. 
9 Acosta JM, Rossi R, Ledesma CL. The usefulness of stool screening for diagnosing cholelithiasis in 
acute pancreatitis. A description of the technique. American Journal of Digestive Diseases. 1977;22:168-172. 
10 van Geenen EJM, van der Preet DL, Bhagirath R, et al. Etiology and diagnosis of acute biliary 
pancreatitis. Gastroenterology & Hepatology. 2010;7:495-502. 
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biliary pancreatitis. Patients with a history of ABP were found to be twice as likely to have a 
common pancreaticobiliary channel when compared to those with choledocholithiasis and 
cholelithiasis without a history of pancreatitis.11 
3.2 Genetic 
Genetic variations and mutations have been well described in idiopathic pancreatitis, and it 
appears that genetics may play a role in selected circumstances of biliary pancreatitis as 
well. Marschall et al. recently published a review of the genetic basis for gallstone formation 
and symptomatic gallstone disease including the development of biliary pancreatitis.12 
Using data from 43,141 mono- and dizygotic twins born between 1900 and 1958, they 
calculated that genetics account for up to 25% of the phenotypic variation among twins. As 
cholesterol stones account for over 90% of all gallstones, metabolic pathways involved in the 
formation of cholesterol stones have been studied. Bile is made up of water and three lipid 
components, namely cholesterol (4%), phospholipids (24%), and bile salts (72%). Genes 
encoding for transport proteins have been identified for each of these components with 
varying significance for the risk of ABP.  
One such susceptibility locus is the D19H variant of ABCG8, a cholesterol transport protein. 
This allele increases the ABCG5/8 mediated transfer of cholesterol into bile, resulting in 
biliary cholesterol hypersaturation, a necessary pre-requisite for cholesterol stones. 
Marschall et al. determined an odds ratio of 2.5 (95% CI 1.3-4.8) for the formation of 
symptomatic gallstones disease in 341 Swedish twins with at least one D19H allele.  
Cases of recurrent ABP have been associated with a mutation in the ABCB4 gene, which 
encodes for multidrug resistant p-glycoprotein MDR3, a protein involved translocation of 
phospholipids from the inner to the outer leaflet of the canalicular membrane of 
hepatocytes. Point mutations in ABCB4 have been associated with low phospholipid-
associated cholelithiasis syndrome, which is characterized by early gallstone disease (<40 
years old), intrahepatic sludge and microlithiasis, and recurrent biliary disease after 
cholecystectomy. Mutations in ABCB4 have also been associated with several other 
hepatobiliary diseases including intrahepatic cholestasis of pregnancy, progressive familial 
intrahepatic cholestasis type 3, and adult biliary cirrhosis.13,14 
Bile salts are the third lipid component with several susceptibility loci identified. The 
ABCB11 gene, encoding the bile salt export pump (BSEP), has been found as a rare cause of 
cholesterol stones with less than 2% of young adults being heterozygous for functionally 
relevant mutations. Expression of ABC transporters ABCB11 and ABCB4 are induced by the 
farnesoid X receptor (FXR), a bile acid sensor that regulates hepatic bile acid synthesis, 
uptake, and excretion genes, as well as other genes involved with turnover of cholesterol 
                                                 
11 van Geenen EJM, van der Preet DL, Bhagirath R, et al. Etiology and diagnosis of acute biliary 
pancreatitis. Gastroenterology & Hepatology. 2010;7:495-502. 
12 Marschall HU, Katsika D, Rudling M, Einarsson C. The genetic background of gallstone formation: an 
update. Biochemical and Biophysical Research Communications. 2010;396:58-62. 
13 van Geenen EJM, van der Preet DL, Bhagirath R, et al. Etiology and diagnosis of acute biliary 
pancreatitis. Gastroenterology & Hepatology. 2010;7:495-502. 
14 Marschall HU, Katsika D, Rudling M, Einarsson C. The genetic background of gallstone formation: an 
update. Biochemical and Biophysical Research Communications. 2010;396:58-62. 
 
Pancreatitis – Treatment and Complications 
 
16
and glucose homeostasis. The reduction in bile acid synthesis that results is associated with 
increased cholesterol gallstone formation. The A105G variant of the SLC10A2 gene, 
encoding the apical sodium-dependent bile acid transporter (ASBT) was also identified as a 
risk factor for cholesterol stones with an odds ratio of 2.04 (95% CI 1.19-3.55).15 
4. Diagnosis 
The presentation of acute pancreatitis may be quite similar whether the etiologic basis is 
biliary or non-biliary in origin. This makes distinguishing acute biliary pancreatitis from 
other etiologies somewhat challenging. Certain clues may exist on history and physical 
examination, however laboratory investigations and abdominal imaging are often required 
for a more definitive diagnosis.  
4.1 Clinical presentation 
Abdominal pain, classically severe epigastric pain radiating to the back that is worse in the 
supine position, is a hallmark of acute pancreatitis of any etiology. The abdominal pain may 
worsen over the course of several hours and may be associated with nausea and vomiting. 
Patients may also report worsening of their pain following meals. Due to the significant 
inflammatory process and release of cytokines, fever is another common manifestation. Still, 
most patients will have a mild, self-limited course of their biliary pancreatitis. In one early 
series of 153 patients with ABP, only twenty-two (14%) were febrile and thirty (20%) were 
volume depleted. Eighty-one (53%) had right upper quadrant tenderness, and seventy-one 
(46%) had mid-epigastric tenderness. Notably, twenty-one (14%) had completely benign 
abdominal examinations, and only nine patients (6%) had diffuse peritonitis.16 
During an episode of acute pancreatitis, pancreatic enzymes, vasoactive materials such as 
kinins, and other toxic substances extravasate from the pancreas into surrounding areas 
resulting in chemical irritation and contribute to third space losses that may lead to 
hypovolemia, tachycardia, and hypotension. In this situation, the abdomen may also 
become distended and tympanic due to paralytic ileus. When toxic mediators reach the 
systemic circulation, the corresponding systemic inflammatory response syndrome (SIRS) 
may be severe and result in end-organ damage including acute respiratory distress 
syndrome (ARDS) and acute kidney injury. Hemorrhagic pancreatitis may lead to the classic 
Cullen’s sign, with ecchymosis in the periumbilical region, and Grey Turner’s sign, with 
ecchymosis of the flank.  
History of known gallstones, especially symptomatic gallstone disease such as biliary colic 
may indicate a biliary etiology, although it cannot rule out other etiologies of acute 
pancreatitis, nor can the absence of gallstones rule out a biliary source, as pancreatitis can be 
the first presentation of gallstone disease, and sludge and microcalculi are still a possibility. 
The absence of other associated etiologies including significant alcohol intake, initiation of 
medications known to be associated with pancreatitis, recent endoscopic retrograde 
cholangiopancreatography (ERCP), and known hypertriglyceridemia or hypercalcemia may 
                                                 
15 Marschall HU, Katsika D, Rudling M, Einarsson C. The genetic background of gallstone formation: an 
update. Biochemical and Biophysical Research Communications. 2010;396:58-62. 
16 Frel G, Frel V, Thirlby R, McClelland R. Biliary pancreatitis: clinical presentation and surgical 
management. American Journal of Surgery 1986;151:170-175. 
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also lead to the diagnosis of ABP. Scleral icterus or overt jaundice may be associated with 
acute pancreatitis in select cases due to edema of the head of the pancreas or an obstructing 
stone in the case of biliary pancreatitis. History and physical examination should also aim to 
rule out mimickers of pancreatitis including acute cholecystitis, perforated duodenal ulcer, 
intestinal obstruction, mesenteric ischemia, or ruptured aneurysm amongst other etiologies.  
4.2 Biochemistry 
The diagnosis of pancreatitis of any etiology is classically made with elevations in serum 
amylase and lipase. Enzyme levels tend to rise within 4 - 8 hours of onset, peak around 24 
hours, and return to normal between 2 - 14 days after onset of acute pancreatitis. Lipase has 
a longer half-life, up to 12 hours, compared to a half-life of only 2 hours for serum amylase, 
and thus lasts several days longer in the bloodstream. Most would consider elevations in 
amylase and lipase upwards of three times the upper limit of normal significant in the 
diagnosis of acute pancreatitis. However, in one retrospective study of 284 patients with a 
first episode of acute pancreatitis, over 30% of patients had amylase levels below three times 
the upper limits of normal and 18% had lipase levels below three times the upper limit of 
normal.17 They did show that patients with a biliary origin of their acute pancreatitis were 
significantly (p = 0.007) more likely to have elevations in serum amylase over three times the 
normal limit compared to non-biliary etiologies. This study also determined that there was 
no association between level of elevation of enzymes and severity of disease looking at 
factors such as development of pseudocysts, renal impairment and need for dialysis, ICU 
admission requiring ventilatory support, need for surgery, and overall mortality.18  
It is important, however, to remember that a long differential diagnosis exists for elevations in 
serum amylase and lipase. Other pancreatic diseases, acute cholecystitis or cholangitis, post-
ERCP, trauma, bowel obstruction or ischemia, and medications may lead to elevations in both 
serum amylase and lipase. Additionally, renal impairment, penetrating peptic ulcer disease, 
salivary disease, several solid tumors and multiple myeloma, and gynecologic disease can 
raise serum amylase but not serum lipase, making lipase a more specific serum marker.  
With a diagnosis of acute pancreatitis made, biliary etiology may be determined using 
several serum markers, especially serum alanine aminotransferase (ALT). As with serum 
amylase and lipase, elevations over three times the upper limit of normal are considered 
significant, however, up to 15% of patients with biliary pancreatitis will have normal liver 
enzymes.19 There is also a differential diagnosis for elevations in ALT, most significantly 
alcohol (the second leading cause of acute pancreatitis in Western countries), viral hepatitis, 
and non-alcoholic fatty liver disease. 
There have been several studies looking at the diagnosis of biliary pancreatitis through the 
use of ALT, either alone or in combination with other serum markers. Early studies looked 
                                                 
17 Lankisch PG, Burchard-Reckert S, Lehnick D. Underestimation of acute pancreatitis: patients with 
only a small increase in amylase/lipase levels can also have or develop severe acute pancreatitis. Gut. 
1999;44:542-544. 
18 Lankisch PG, Burchard-Reckert S, Lehnick D. Underestimation of acute pancreatitis: patients with 
only a small increase in amylase/lipase levels can also have or develop severe acute pancreatitis. Gut. 
1999;44:542-544. 
19 van Geenen EJM, van der Preet DL, Bhagirath R, et al. Etiology and diagnosis of acute biliary 
pancreatitis. Gastroenterology & Hepatology. 2010;7:495-502. 
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at using multiple serum and urine biomarkers and occasionally clinical data to distinguish 
biliary from non-biliary etiologies. One such study developed a scoring system using seven 
variables including serum and urine amylase, serum AST and ALT, ALP, lipase/amylase 
ratio, and erythrocyte mean corpuscular volume (MCV) to differentiate biliary from 
alcoholic pancreatitis.20 Each parameter was given a single point, and a score of 4 or greater 
out of 7 was significantly correlated to a biliary etiology of pancreatitis (p < 0.0001), and a 
score below 4/7 correlated with alcoholic etiology with a sensitivity of 92% and specificity 
of 94%. On the other hand, Davidson et al. argued against multi-factor systems in their 
study that compared test characteristics of a one-, three-, and five-factor test for biliary 
pancreatitis.21 The one-factor test used serum ALT and aspartate aminotransferase (AST) 
alone, the three-factor test used alkaline phosphatase (ALP) and bilirubin in addition to 
transaminases, and the five-factor test included clinical data such as age and female sex, as 
well as amylase, alkaline phosphatase, and transaminases. In their study, the one- and three-
factor tests performed slightly better than the five-factor test, and thus using serum 
transaminases alone were recommended for simplicity.  
More recent studies have lent support for single-factor systems. One study looked at serum 
ALT ≥ 80 (U/L) in a cohort of 68 patients with acute pancreatitis, of which 44 (65%) had a 
biliary etiology.22 They demonstrated that serum ALT ≥ 80 (two times the upper limit of 
normal) had a sensitivity of 91%, specificity of 100%, positive predictive value (PPV) of 
100% and negative predictive value (NPV) of 86%. Combined with abdominal ultrasound, 
test characteristics improved somewhat with a sensitivity of 98%, specificity of 100%, PPV of 
100% and NPV of 96%. A subsequent study looked at a cohort of 213 patients, of which 62% 
had ABP confirmed with endoscopic ultrasound (EUS), and found serum ALT levels over 
two times the upper limit of normal had a sensitivity of 74%, specificity of 84%, PPV of 88%, 
and NPV of 66% for predicting a biliary etiology, whereas serum ALT levels over three 
times the upper limit of normal had a sensitivity of 61%, specificity of 91%, PPV of 92%, and 
NPV of 59%.  
4.3 Abdominal imaging 
The contribution of medical imaging to the diagnosis and evaluation of pancreatitis has 
evolved substantially. Early plain film description of the effects of pancreatic inflammation 
on the intra-abdominal bowel gas pattern has emerged over 50 years ago. Despite today’s 
widespread use of modern imaging technology including MRCP, these alterations in bowel 
gas patterns remain an occasional useful adjunct in the diagnosis of pancreatitis.  
Various abdominal film patterns have been described and may be occasionally seen in the 
setting of pancreatitis. One of the better described is the “colon cutoff sign”. In this pattern a 
dilated transverse colon appears to be abruptly cutoff occasionally simulating the 
appearance of colonic obstruction. This pattern is likely related to inflammation of the 
phrenicocolic ligament causing spasm or occasionally actual mechanical narrowing in the 
                                                 
20 Stimac D, Lenac T, Marusic Z. A scoring system for early differentiation of the etiology of acute 
pancreatitis. Scandinavian Journal of Gastroenterology 1998;33:209-211. 
21 Davidson BR, Neoptolemos JP, Leese T, Carr-Locke DL. Biochemical prediction of gallstones in acute 
pancreatitis: a prospective study of three systems. British Journal of Surgery 1988;75:213-215. 
22 Ammori BJ, Boreham B, Lewis P, Roberts SA. The biochemical detection of biliary etiology of acute 
pancreatitis on admission: a revisit in the modern era of biliary imaging. Pancreas 2003;26(2):e32-e35. 
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region of the splenic flexure. This appearance is further accentuated on the background of 
an adynamic colon. Additional imaging findings may include a mottled appearance of the 
peripancreatic region secondary to fat necrosis or peripancreatic gas in the setting of 
suppurative pancreatitis. Numerous other non-specific signs in the setting of pancreatitis 
have been described including ascites, left sided pleural effusion and diaphragmatic 
elevation. Needless to say all these signs require additional imaging modalities, clinical and 
biochemical correlation for to establish the diagnosis. 
4.3.1 Ultrasonography 
Despite its dependence on operator skill and patient’s body habitus ultrasonography has 
become a mainstay in the imaging of suspected biliary pancreatitis. In the setting of acute 
inflammation the pancreas may appear focally or diffusely enlarged, as well as relatively 
hypoechoic secondary to parenchymal edema. This is a reversal of the normal pattern in 
which the pancreas is echogenic relative to the adjacent liver. The main utility of 
sonography however is in its ability to image the biliary system in the search for 
cholelithiasis/choledocholithiasis as the etiology in order to guide further management. The 
widespread availability, sensitivity and relatively low cost of ultrasonography makes it 
particularly suitable for this role. Biliary stones typically appear as echogenic foci with 
posterior clean shadowing (Figure 1). Small stones and sludge however may not  
demonstrate posterior shadowing. Stones are more easily appreciated in the setting of 
biliary dilatation although distal CBD stones may remain obscured by overlying bowel gas. 
 
Fig. 1. Sonographic image demonstrating the typical appearance of CBD stones. Three 
stones (arrows) are visualized within a mildly dilated distal CBD. The stones appear as 
echogenic foci with posterior shadowing (best appreciated in the most proximal stone). 
Layering sludge and stones (asterisks) are also appreciated within the gallbladder (GB). 
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4.3.2 Computed tomography  
Computed tomography (CT) has unique advantages in the evaluation of pancreatitis. It is 
relatively cheaper, non-invasive and more available as compared to ERCP and its sensitivity 
does not depend on the sonographer or the patient’s body habitus as is the case with 
ultrasound. An inflamed pancreas may appear enlarged and heterogeneous with 
surrounding inflammatory changes. CT is also particularly useful is the evaluation of 
pancreatic necrosis, pseudocyst formation or other secondary complications of pancreatitis.  
In the evaluation of a biliary cause of pancreatitis, CT however does have a significant 
weakness as up to 25% of biliary stones may be isodense to bile and therefore poorly 
visualized. Visible CBD stones may appear as a dense intraluminal mass with the so called 
“target sign” (Figure 2). As with other modalities, CBD dilatation may signal an underlying 
obstructing stone or mass and may require further evaluation with other methods in order 
to elucidate the underlying cause.  
 
Fig. 2. Coronal reformatted CT centered on the distal CBD. Two dense stones(arrows) are 
noted in the distal CBD. The CBD is dilated secondary to the obstructing stones.  
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4.3.3 Magnetic resonance cholangiopancreatography 
Magnetic resonance cholangiopancreatography (MRCP) is the most sensitive and specific 
non-invasive method of assessing the biliary system for choledocholithiasis as an 
underlying etiology for pancreatitis. MRCP uses a heavily T2 weighted sequence which 
highlights the biliary ducts due to their high water content. The signal of the surrounding 
soft tissues saturates out, thus allowing for exquisite visualization of the bright bile ducts in 
the background of low intensity surrounding soft tissues (Figure 3). In this setting biliary 
duct stones appear as dark signal voids within the bright bile fluid (Figure 4).  
MRCP is comparable to ERCP with respect to its sensitivity in the detection of 
choledocholithiasis (Table 1). Although MRCP has lower special resolution as compared to 
ERCP and therapeutic interventions cannot be performed, it does afford several advantages. 
MRCP is non-invasive, it is less operator dependent, does not use ionizing radiation, and 
allows for visualization of the surrounding tissues when combined with additional MR 
sequences. Major disadvantages of MRCP include increased cost, decreased availability in 
many centers, and it requires a compliant patient to lie still and flat for 30-60 minutes, which 
may be difficult in the setting of acute pancreatitis when patients are in a significant amount 
of pain that may be worsened by a supine position. 
 
Fig. 3. Axial T2 image obtained as a part of the MRCP study demonstrating a stone at the 
distal CBD (arrow). The insertion point of the pancreatic duct into the distal CBD near the 
ampulla is also well visualized (double arrows). Courtesy of Dr. Y. Krakowsky. 
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Fig. 4. Coronal MRCP image in the same patient at Figure 2. Image demonstrates two signal 
voids (arrows) on the background of the high intensity bile in the dilated CBD. The high 
water content intraluminal fluid in the duodenum (D) is also well appreciated.  
4.3.4 Endoscopic retrograde cholangiopancreatography  
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a highly sensitive and specific 
test for assessing the biliary tree and in particular looking for choledocholithiasis (Table 1). 
Using a side-viewing endoscope, the ampulla is identified and cannulated, after which dye 
is injected into the biliary tree. Stones in the common bile duct show up as a filling defect on 
fluoroscopic imaging (Figure 5). During ERCP, endoscopic sphincterotomy (ES) may be 
performed to allow for improved passage of sludge and stones into the duodenum. 
ERCP is the only imaging modality that can also be used therapeutically for removing CBD 
stones and sludge from the common bile duct. However, the major disadvantage to using 
ERCP for the initial diagnosis of a biliary etiology of pancreatitis is the potential for 
exacerbating the acute episode of pancreatitis, and therefore this modality should only be 
used in conjunction with endoscopic sphincterotomy for treatment of impacted stones in 
jaundiced patients, those with signs and symptoms of biliary sepsis or potentially in severe 
ABP. 
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Fig. 5. Fluoroscopic image demonstrating a dilated common bile duct and several common 
bile duct stones seen as filling defects (arrows) at the time of ERCP. 
4.3.5 Endoscopic ultrasound 
Endoscopic ultrasound (EUS) has the highest sensitivity and specificity of any imaging 
modality for the identification of choledocholithiasis (Table 1). It is also a very sensitive 
technique for visualization of pancreatic lesions, pseudocysts, and elucidating pancreatic 
ductal anatomy. Like transabdominal ultrasound, EUS is somewhat operator dependent, 
and access to EUS may be limited in some centers. 
 
Imaging Modality Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
U/S – Gallstones 67-87 93 100 75-80 
U/S – CBD Stones 20-50 83 67 39 
CT 40 92 89 48 
MRCP 80-100 83-98 89 71-100 
ERCP 90-100 92 95 85 
EUS 91-100 85-100 92-98 88-92 
PPV = positive predictive value, NPV = negative predictive value, U/S = ultrasound,  
CBD = common bile duct, CT = computed tomography, MRCP = magnetic resonance 
cholangiopancreatography, ERCP = endoscopic retrograde cholangiopancreatography,  
EUS = endoscopic ultrasound 
Table 1. Test characteristics of the common abdominal imaging modalities 
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5. Assessment of severity 
Determining whether a given case of acute pancreatitis is mild or severe has important 
management and prognostic implications. Those with severe disease (up to 20% of ABP) 
may require admission to a monitored setting as they have morbidity rates of 30-50% and 
mortality rates up to 10-30% despite ICU management.23 Several scoring systems exist, 
including Ranson’s score, which combines 11 clinical data criteria, 5 from the first 24 hours, 
and the remaining 6 at 48 hours (Table 2). Each criterion is assigned 1 point, with scores ≥3 
points representing severe pancreatitis, correlating with a 15% mortality rate, and scores 
more than 6 points carrying a mortality rate upwards of 50%. 
 
 Non-biliary Pancreatitis Biliary Pancreatitis 
On Admission 
 Age >55 >70 
 WBC (mm3) >16,000 >18,000 
 Blood glucose (mg/dl) >200 >220 
 LDH (U/L) >350 >400 
 AST (U/L) >250 >250 
48 Hours 
 Fall in hematocrit (%) >10 >10 
 Rise in BUN (mg/dl) >5 >2 
 Calcium (mg/dl) <8 <8 
 PaO2 (mmHg) <60 <60 
 Base deficit (mEq/L) >4 >5 
 Fluid sequestration (L) >6 >4 
WBC = white blood cell count, LDH = lactate dehydrogenase, AST = aspartate amino- 
transferase, BUN = blood urea nitrogen, PaO2 = arterial partial pressure of oxygen 
Table 2. Ranson’s Criteria of severity for non-biliary and biliary origin of pancreatitis 
A second scoring system validated for use in acute pancreatitis is the Acute Physiology and 
Chronic Health Evaluation (APACHE-II), calculated by adding 12 individual variable 
points, age points, and chronic health points. A score over 8 represents severe pancreatitis, 
and a score below 8 is unlikely to result in a fatal outcome. Although the APACHE-II score 
is cumbersome to calculate, its benefit over Ranson’s score is that it can be repeated over the 
course of illness, whereas Ranson’s score applies only to the initial 48 hours after 
presentation. Another commonly used scoring system is the CT severity index (CTSI), which 
combines CT grade with extent of necrosis to assign a score that reliably correlates with 
morbidity and mortality rates (Table 3). A score of 3 or above represents severe pancreatitis 
with scores 3-6 corresponding to a 35% morbidity and 6% mortality rate, and scores 7-10 
corresponding to morbidity and mortality rates of 92% and 17% respectively.24 
                                                 
23 Howard T. (2008) Management of gallstone pancreatitis, In: Current surgical therapy, 9th ed. Cameron J. 
pp. 477-480. Mosby Elsevier Inc., ISBN: 978-1-4160-3497-1, Philadelphia.  
24 Howard T. (2008) Management of gallstone pancreatitis, In: Current surgical therapy, 9th ed. Cameron J. 
pp. 477-480. Mosby Elsevier Inc., ISBN: 978-1-4160-3497-1, Philadelphia. 
 
Acute Biliary Pancreatitis 
 
25 
CT Grade Points Necrosis (%) Points Total CTSI score 
A 0   0 
B 1 0 0 1 
C 2 <30 2 4 
D 3 30-50 4 7 
E 4 >50 6 10 
Grade A = normal pancreas, B = pancreatic enlargement, C = inflammation of the pancreas and/or 
peripancreatic fat, D = single peripancreatic fluid collection, E = two or more peripancreatic fluid 
collections and/or retroperitoneal air.  
Table 3. CT Severity Index (CTSI).  
6. Management 
Initial management of biliary pancreatitis is mainly directed at supportive care, limiting 
complications, and prevention of infection in the case of pancreatic necrosis. All patient are 
treated with bowel rest, fluid resuscitation, as well as appropriate analgesia and anti-
emetics. Attempts should be made to re-institute oral nutrition, preferably post-pyloric with 
a jejunal nasoenteric feeding tube, however if oral nutrition is to be withheld for more than 
5-7 days on the basis of ongoing fever, tachycardia, nausea, vomiting, severe abdominal 
pain, or leukocytosis, nutritional support with parenteral nutrition should be considered. 
Severe pancreatitis or development of systemic complications should be managed in a 
monitored setting such as the intensive care unit. There may be a role for urgent ERCP in 
select situations with patients who present jaundiced or have evidence of biliary sepsis.  
Unique to a biliary origin of pancreatitis is the requirement for definitive removal of the 
etiologic trigger with cholecystectomy (or ERCP/ES). In severe cases of pancreatitis, 
cholecystectomy should be delayed at least 3 weeks to minimize the risk of infecting the 
pancreatic necrosis at the time of surgery. Also, in patients with evidence of large 
peripancreatic fluid collections, cholecystectomy may be delayed up to 6 weeks to allow for 
the maturation of a pseudocyst that can be drained at the time of surgery. In a study by 
Kelly and Wagner, 165 patients presenting with ABP were randomized to early surgery 
within 48 hours after admission or delayed surgery after 48 hours. The early surgery group 
was associated with higher rates of morbidity and mortality when compared to the late 
group with 83 versus 48% for morbidity and 18 versus 12% for mortality.25 
In the case of mild biliary pancreatitis, practice guidelines from several international 
societies have recommended early cholecystectomy, but the definition of early has not been 
clearly defined and varies between the different guidelines. The International Association of 
Pancreatology has recommended cholecystectomy should be ideally performed prior to 
discharge from the initial hospitalization for pancreatitis.26 The UK Working Party on Acute 
Pancreatitis have recommended that cholecystectomy not be delayed more than two weeks 
                                                 
25 Kelly T, Wagner D. Gallstone pancreatitis: a prospective randomized trial of the timing of surgery. 
Surgery 1988;104:600-605. 
26 Uhl W, Warshaw A, Imrie C, et al. IAP Guidelines for the surgical management of acute pancreatitis. 
Pancreatology 2002;2:565-573. 
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after discharge from the index admission,27 whereas the American Gastroenterological 
Association guidelines allow for 2-4 weeks after discharge.28 Guidelines from the American 
College of Gastroenterology state early cholecystectomy should be performed, but do not 
define a particular target.29 Perhaps the reason for the lack of consensus is due to that 
evidence for these recommendations is largely based on single-center observational studies 
and not large randomized clinical trial data. Studies done to date have demonstrated a risk 
of recurrent biliary pancreatitis from 25 to 63% when cholecystectomy was delayed until 
after discharge from the index hospitalization.30,31,32  
In a retrospective observational study of 281 patients with ABP, Ito et al. demonstrated 
gallstone-related complications in 33% of patients who did not have index cholecystectomy, 
with recurrent ABP found in 13.4% of patients (versus no recurrences in the index 
cholecystectomy group). Of note, almost one third of recurrences occurred within 2 weeks 
after discharge, and half of recurrences occurred within 4 weeks.33 They also looked at 
ERCP with ES as definitive treatment in 42 out of the 119 patients who did not have index 
cholecystectomy. A significant reduction in recurrence of ABP was noted in the ES group 
compared to no intervention group with rates of 4.8 versus 18.2% respectively. However, 
rates of biliary complications such as acute cholecystitis, jaundice, and cholangitis did occur 
with greater frequency in the ES group versus no intervention group. This trend of 
decreased recurrence of ABP but increased biliary complications has been replicated in 
several other studies, and as such, ERCP with ES should not be used in place of 
cholecystectomy for definitive treatment except in the case of patients who are deemed to be 
poor surgical candidates.34 
Other than reduced recurrence rates, several benefits have been identified with early 
cholecystectomy during index hospitalization. A recent randomized prospective study has 
suggested that early cholecystectomy may actually reduce length of index hospitalization. 
This study looked at 50 patients who were admitted with mild ABP, with half randomized 
to the early group where cholecystectomy was performed within 48 hours of admission 
regardless of whether abdominal pain had subsided or laboratory values had normalized. 
They found that hospital length of stay was shorter for the early cholecystectomy group 
with an average of 3.5 days as compared to the control group with an average stay of 5.8 
                                                 
27 UK Working Party on Acute Pancreatitis. UK guidelines for the management of acute pancreatitis. 
Gut 2005;54(Suppl 3):iii1-9. 
28 Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology 
2007;132(5):2022-44. 
29 Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. American Journal of Gastroenterology 
2006;101(10):2379-400. 
30 Uhl W, Muller CA, Krahenbuhl L, Schmid SW, Scholzel S, Buchler MW. Acute gallstone pancreatitis: 
timing of laparoscopic cholecystectomy in mild and severe disease. Surg Endo 1999;13:1070-1076. 
31 Ranson JH. The role of surgery in the management of acute pancreatitis. Ann Surg 1990;211:382-393. 
32 Ranson JH. The timing of biliary surgery in acute pancreatitis. Ann Surg 1979;189:654-663. 
33 Ito K, Ito H, Whang E. Timing of cholecystectomy for biliary pancreatitis: do the data  
support current guidelines? Journal of Gastrointestinal Surgery 2008;12:2164-2170. 
34 Kimura Y, Arata S, Takada T, et al. Gallstone-induced acute pancreatitis. Journal of Hepatobiliary 
Pancreatic Sciences 2010;17:60-69. 
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days (p=0.0016).35 Of note, they did not find any statistically significant differences in the 
need to convert to open cholecystectomy or peri-operative complications between the two 
groups. Previous observational studies have also shown similar results. One of the largest 
series is that of 281 patients, of which 162 underwent cholecystectomy during index 
admission, where length of stay was 5 days for the early group compared to 7 days for the 
post-discharge cholecystectomy group. This difference was exaggerated further by the fact 
that 33% of the post-discharge cholecystectomy group required at least one other pre-
cholecystectomy admission for gallstone-related events, resulting in an average of 3 
additional days in hospital.36 
Despite the decrease in biliary complications, reduced length of stay, and reduced 
readmissions, several studies have shown that most jurisdictions are still not following 
guidelines for early cholecystectomy. One retrospective study looked at 100 consecutive 
patients admitted with ABP and found only 40 had surgery within the index admission, 
with another 38 who were discharged for interval cholecystectomy. Two of the 38 were re-
admitted while waiting for surgery with biliary complications.37 Nguyen et al. explored 
whether lack of resources was a contributing factor to low compliance with guidelines, and 
they demonstrated that the rate of cholecystectomy during index admission increased at 
centers with the highest annual volume of cholecystectomies, decreased at centers with the 
highest volumes of acute pancreatitis, and decreased in centers with the highest volumes of 
ERCP.38 These results confirm the hypothesis that resource intensification may be necessary 
to more consistently meet international guidelines. 
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1. Introduction  
Most of the available English literature on pancreatitis is adult based. The last few decades 
have witnessed increasing interest in childhood pancreatitis and attention to research into 
the subject. Many recent published works have focused on various aspects of pancreatitis. 
The incidence of childhood pancreatitis is a rare event though it appears to be increasing. 
Despite its rarity, pancreatitis in children deserves special attention because of the 
significant morbidity and mortality associated with it. The management of childhood 
pancreatitis has also witnessed remarkable development in the last few decades. The 
improvement in the imaging resolutions, biochemical tests, endoscopic procedures and the 
intensive care facilities have resulted in better outcome. 
This chapter aims at providing an up-to-date review of childhood pancreatitis. It includes 
the aspects of aetiological factors, pathophysiology, classification, typical and atypical 
clinical presentation with abdominal and extra-abdominal manifestations of the disease and 
its complications, applicability of severity scores, the diagnostic and prognostic 
investigations, various methods of medical and surgical treatment - with indications thereof 
- touching on the pros and cons of the different methods, and the overall prognosis. 
2. Aetiology   
2.1 Acute pancreatitis  
The causes of acute pancreatitis in children are diverse (Table 1) and unlike in the adults 
where the majority of the cases are due to alcoholism or gallstone disease, most of the cases 
in children are due to pancreaticobiliary tract anomalies, biliary tract stones, trauma, drugs 
and a plethora of systemic diseases. In a considerable proportion of up to 25% of the 
patients, no aetiological factor is identified and is therefore labeled as idiopathic (Haddock 
et al., 1994; Uretsky et al., 1999; Mehta & Gittes, 2005; Hebra et al, 2009; Werlin, 2003).  
2.1.1 Pancreaticobiliary anomalies 
Pancreaticobiliary malunion (PBMU) accounts for approximately 6-33% of cases of 
pancreatitis in children. PBMU is used synonymously with common pancreaticobiliary 
channel, anomalous pancreaticobiliary channel, pancreaticobiliary maljunction, anomalous 
pancreaticobiliary ductal union or long common pancreaticobiliary channel, with or without 
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a choledochal cyst or common bile duct (CBD) dilatation. PBMU is complicated by bile 
reflux into the pancreatic duct predisposing to pancreatitis. Common channel and 
pancreatic duct obstruction by protein plugs, biliary stones or sludge may result in 
pancreatitis or jaundice. Presence of a choledochal cyst may produce pancreatitis by direct 
mechanical pancreatic duct compression (Miyano, 2006).   
Pancreas divisum is a persistence of the developmental pancreatic ductal system due to 
failure of fusion of the dorsal (Wirsung) and the ventral (Santorini) ducts. As a result, the 
exocrine drainage of the pancreatic body and tail is impaired due to the narrow minor duct 
and its papilla. The resultant flow impediment may cause recurrent episodes of acute 
pancreatitis. The anomaly is encountered in approximately 4-11% of patients and, as such, is 
one of the most common congenital anomalies of the pancreas (Miyano, 200; Mehta & Gittes, 
2005). Annular pancreas was reported to cause recurrent acute pancreatitis in children 
(Hwang et al 2010, Ohno & Kanematsu, 2008).  
2.1.2 Biliary stone disease 
Choledocho- or cholcystolithiasis are uncommon in children; however, when they exist 
they cause pancreatitis secondary to transient pancreatic duct obstruction. Biliary stones 
may result from haemolytic disorders such as hereditary spherocytosis, B thalassemia and 
sickle cell disease. Occasionally, biliary stones may complicate obesity or cholestasis due 
to biliary dyskinesia or prolonged use of total parenteral nutrition (TPN) (Mehta & Gittes 
2005). 
2.1.3 Trauma 
Trauma is a major cause of pancreatitis in children. By virtue of the position of the pancreas 
against the lumbar spine, accidents or violent acts leading to blunt abdominal trauma in 
children and adolescents - typically as in bicycle handle bar injuries- may cause acute 
pancreatitis. The severity of the trauma influences the onset of symptoms, severity of clinical 
manifestations and course of the disease. In cases of ambiguity of the history, child abuse 
must be taken into consideration. Iatrogenic pancreatitis may be experienced following 
pancreatic injury that occur during the course of abdominal surgery or may complicate 
endoscopic retrograde cholangiopancreatography ERCP (Miyano, 2006; Mehta & Gittes, 
2005; Uretsky et al., 1999; Ibrahim et al., 2011).       
2.1.4 Systemic infections 
Infection with viruses including Mumps, Rubella, Coxsackie B and Rotavirus can be 
incriminated in the aetiology of pancreatitis. Also, generalised bacterial sepsis may cause 
pancreatitis (Mehta & Gittes, 2005). 
2.1.5 Systemic diseases and metabolic abnormalities 
Including hypercalcaemia, hyperlipidaemia, hypertriglyceridaemia, Reye syndrome and 
Kawasaki’s disease, may be associated with cases of acute pancreatitis. Cystic fibrosis with 
inspissation of pancreatic secretions within the pancreatic ducts may cause recurrent acute 
pancreatitis (Uretsky et al., 1999; Mehta & Gittes, 2005).  
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2.1.6 Drugs 
Use of a wide range of drugs, including corticosteroids, HIV therapeutic agents, 
immunosuppressants and cytotoxic drugs, has been associated with incidents of acute 
pancreatitis accounting for 8-25% of cases (Miyano, 2006).  
Pancreatitis may be induced by the administration of corticosteroids and valproic acid. 
Perhaps young children are more commonly affected when valproic acid is incriminated. 
Bai found that there was a higher frequency of valproic acid-associated pancreatitis in 
children younger than 11 years of age (Bai et al., 2011).  
Didanosine (Nucleoside analogue) and Zalcitabine used in the treatment of human 
immunodeficiency viral (HIV) infection were incriminated as causative agents of acute 
pancreatitis (Ridout & Lakhoo, 2011). Butler et al found that pancreatitis developed in 7% of 
95 children with HIV who received the reverse transcriptase inhibitor Dideoxyinosine (ddI) 
at 60 to 540mg/m2 per day for a mean of 56 weeks. They also noted that pancreatitis 
occurred only in patients who received the highest dose levels and resolved in all of the 
affected children upon withdrawal of the drug (Butler et al, 1993).  
Immunosuppressive drugs such as Azathioprine and Mercaptopurine were incriminated as 
causative factors in approximately 5% of cases. The causative effect of Immunosuppressants 
can be reversed by early use of high doses of the synthetic protease inhibitor gabexate 
mesylate (Miyano, 2006). 
The use of the cytotoxic drug L asparaginase in leukaemia regimens was associated with a 
marked increase in acute pancreatitis in childhood oncology clinics (Nydegger et al., 2006). 
Ifosfamide used in the treatment of paediatric solid tumours is known to have serious 
adverse effects, including acute pancreatitis as a rare complication of therapy (Garg et al., 
2010). Tetracycline, erythromycin, metronidazole and nitrofurantoin are among other drugs 
reported to induce acute pancreatitis (Kuhls, 2004). 
Alcohol abuse is an uncommon cause of acute pancreatitis in children, however, it was 
reported to be implicated in older children and adolescents (Camp et al., 1994; Uretsky et al., 
1999). 
2.1.7 Miscellaneous 
Acute pancreatitis can be caused by hypovolaemia. The disease was related to 
hypovolaemia in one third (33%) of 21 children following cardiopulmonary bypass or severe 
GI bleeding (Berney, 1996).  
Liver transplantation was recently reported as a possible cause for acute pancreatitis, with 
an incidence of 1.9% and a mortality rate of 43% (Miyano, 2006). 
Early antenatal destruction of pancreas, Shwachman Diamond syndrome, is an autosomal 
recessive disorder recently mapped to the centromeic region of chromosome 7. Children 
suffering from this condition have pancreatic insufficiency at birth, generally with very low 
serum trypsinogen levels, indicative of nearly total exocrine pancreatic atrophy by birth 
(Miyano, 2006). Hereditary pancreatitis may present with acute recurrent pancreatitis 
(Aamarapurkar, 2001). 
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Congenital anomalies of the biliary system: Choledochal cyst 
                                                                           Pancreatico-Biliary Malunion (PBMU) 
                                                                           Pancreas divisum  
Biliary stone disease: Cholelithiasis  
                                      Choledocholithisis 
Trauma: Blunt 
                Iatrogenic: Surgery, ERCP 
Infections: Viral and others:Mumps 
                                                 Rubella 
                                                 Coxsakie B virus 
                                                 Rota virus 
                                                 Generalised bacterial sepsis 
Chronic inflammatory diseases 
Systemic diseases:Cystic fibrosis,  
                              Reye syndrome,  
                              Kawasaki’s disease,                   
                              Hyperlipidaemia,  
                              Hypercalcaemia  
                              Hypertriglyceridaemia 
Drugs: Corticosteroids 
            Valproic acid  
 
            Anti HIV drugs: 
                             Didanosine (Nucleoside analogue)  
                             Zalcitabine  
 
            Immunosuppressive drugs  
                             Azathioprine  
                             Mecaptopurine 
            Cytotoxic drugs: L-Asparaginase 
                                         Ifofamide  
                                         Tetracycline, Pentamidine, 
                                         Sulphonamides, Metronidazole, Nitrofurantoin, 
                                         Ceftriaxone, Furosemide, 
                                         Rifampin, Interferon alpha-2b, Erythromycin 
  
Miscellaneous: Hypovolaemia 
                           Liver transplantation  
                           Early antenatal destruction of pancreas,  
                           Shwachman Diamond syndrome 
                           Hereditary pancreatitis 
                           Hyperactive sphincter of Oddi  
                           Extracorporeal Shock Wave Lithotripsy (ESWL) 
 
Idiopathic 
Table 1. Aetiological factors of acute pancreatitis in children   
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2.2 Chronic pancreatitis  
In children, the most common causes of chronic and chronic relapsing pancreatitis are 
trauma, hereditary, systemic disease and malformations of the pancreaticobiliary ductal 
system such as pancreas divisum and annular pancreas, and choledocholithiasis.  
Chronic pancreatitis could either be calcifying (commoner) or obstructive (less common).  
2.2.1 Calcifying chronic pancreatitis 
The most common cause of calcifying pancreatitis is hereditary or familial pancreatitis. 
Comfort and Steinberg gave the first description of hereditary pancreatitis in 1952 (Comfort 
& Steinberg, 1952). Since then a number of cases of hereditary pancreatitis have been 
reported. The mode of inheritance strongly suggested was an autosomal dominant trait 
(Aamarapurkar, 2001). The gene mutations identified in early-onset idiopathic chronic 
pancreatitis (ICP) are the serine protease inhibitor, Kazal type 1 (SPINK1) gene mutations, 
and the cystic fibrosis transmembrane regulator (CFTR) gene mutations. Recently, Cationic 
trypsinogen protease serine 1 PRSS1 gene mutations were detected in "idiopathic 
pancreatitis" and SPINK1 gene mutations in idiopathic and tropical pancreatitis. It is also 
very likely that SPINK1 gene mutations are important in tropical calcific pancreatitis (TCP) 
(see below) (DiMagno M & E., 2003). As many as 10% of patients with "idiopathic 
pancreatitis" may have hereditary pancreatitis if finding a PRSS1 gene mutation without a 
family history is considered an acceptable diagnostic criterion (DiMagno M & E, 2003). 
The association of CFTR gene mutations and chronic pancreatitis is well known. Even in 
classic cystic fibrosis (CF) with pancreatic functional preservation, the prevalence of 
pancreatitis may be 17% or higher because such patients have recurrent, severe abdominal 
pain that may be due to unrecognized pancreatitis (DiMagno M & E., 2003). 
Gene sequencing of the 7q35 chromosome region revealed a strong association of the 
(p.R122 H) mutation of the PRSS1 gene encoding cationic trypsinogen with hereditary 
pancreatitis (Teich et al., 2006). Developments in genetics have shown that in the majority of 
patients, hereditary pancreatitis is usually associated with expression of one of two specific 
mutations in the cationic trypsinogen PRSS1 gene, specifically R122H or N29I. Further 
sequencing of the PRSS1 gene in the proband of families without these common mutations 
revealed R122C and N29T mutations in independent families that segregated with the 
disease in an autosomal dominant fashion. The R122C mutation eliminates the arginine 
autolysis site as with R122H mutations. The N29T mutation may also enhance 
intrapancreatic trypsin activity as has been demonstrated in vitro (Pfutzer et al., 2002). 
Further mutations of this gene were discovered in patients with hereditary or idiopathic 
chronic pancreatitis. In vitro the mutations increase autocatalytic conversion of trypsinogen 
to active trypsin and thus probably cause premature intrapancreatic trypsinogen activation 
in vivo. The clinical presentation is highly variable, but most affected mutation carriers have 
relatively mild disease (Teich et al, 2006).  
Tropical calcific pancreatitis is a type of pancreatitis seen exclusively in tropics. Though the 
exact aetiology of tropical chronic pancreatitis is obscure, malnutrition with protein 
deficiency, cassava toxicity, impaired immune response, viral infection and genetic 
susceptibility have been considered as various factors in the aetiopathogenesis 
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(Aamarapurkar, 2001). It is also very likely that SPINK1 gene mutations are important in 
tropical calcific pancreatitis (TCP), a disease associated with malnutrition and cassava 
consumption in Afro-Asian countries that is characterized by onset at an early age and 
variable familial clustering (DiMagno M & E., 2003).. 
2.2.2 Obstructive chronic pancreatitis 
Encompasses the other causes of chronic pancreatitis in children which include congenital 
anomalies of the pancreaticobiliary duct system such as pancreas divisum, 
pancreaticobiliary malunion and annular pancreas. Trauma is also a major cause leading to 
chronic pancreatitis, particularly when fibrosis complicates pancreatic duct disruption, 
resulting in pancreatic duct stricture and, consequently, obstructive chronic pancreatitis. 
Other aetilogical factors include biliary disease, systemic inflammatory and metabolic 
diseases (table 2). Hypertriglyceridaemia and hyper parathyroidism, though rare, were 
reported to cause chronic pancreatitis in children (Aamarapurkar, 2001).  
Idiopathic fibrosing pancreatitis is a rare condition that affects children and adolescents. It 
can be a cause of recurrent abdominal pain and obstructive jaundice (Harb & Naon, 2005).  
Biliary disease  
                      Congenital anomalies of the biliary system:  Pancreas divisum  
                                                                                                  PBMU  
                                                                                                  Choledochal cyst 
                                                                                              
                       Biliary stone disease:   Cholelithiasis  
                                                              Choledocholithisis 
 
Hereditary pancreatitis 
Systemic and metabolic diseases:       Hyperlipoproteinaemia 
                                                               Hyperparathyroidism   
                                                               Hypercalcaemia 
                                                               Hypertriglycaedaemia 
                                                               Cystic fibrosis 
                                                               Inborn errors of metabolism  
                                                               Systemic lupus erythematosus 
                                                               Haemophilia 
                                                               Shwachman Diamond Syndrome  
Infection 
 
Chronic inflammatory diseases 
                                                            Crohn’s disease 
                                                            Ulcerative colitis                                                             
                                                            Chronic fibrosing pancreatitis 
                                                            Juvenile tropical pancreatitis 
                                                            Tropical calcific pancreatitis  
                                                            Idiopathic chronic pancreatitis 
                                                            Idiopathic fibrosing pancreatitis   
Table 2. Aetiological factors of chronic pancreatitis in children:  
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3. Pathophysiology 
The pancreas matures after birth and by 2 years of age it is functioning in the same way as 
an adult pancreas. Due to its excellent reserve, the immature pancreas does not seem to 
affect the healthy children significantly, however, it can have a major impact on very ill or 
malnourished children (Durie, 2011).  
3.1 Acute pancreatitis 
3.1.1 Acinar cell injury  
Acute pancreatitis originates from acinar cell injury due to factors such as trauma, drugs, 
metabolic disorders and infection which lead to premature intraductal activation of 
proenzymes, specifically trypsinogen to trypsin. The resultant autodigestion of the 
pancreatic tissue and accompanying aggressive immune response cause the pathological 
process of pancreatitis and subsequent complications (Uretsky et al.,1999; Nydegger et al., 
2006) 
3.1.2 Proenzyme activation 
Inappropriate, premature proenzyme activation in the pancreas, and consequently 
autodigestion of pancreatic tissue, may occur due to either ductal flow obstruction 
(structural) with extravasation of enzyme rich ductal fluid into the parenchyma of the 
pancreas, reflux of duodenal enterokinase into the pancreas or failure in feed-back control 
(hereditary).  
3.1.3 Inflammatory mediators 
Once activated, elastase, phospholipase A2 and superoxide free radicles in addition to 
release from the pancreas of other active mediators including cytokines such as tumour 
necrosis factor-alpha; and vasoactive substances such as histamines, prostaglandins, kinins 
and kallikreins, are thought to play an important role as mediators of tissue damage (Weber 
& Adler, 2003; Mehta & Gittes, 2005).  
Along with premature activation of digestive enzymes, disturbances of intracellular 
calcium, and activation of transcription factors such as NF-κB characterize the initial phase 
of acute pancreatitis. Depending on the severity of pancreatic injury, the impact may not be 
confined to the pancreas. Pancreatic enzymes can cause damage at distant sites either by 
vascular dissemination or by the release of proinflammatory mediators and the recruitment 
of immune cells which may expand the local disturbances to a systemic inflammatory 
response associated with diffuse tissue damage throughout the body and failure of distant 
organs such as lungs or kidneys, a form of multiple system organ failure (MSOF). Patients 
with severe acute pancreatitis are, therefore, likely to have a high incidence of refractory 
sepsis and death (Weber & Adler, 2003; Mehta & Gittes, 2005). 
3.1.4 Role of cytokines 
Cytokines themselves do not induce pancreatitis but rather mediate the progression of 
pancreatitis. Cellular immune responses are the major determinants of severity. The most 
important step for the development of severe pancreatitis appears to be the activation of the 
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T helper cell type 1 (Th1) response. Pancreatic production of proinflammatory cytokines 
such as TNF-alpha, interleukin IL-1B, IL-6 and IL-8 modulates local injury, systemic 
inflammatory response and distant organ failure. This modulation, coupled with pancreatic 
necrosis, determine the outcome from acute pancreatitis. The TNFa, IL1B, IL6 & IL8 released 
from granulocytes and macrophages also reach the liver through the portosystemic 
circulation and act on Kupffer cells that produce more cytokines and acute phase proteins. 
Other factors determining the severity of pancreatitis include free radicles, pancreatic 
glutathione, ischaemia, chemokines and neurokines. Because the onset of cytokines action 
follows immediately after the onset of pancreatitis and peaks after 36-48 hours, cytokine 
antagonists therapy represent a potential therapeutic target and therefore is of intense 
interest (Nydegger et al, 2006; Berney et al, 1999).   
3.2 Chronic pancreatitis 
Chronic pancreatitis is an inflammatory disorder that results in anatomical changes that 
include chronic inflammatory cell infiltration and gland fibrosis, with loss of exocrine 
function (malabsorption) and endocrine function (diabetes mellitus). In susceptible children, 
repeated episodes of acute inflammation may lead to chronic pancreatitis, the so called 
necrosis-fibrosis hypothesis of Comfort et al. and, accordingly, it is likely that there is 
significant overlap in the underlying pathophysiology of these conditions (Nydegger et al, 
2006).  
Whitcomb has proposed a sentinel acute pancreatitis event SAPE which acts as a priori step 
toward the development of chronic pancreatitis. The acute injury must be sufficiently severe 
to attract monocytes and to cause infiltration, differentiation and proliferation of pancreatic 
stellate cells. For fibrosis to occur there must be recurrent acinar injury resulting in 
chemocytokine release that then stimulates stellate cells (Whitcomb 1999, 2004).   
Genetics: Cationic trypsinogen gene Protease Serine 1 (PRSS1) gene accounts for 65% of 
trypsinogen and is one of the most abundant molecules produced by acinar cells. In 
chronic pancreatitis, it has been suggested that mutations of the cationic trypsinogen 
PRSS1 gene lead to an alteration in the trypsin recognition site that prevents deactivation 
of trypsin within the pancreas. Consequently, autodigestion occurs resulting in 
pancreatitis. The genetic mutations responsible for hereditary pancreatitis have been 
isolated to chromosome 7q35. The most common hereditary pancreatitis causing 
mutations in PRSS1 gene are R122H and N29I (Pfutzeret al., 2002; Teich et al, 2006; 
Nydegger et al., 2006). These two mutations in the cationic trypsinogen gene appeared to 
allow prematurely activated trypsinogen to cause acinar cell auto-digestion and acute 
pancreatitis. Chronic pancreatitis in these patients certainly arises from recurrent acute 
pancreatitis (Aamarapurkar, 2001). Several other mutations in the PRSS1 gene have been 
identified including mutations in codons 16, 22, 23 and 122. This discovery of genetic 
mutations associated with hereditary pancreatitis support the hypothesis that 
intrapancreatic activation of pancreatic zymogens is crucial to the pathogenesis of acute 
pancreatitis. The mutant trypsin in hereditary pancreatitis is resistant to lysis, remains 
active and causes auto-digestion of the pancreas and episodes of acute pancreatitis. 
Median age at onset of disease is 11 years in patients with the N29I mutation and 10 years 
in those with the R122H. Approximately half of patients with hereditary pancreatitis 
develop chronic pancreatitis (Nydegger et al., 2006). 
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Trypsin can exert a negative feed-back, self inactivation to protect the pancreas from auto-
digestion. The serine protease inhibitor SPINK1 produces a similar pancreas sparing effect by 
inhibition of prematurely activated trypsinogen. This gene may have a role in tropical 
pancreatitis, an idiopathic form of pancreatitis seen in southern Asia and parts of Africa and 
probably related to malnutrition, together with cassava intake. SPINK1 mutations were also 
shown to be associated with a subtype of tropical pancreatitis, fibrocalculous pancreatic 
diabetes. SPINK1 mutations alone probably do not cause pancreatitis but act as disease 
modifier. The SPINK1 mutations are relatively common, being present in approximately 2% of 
the general population. However, the frequency of SPINK1 mutations in populations with 
idiopathic chronic pancreatitis is markedly increased, approximately 25%, an evidence that an 
association exists between the SPINK1 mutations and pancreatitis (Nydegger et al., 2006).  
Cystic fibrosis transmembrane regulator (CFTR): An association between idiopathic chronic 
pancreatitis and CFTR gene mutations was reported. Several mild CFTR mutations were 
found to be associated with idiopathic pancreatitis. Available data suggest that patients with 
two severe mutations have classical cystic fibrosis (CF), those with a single mutation are 
carriers and those who are compound heterozygotes with one severe and one mild mutation 
are at risk of developing pancreatitis (Ridout & Lakhoo, 2011; Nydegger, 2006).  
4. Classification  
Pancreatitis can be classified as: 
- Acute pancreatitis: Simple 
                                       Necrotizing 
                                       Haemorrhagic 
- Acute recurrent pancreatitis  
- Chronic pancreatitis: Calcific or Obstructive 
- Chronic relapsing pancreatitis 
5. Clinical presentation 
5.1 Acute pancreatitis 
Diagnosis is based on symptoms and signs accompanied by a three fold increase in either 
amylase or lipase. Presentation is variable in children and symptoms may range from mild 
abdominal pain to severe systemic involvement, metabolic disturbances and shock. 
Abdominal pain, anorexia, nausea and vomiting are the most frequent symptoms (Hebra 
et al., 2009; Mehta & Gittes, 2005). The pain can be of a sudden or insidious onset with slow 
and gradual progression with increasing intensity. Although the pain is usually epigastric in 
origin, right and left upper abdominal quadrants are infrequently involved. Central and 
lower abdominal pain may also be encountered (Uretsky et al, 1999). The typical radiation of 
pain to the back observed in adults is not a common feature in children. Food intake 
exacerbates pain and vomiting (Haddock et al, 1994) while drawing the knees up to the 
chest relieves the pain (Uretsky et al, 1999). Extracellular fluid losses can be enormous 
(Mehta & Gittes, 2005).  
On examination, the child may be ill, irritable, quiet or a combination of these. Movement 
aggravates the abdominal pain, therefore children typically tend to assume a still, supine 
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position, or they may lie on their side or doubled up with the hips and knees flexed (Hebra 
et al, 2009). Tachycardia, mild fever, hypotension, jaundice and abdominal signs such as 
diffuse tenderness, rebound tenderness, guarding, distension and decreased or absent bowel 
sounds may be elicited (Nydegger et al., 2006, Hebra et al., 2009, Ibrahim & Gabr, 2011). 
Parotid enlargement may be observed occasionally (Haddock et al, 1994). In severe cases of 
necrotizing or haemorrhagic pancreatitis, haemorrhage may dissect from around the 
pancreas along the abdominal wall tissue planes appearing as discoloration either in the 
flanks (Grey Turner’s sign) or at the umbilicus (Cullen’s sign). These echymoses may take 1-
2 days to develop (Mehta & Gittes, 2005). These signs of haemorrhagic pancreatitis are 
seldom present in children (Nydegger et al, 2006). Evidence of pleural effusion or dyspnoea, 
with or without acute respiratory distress syndrome, may be found on examination of the 
chest (Uretsky et al, 1999, Ali et al, 2010). Recurrent acute pancreatitis is seen in 10% of 
children after the initial acute episode. It is more likely in children with structural 
anomalies, idiopathic and familial causes (Nydegger et al, 2006).  
5.2 Chronic pancreatitis     
Unlike acute pancreatitis in which complete reversal of the inflammatory changes occurs 
upon resolution of the episodes, chronic pancreatitis is characterised by permanent 
structural changes in the pancreas associated with varying degrees of pancreatic 
dysfunction and, accordingly, increased risk of developing pancreatic insufficiency, 
adenocarcinoma, and pancreatic pseudocysts. Patients with this disease typically present 
with chronic or recurrent upper abdominal pain with significant morbidity. The pain is most 
commonly described as epigastric, deep or radiating towards the back and accompanied by 
nausea and vomiting. It is often relieved by sitting and leaning forward and may increase 
following meal. It may commence as intermittent attacks with periods of well-being and 
then become more continuous, others may have little or no pain. Common other associated 
clinical features include weight loss and diabetes mellitus. Paediatric data on prevalence and 
incidence of exocrine and endocrine failure are limited, however, steatorrhea and weight 
loss will not occur until pancreatic exocrine function has been reduced to around 2% of the 
normal output. Because insulin and glucagons secreting cells are destroyed in chronic 
pancreatitis, the diabetes in these patients can be particularly refractory to treat (Nydegger 
et al, 2006; Mehta & Gittes 2005).  
Tropical calcific pancreatitis is characeritized by recurrent episodes of abdominal pain, 
severe malnutrition, and ketosis resistant diabetes. Ten per cent of patients with tropical 
calcific pancreatitis develop pancreatic cancer. Almost one third of patients with tropical 
calcific pancreatitis get recurrent episodes of pain in childhood and may develop diabetes in 
childhood (Aamarapurkar, 2001).  
6. Investigations  
6.1 Acute pancreatitis   
Serum amylase levels are usually, but not invariably elevated. Normal levels do not exclude 
the diagnosis of acute pancreatitis. Also, the degree of serum amylase elevation does not 
correlate with severity of the disease. Goh found that serum amylase levels were elevated in 
all the 11 patients in his study. Their serum amylase levels ranged from 190 to 1370 U/L 
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(Median 512.5). One third of them had amylase levels lower than 4 times the upper limit of 
normal, ie. 440 U/L. (Goh et al., 2003). Amplified elevations of serum amylase are 
suggestive of development of a pseudocyst or other complications of pancreatitis. 
Amylase is excreted in the urine when the level of hyperamylasemia exceeds the tubular 
reabsorptive capacity. Therefore, moderately elevated levels of serum amylase may not be 
detectable in the urine. It is important to note that other conditions may cause 
hyperamylasemia or hyperamylasuria. These include salivary inflammation or trauma, 
intestinal disease including perforation, ischaemia, necrosis or inflammation, renal failure 
and macroamylasemia (Mehta & Gittes, 2005). To differentiate the likely underlying cause, a 
three fold, or more, elevation of serum amylase concentration is strongly in favour of the 
diagnosis of acute pancreatitis. The half life of amylase is approximately 10 hours and the 
value frequently becomes normal after 2-5 days. 
Initial serum amylase level does not correlate with the severity of pancreatic injury. 
Schmittenbecher noted a longer lasting elevation of serum amylase in patients with 
traumatic pancreatitis (Schmittenbecher et al., 1996). 
Elevated level of pleural effusion fluid-amylase in children with respiratory symptoms 
secondary to pancreatitis is a useful diagnostic test (Segura, 2004). Thoracic pancreatic 
pseudocyst as a complication of traumatic pancreatitis has been reported (Ali et al, 2010).  
Lipase: Unlike amylase, lipase is produced only in the pancreas and its measurement is 
particularly helpful for distinguishing pancreatic trauma from salivary trauma. In children 
with acute pancreatitis, the serum lipase level is usually elevated for many days. Therefore, 
lipase levels have been proposed as a more specific test of pancreatic tissue damage. An 
important caveat to note here is that the degree of lipase elevation has little correlation with 
the extent of the pancreatitis and that intestinal perforation does cause an elevation of lipase 
through reabsorption via the peritoneum. Urinary lipase levels may remain elevated for a 
few days longer than serum levels (Mehta & Gittes, 2005).  
Calcium and Glucose: Hypocalcaemia was reported in 10-15% of children with pancreatitis 
(Goh et al., 2003; Uretsky et al., 1999) while hypoglycaemia was noted in 25% of cases 
during the acute attack (Uretsky et al., 1999).  
The blood glucose level measurement is a key investigation when chronic pancreatitis is 
suspected. Persistently elevated blood glucose level indicates significant pancreatic 
endocrine-reserve impairment.  
Haematological: Elevated total white blood cell counts (with increased band counts) are 
usually present (Goh et al., 2003). An increased haematocrit secondary to 
haemoconcentration that occurs after volume depletion may be found.  
Genetics: The majority of pancreatic diseases are associated with genetic polymorphism. 
Early use of genetic testing is likely to play a critical role in early diagnosis and prognosis of 
pancreatic diseases (Whitcomb, 2004).  
The levels of cationic trypsinogen gene and SPINK1 mutations are said to be a more 
sensitive early marker of pancreatic inflammation (Uretsky et al., 1999).  
Gene testing for CFTR gene is helpful in the diagnosis of pancreatitis in cases thought to be 
related to cystic fibrosis. 
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Imaging: plain abdominal radiographs may reveal obscured psoas margins, a sentinel loop 
of a dilated duodenum and a gasless segment of mid transverse colon. The latter is caused 
by local spasm with proximal dilatation known as colon cut-off sign due to inflammation of 
the adjacent pancreas. Pancreatic calcifications suggest chronic pancreatitis. In cases of 
tropical calcific pancreatitis, dense calcification is seen in pancreatic parenchyma (Mehta & 
Gittes, 2005).  
Plain chest x rays should be performed in all patients with acute pancreatitis to look for 
evidence of pleural effusion and pulmonary oedema (Mehta & Gittes, 2005). One fifth of 
children show evidence of pleural effusion (Uretsky et al., 1999).  
Ultrasound Scan (US): is one of the most useful imaging tools in childhood pancreatitis 
(Haddock et al., 1994). Abdominal US may show pancreatic swelling or a decrease in 
pancreatic echogenicity due to oedema or peri-pancreatic fluid collection. These findings per 
se are not sufficient to coin the diagnosis of acute pancreatitis or estimate its severity. The 
main use of US is to demonstrate gallstones as a possible cause of pancreatitis and to follow 
up the treatment by serial observation of improvement in oedema or peripancreatic fluid 
collection (Mehta & Gittes, 2005).  
Abdomominal CT scan: provides images of the pancreas superior to those obtained by US 
scan in as far as determining the size of the pancreas, the degree of oedema and the presence 
of fluid collection is concerned. Due to the much better resolution, the size and anatomy of 
the pancreatic duct can often be delineated much more accurately with CT than with US. 
The presence of complications such as pancreatic abscess or pseudocyst may also be 
determined. Dynamic CT pancreatography, using an intravenous bolus of contrast with 
rapid scanning in fine cuts through the pancreas, has the advantage of differentiating 
perfused from non-perfused (necrotic) pancreas. It has the ability to provide a precise 
assessment of the percentage of and distribution of pancreatic perfusion. Furthermore, CT 
scan can be used for interventional procedures for diagnosis or drainage of fluid collections 
(Mehta & Gittes, 2005).  
 
Fig. 1. An abdominal CT scan of a 10 year old child with blunt abdominal trauma. Note the 
radiolucency at the neck of the pancreas indicating parenchymal disruption  
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ERCP: although the literature suggest that the complication rates with ERCP are higher in 
children than in adults, ERCP is being used increasingly in children. ERCP can provide 
detailed information on the pancreatic duct. It is particularly helpful for its diagnostic and 
therapeutic roles in the management of children with acute obstructive biliary pancreatitis. 
ERCP and pancreatic duct stenting can also be beneficial in trauma patients in whom a 
ductal injury is suspected or a pancreatic pseudocyst has formed (Mehta & Gittes, 2005, Ali 
et al., 2010). In cases of pancreas divisum, however, cannulation of the minor papilla is 
possible in less than half of the cases because of its small size and the angle at which it meets 
the duodenum (Miyano, 2006).   
MRCP: the magnetic resonance cholangio-pancreatography is a useful, non invasive 
diagnostic tool for evaluating the biliary tree and the pancreatic duct. This technique 
precludes the risk of complications encountered with ERCP. The study is cheaper and 
employs no radiation or administration of contrast media which is routinely performed with 
ERCP. MRCP is not without disadvantages. As an essentially diagnostic study, it does not 
facilitate therapeutic intervention and it has a tendency to overestimate the stenosis of the 
main pancreatic duct in patients with pancreatitis. Despite the recognized disadvantages, 
MRCP is now the initial imaging study of choice in the evaluation of pancreatic ductal 
anatomy in children with unexplained or recurrent pancreatitis (Mehta & Gittes, 2005).  
6.2 Chronic pancreatitis   
In children with suspected chronic pancreatitis the following investigations are suggested:  
- Sweat test and gene testing for CFTR  
- Testing for cationic trypsinogen and SPINK1 mutations  
- Assessment for autoimmune causes  
- Biochemical investigations for diabetes mellitus, lipase, electrolytes and stools for 
evidence of malabsorption 
- Imaging to exclude structural (congenital or acquired) abnormalities. In children with 
chronic pancreatitis, changes on imaging studies are usually encountered  
- Pancreatic biopsy, considered to be a gold standard for diagnosis in adults, is rarely if 
ever required in children (Nydegger et al., 2006).  
7. Severity scores  
Many scoring systems were used to assess the severity of acute pancreatitis in adults, 
however, there is no widely adopted robust severity scoring system that is specifically 
targeting children (Nydegger et al., 2006). The applicability of adult scoring systems such as 
Ranson's and the Imrie prognostic criteria, the Glasgow and modified Glasgow scores and 
the Acute Physiology and Chronic Health Evaluation (APACHE) II score have not been 
validated in children. An alternative severity scoring system has been suggested by other 
researchers. This group has compared a scoring system designed specifically to paediatric 
patients with selected adult scoring systems (DeBanto et al., 2002). This system compares 
eight variables to predict severe outcome and mortality during an episode of acute 
pancreatitis. An episode of pancreatitis is considered to be severe if the patient died, had 
surgery on the pancreas, developed a pseudocyst or abscess or infected necrosis, or met 
criteria for multiple organ dysfunction. The admission criteria considered are: 
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- Age <7 yrs  
- Weight <23Kg 
- WBC (Admission) >18.5/cmm 
- LDH (Admission) >2000 IU/L 
- 48hr trough albumin <2.6mg/dl 
- 48hr trough calcium <8.3mg/dl 
- 48hr fluid sequestration >75ml/kg/48hrs 
- 48hr rise in blood urea nitrogen >5mg/dl 
Each factor is allocated a score of 1 point and higher total scores are associated with an 
increased chance of severe pancreatitis and mortality.  
Scores of 5-7 points showed 80% severe outcome and 10% mortality  
                2-4 points showed 38.5 severe outcome and 5.8% mortality   
                0-2 points showed 8.6% severe outcome and 1.4% mortality 
When the cutoff for predicting severe outcome was set at 3 criteria, this new system had a 
sensitivity of 70%, a –ve predictive value of 91%, a specificity of 79% and a +ve predictive 
value of 45%. The system probably performs better in identifying those patients who are at 
risk for severe pancreatitis than the existing systems used in adults (DeBanto et al., 2002). 
When compared with the Ranson’s and Glasgow systems used in adult patients with 
pancreatitis, this system showed a better sensitivity (70%) versus Ranson (30%) and 
Glasgow (35%) scores and a better negative predictive value (91% vs 85% and 85% 
respectively) (DeBanto et al., 2002). In trauma, the grade of pancreatic injury was an 
independent predictor of both pancreatic complications (Kao et al., 2003).  
Some researchers associated the severity of pancreatitis to the aeiology. Haddock found that 
severe pancreatitis was most commonly associated with systemic disease (22 of 51; 43.1%) 
and trauma (13 of 51; 25.4%), beside associated factors such as significantly higher body 
weight, higher frequency of dyspnoea and pleural effusion, and lower serum calcium and 
albumin levels (Haddock et al., 1994; Chang et al., 2011). 
Many classification systems were adopted for grading of disease severity based on various 
factors. Examples of these classification systems include: 
- Marseille classification which relies on grading of biopsy specimens. 
- Cambridge classification with more emphasis on imaging to provide grading and 
severity scoring, Computed tomography (CT) was more accurate than ultrasound in 
evaluation of the severity of pancreatitis. 
- TIGAR-O system: more recently, the Toxic, Idiopathic, Genetic, Autoimmune, 
Recurrent severe associated chronic pancreatitis and Other systems has been developed 
and allows multiple risk factors to be assessed in an individual patient either as a risk 
factor or as an aetiology (Nydegger et al., 2006). 
- Atlanta criteria: though this is still controversial with lack of consensus (Berney et al., 
1999; Bollen et al., 2007). 
Overall, it is relevant to state that up till now commonly used scoring systems have limited 
ability to predict disease severity in children and adolescents with acute pancreatitis. 
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Careful and repeated evaluations are essential in managing these patients as they may 
develop major complications without early signs (Lautz et al., 2011). 
8. Treatment  
8.1 Acute pancreatitis 
8.1.1 Conservative treatment  
Treatment of acute pancreatitis is primarily and essentially supportive. It aims at limiting 
exocrine pancreatic secretion and monitoring for acute and long term complications. Key 
features in the empirical therapeutic regimen commonly used in treating patients with acute 
pancreatitis are: aggressive IV fluid administration to replace the profound fluid deficit and 
to maintain a good hydration as indicated by adequate urine output (2ml/kg/hr), usually 
measured with the aid of an indwelling urinary catheter. Pain control should be achieved 
with parenteral analgesia. Adequate analgesia is critical to minimize the additional stress 
from pain. Meperidine (Demerol) is thought to be a better analgesic in pancreatitis because 
morphine is well known to cause spasm of the sphincter of Oddi which in turn is known to 
increase pancreatic duct pressure and potentially worsen the pancreatitis (Mehta & Gittes, 
2005). It is also important to be certain of the diagnosis of pancreatitis before giving the 
patient significant doses of narcotics because the ability to diagnose serious non-pancreatic 
problems, such as intestinal ischaemia or perforated ulcer, may be lost. It is imperative to 
have a very low threshold for transferring the patient to an intensive care unit and provide 
constant monitoring to avoid development of profound hypovolemia. Initially, bowel 
should be kept at rest with NG suction. Most mild to moderate cases will settle if food and 
drink is withheld for a few days. Proton pump inhibitors (PPI) or H2 receptor antagonists 
administration helps to prevent exposure of the duodenal secretin producing cells to gastric 
acid, which is a potent stimulator of pancreatic secretion. These antagonists also may help 
prevent stress ulceration seen in patients with pancreatitis. While clinical trials have shown 
improved outcome in acute pancreatitis by using long acting somatostatin analogues 
octreotides, controversy still exists concerning the use of prophylactic antibiotics. In 
general, mild to moderate cases probably do not benefit from antibiotics. More severe cases 
of pancreatitis, however, may benefit because of the high rate of sepsis. Prophylactic 
antibiotics are indicated when there is pancreatic necrosis or when infection is either 
suspected or documented in severe acute pancreatitis. Studies have related prophylactic 
antibiotic administration for 10-14 days in adult patients with severe acute pancreatitis and 
proven pancreatic tissue necrosis with decrease in superinfection of necrotic tissue and 
mortality (Nydegger et al., 2006; Mehta & Gittes, 2005; Miyano, 2006)). Some advantages 
have been demonstrated with the use of imipenem with reduction in the incidence of 
pancreatic sepsis in patients with necrotizing pancreatitis. Because the onset of cytokine 
action follows immediately after the onset of pancreatitis and peaks after 36-48 hours, 
cytokine antagonist therapy represents a potential therapeutic target and therefore is of 
intense interest (Nydegger et al., 2006). In children with relapsing attacks of pancreatitis we 
would advocate similar management and also include investigations to exclude structural, 
metabolic and hereditary pancreatitis (Nydegger et al., 2006). Nutrition is a crucial factor in 
the management of patients with pancreatitis. Early positive nitrogen balance has been 
shown to improve survival rates. This need for aggressive nutrition should come in the form 
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of early TPN administration. The TPN should include lipid formulations. To minimise the 
causal association of hyperlipidaemia and pancreatitis, it is recommended that serum lipid 
levels should be monitored to maintain triglyceride levels no greater than 500 mg/dl (Mehta 
& Gittes, 2005).  
The results of several controlled studies in adult patients with acute pancreatitis, support 
enteral nutrition. It costs less than TPN by approximately 1/4. Total enteral nutrition 
moderates the acute phase response and improves disease severity and clinical outcome 
despite unchanged pancreatic imaging findings (Windsor et al., 1998; Nydegger et al., 2006). 
Although there are sparse paediatric data, enteral feeding has been widely adopted. Perhaps 
a nasojejunal feeding with high protein and low-fat formula through a tube inserted under 
radiological or endoscopic guidance can be implemented until the child is ready to 
commence oral intake (Nydegger et al., 2006). Naso-jejunal feeding may be particularly 
useful in places where TPN availability is considered to be a luxury!.  
It is imperative to note that despite the known advantage of nutritional support in 
facilitating resolution of pancreatitis, quite often early commencement of enteral feeding 
results in relapse of acute abdominal pain and elevation of amylase levels. 
In general, the resumption of enteral nutrition should be cautious, usually after complete 
resolution of abdominal pain and preferably after normalization of the serum enzyme levels 
(Mehta & Gittes 2005).  
8.1.2 Surgical treatment  
Surgery for pancreatic disorders in children is rarely required. Surgical intervention in 
children with acute pancreatitis is even less practiced. It should be restricted to patients with 
complications such as severe necrotizing pancreatitis requiring debridement or patients 
with other complications associated with acute pancreatitis including pancreatic ascites, 
pancreatic abscess collections not amenable for percutaneous drainage and pancreatic 
pseudocyst (Rabinovich et al., 2006) (see below). 
In traumatic pancreatitis, as most children with a solid-organ abdominal injury can be 
managed conservatively, the pancreas is no exception. Non-operative management of low 
grade pancreatic injury is widely accepted. Management of major pancreatic parenchymal 
or ductal injury in children, however, remains controversial (Haddock et al., 1994; Stringer 
et al., 2005). Initial nonoperative management of injuries of the proximal pancreatic duct is a 
common practice and allows for the formation and uneventful delayed drainage of a 
pseudocyst, rather than the risks of early radical interventions (Jobst et al., 1999). If there is 
delayed or no response to conservative management, ERCP with sphincterotomy and/or 
stenting of injured pancreatic duct may be attempted as it has reportedly had a proven 
efficacy in resolving the symptoms in such patients (Cay et al., 2005; Canty & Weinman, 
2001; Ali, 2010). Distal duct injuries are best managed by prompt spleen-sparing distal 
pancreatectomy (Jobst et al., 1999). Removal of impacted stones in gallstone pancreatitis in 
children should be performed endoscopically (Mehta & Gittes, 2005).  
When discovered incidentally during the course of laparotomy for other suspected causes of 
peritonitis, it is imperative to palpate the gallbladder (GB) for stones. In the presence of 
gallstones and mild pancreatitis, cholecystectomy can be performed. However, with severe 
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pancreatitis, cholecystostomy may be the safer option which can provide an access to the 
biliary calculi later. Cholecystectomy can be done at a later stage when the patient’s 
condition is favourable. If no gallstones are present, but the patient has severe necrotizing 
pancreatitis, limited debridement and/or leaving large sump drains in place is probably 
adequate (Mehta & Gittes, 2005).  
Overall, early pancreatic lavage, pancreatic drainage, and pancreatic resection have not been 
shown to improve survival rates in cases of severe pancreatitis (Mehta & Gittes, 2005) and 
early intervention for pancreatic injury, in the absence of clinical deterioration or major 
ductal injury, is not recommended either (Keller et al., 1997). There is also an iatrogenic 
dimension to the problem as the rarity of pancreatic surgery in children caused an 
unfamiliarity that can be associated with contracting significant morbidity and mortality.  
When comparing traumatic and non-traumatic pancreatitis, Schmittenbecher and co-
researchers found that more patients with traumatic pancreatitis were operated on in 86% of 
cases and the rate of pseudocysts reached 61.5% whereas non-traumatic pancreatitis 
required surgical intervention in 50% and developed pseudocysts in 17% of cases. In non-
traumatic pancreatitis it is recommended that surgery should be avoided and reserved for 
complications. Exceptions are obstructions of the pancreaticobiliary ducts which need early 
removal to prevent chronicity of the disease and functional loss of the organ 
(Schmittenbecher, 1996). In their study, Stringer et al summarized the indications for 
surgery in acute pancreatitis in persistent pseudocysts and treatment of an underlying cause 
of pancreatitis (Stringer et al., 2005).  
Key points in the management of acute pancreatitis  
IV Fluids 
ICU admission 
Pain control 
NGT aspiration 
PPI or H2 receptor-blockers 
Somatostatin analogues 
Prophylactic antibiotics 
Cytokine antagonists 
Adequate nutrition 
Endoscopic intervention  
Surgical intervention 
8.2 Chronic pancreatitis      
Management of chronic pancreatitis is directed towards identification of the aetiological 
factors, diagnosis of the condition and hence implementation of the appropriate therapy. 
Due to the structural changes associated with chronic pancreatitis, many more surgical 
indications exist here when compared with acute pancreatitis. As appropriate, conservative 
management consists of provision of medications, analgesia, antibiotics and nutrition. 
Emphasis should be made on treatment of pancreatic exocrine insufficiency, therefore, 
digestive problems related to failure of the pancreas require enzyme replacement therapy 
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with meals as well as fat soluble vitamins supplements (Durie, 2010). Endocrine 
insufficiency, particularly diabetes mellitus, should be controlled.  
Indications for operative intervention include unsuccessful conservative medical therapy, 
intractable pain, narcotic addiction, impaired nutrition and poor weight gain. 
The goal of surgery in these patients is to relieve pain by provision of adequate analgesia 
and to preserve the exocrine and endocrine functions of the pancreas through 
decompression of pancreatic ducts and restoration of adequate pancreatic drainage.  
Surgical options include lateral longitudinal pancreaticojejunostomy (Puestow procedure), 
distal pancreatectomy with Roux-en-Y pancreaticojejunostomy (Duval procedure), ERCP 
sphincterotomy or operative sphincteroplasty. In cases of intractable and refractory disease, 
a few pediatric patients with chronic pancreatitis and chronic abdominal pain were 
successfully treated with total pancreatectomy and islet cell transplantation (Hebra et al., 
2009; Bellin et al., 2008).   
Surgical intervention is indicated for the management of congenital anatomic defects, such 
as pancreas divisum. The primary goal of treatment of pancreas divisum associated with 
pancreatitis is to establish adequate drainage of the duct of Santorini. This can be achieved 
with accessory papilla sphincteroplasty. Correct use of this procedure demands that 
intrapancreatic ductal obstruction be ruled out by pancreatography. The progression of 
disease to pancreatic insufficiency can be arrested when the obstruction is relieved early. 
Endoscopic stenting with or without sphincterotomy has been described, however, the 
technique requires particular skill with the endoscope in cannulation of the small ducts 
encountered in children. Re-stenosis and recurrence of symptoms have been reported 
following endoscopic sphincterotomy. 
If chronic pancreatitis has developed in the presence of a dilated duct, longitudinal 
pancreaticojejunostomy (Puestow) should be performed. The indication for the use of a 
direct ductal decompression procedure is evidence of pancreatic ductal ectasia with 
multiple intrapancreatic duct strictures, particularly when symptomatic (Stringer et al., 
2005). An important precautionary measure in any drainage procedure is preservation of 
existing endocrine function by avoiding major pancreatic resection. Longitudinal 
pancreaticojejunostomy (Puestow technique) in adults has been successful in eliminating or 
reducing pain intensity from chronic pancreatitis in 70 to 97% of patients. In children, some 
authors maintain that the Puestow procedure improves pancreatic function, decreases 
hospitalization and increases body weight toward ideal. Others have reported that distal 
pancreatectomy and pancreatico-jejunostomy are effective whereas longitudinal 
pancreaticojejunostomy is ineffective (Miyano, 2006). Traditionally, these procedures were 
performed with open surgery. A minimally invasive approach to the longitudinal 
pancreaticojejunostomy using robotic surgery in a child has been reported recently (Meehan 
& Sawin, 2011). Due to this controversy regarding appropriate operative procedures in 
paediatric cases, further consideration is warranted.  
Subtotal or total pancreatectomy is associated with considerable morbidity and mortality 
and is reserved for patients with intractable pain who have diffuse parenchymal damage 
without ductal dilatation. The procedure is not generally indicated in children. 
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DuBay et al. reported that in the treatment of complicated hereditary pancreatitis (HP) in 
children, the modified Puestow procedure (longitudinal pancreaticojejunostomy) improves 
the quality of life by improving pancreatic function, decreasing hospitalizations, and 
increasing the percentile ideal body weight. Direct pancreatic duct localization during the 
procedure reduces morbidity rate than localization via distal pancreatectomy. Surgery 
performed in the early stage of complicated disease may preserve pancreatic function 
(DuBay et al., 2000). Likewise, surgery for chronic relapsing pancreatitis is done to relieve 
pain, treat complications or both. Adequate surgical decompression, ultimately, can prevent 
disease recurrence (Clifton et al., 2007; Bellin et al., 2008).  
In children suffering from chronic pancreatitis complicated by diabetes mellitus, 
pancreatectomy and islet autotransplantation can prevent or reduce the severity of diabetes 
in about 75% of patients. Furthermore, outcome is noted to be better in younger than older 
children (Bellin et al., 2008).    
Treatment of chronic calcific pancreatitis includes control of diabetes, relief of pain with 
analgesics, pancreatic enzyme replacements, endoscopic or surgical decompression of 
dilated ducts and removal of pancreatic calculi (Aamarapurkar, 2001). 
The role of laparoscopy: laparoscopy has been reported to be used for common bile duct 
(CBD) exploration in obstructive recurrent pancreatitis (Shah et al., 1997). The commoner 
use of laparoscopy is for cholecystectomy when gallstones are incriminated in childhood 
pancreatitis. Laparoscopy has also been used in the treatment of pancreatic pseudocysts (see 
below). 
Surgery of the pancreas is generally of 3 types,  
1. Sphincteroplasty  
2. Pancreatic drainage via longitudinal pancreaticojejunostomy (Puestow)  
                                       or end to end pancreaticojejunostomy (Duval)  
                                       or pancreatogastrostomy (Smith)  
3. Pancreatectomy: partial or total  
9. Complications  
Expected local complications of childhood pancreatitis include necrotizing pancreatitis, 
haemorrhagic pancreatitis, pseudocyst and pancreatic fistula. While systemically, as cases of 
severe pancreatitis progress, close monitoring of the patients should be exercised for signs of 
development of hypovolaemic shock and of multiorgan system failure. Pleural effusion and 
pulmonary oedema can progress to severe adult respiratory distress syndrome with 
hypoxia requiring endotracheal intubation. The tense abdominal distention associated with 
pancreatitis, either due to ileus or ascites, frequently contributes to the hypoventilation. 
Hypocalcemia, hypomagnesemia, anaemia from haemorrhage, hyperglycemia, renal failure 
and late sepsis can be seen in these patients and require close monitoring and treatment.  
9.1 Acute haemorrhagic pancreatitis  
Most of the complications related to acute pancreatitis tend to occur in the first two weeks of 
onset of pain; and secondary infection and necrosis account for 70-80% of deaths (Munoz & 
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Katerndahl, 2000). Zhu et al. noted that pancreatic damage or pancreatic necrosis in critically 
ill children is characterized by acute onset, profound severity, short course and multiple 
organ failure. It may be asymptomatic in early stage, and can be easily missed (Zhu et al., 
2011).  
Acute hemorrhagic pancreatitis is a rare event in children. This serious complication of 
acute pancreatitis may be attended with a mortality rate approaching 50% because of shock, 
systemic inflammatory response syndrome with multiple organ dysfunction, acute 
respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), 
massive gastrointestinal bleeding and systemic sepsis or peritonitis. Clinical manifestations 
related to hemorrhagic pancreatitis may include Grey Turner sign (bluish discoloration of 
the flanks) or Cullen sign (discoloration of the periumbilical region) because of blood 
extravasation in the fascial planes of the abdominal wall. Additional signs include pleural 
effusions, haematemesis, melaena, and coma (Mehta & Gittes, 2005; Miyano 2006)  
9.2 Pancreatic pseudocysts     
9.2.1 Definition  
Pancreatic pseudocysts are localized collections of pancreatic secretions with no epithelial 
lining. They develop as a complication of pancreatitis where they were reported to 
complicate 10-23% of the acute episodes. When associated with abdominal trauma, the 
frequency rate of pseudocyst identification is higher than 50% (Hebra et al., 2009). The other 
common causes of pseudocysts in children are pancreatic duct obstruction, infection and, 
rarely, drug induced acute pancreatitis such as with valproic acid (Miyano, 2006; Mehta & 
Gittes, 2005).  
9.2.2 Pathology  
As a result of extravasation of digestive pancreatic enzymes, pseudocysts develop in the 
lesser sac between the pancreas posteriorly and the stomach anteriorly. The cavity is lined 
by fibroelastic connective tissue capsule due to inflammatory reaction on the surrounding 
organs such as the pancreas, stomach, duodenum, colon, small bowel and omentum. An 
acute pseudocyst develops a thick fibrous wall in 4 to 6 weeks (Mehta & Gittes, 2005). After 
6 weeks, a pancreatic pseudocyst is considered mature. Cysts may vary in size and if greater 
than 6 cm in size, resolution with conservative medical management is doubtful (Yoder et 
al., 2009). Cyst fluid is clear or straw coloured in most cases and may contain toothpaste-like 
debris. The amylase level of the cyst fluid is typically higher than 50000 U/mL (Miyano, 
2006).  
9.2.3 Diagnosis  
A pancreatic pseudocyst formation should be suspected in patients with a history of 
abdominal trauma or pancreatitis followed by clinical or radiological appearance of an 
upper abdominal mass. Common associated symptoms and signs include persistent 
abdominal pain, tenderness, abdominal mass, gastric outlet obstruction, anorexia, nausea 
and vomiting. Occasionally, gastrointestinal haemorrhage, weight loss, jaundice, chest pain, 
fever and ascites may be encountered (Miyano, 2006; Yoder et al., 2009).   
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Pseudocysts may be acute or chronic. The acute pseudocyst has an irregular wall on CT 
scan, is tender and usually follows a recent episode of acute pancreatitis or trauma. Chronic 
pseudocysts are usually spherical with a thick wall and they are commonly seen in patients 
with chronic pancreatitis. It is important to distinguish these two types of pseudocysts 
because 50% of acute pseudocysts resolve without therapy, whereas chronic pseudocysts 
rarely do (Mehta & Gittes, 2005).  
US, CT and MRI are reliable imaging modalities in the diagnosis of pancreatic pseudocysts 
(Fig 2, a & b). These studies are highly sensitive for evaluating the thickness of the cyst wall 
and for observing changes in the cyst during the ensuing period of treatment. ERCP is often 
useful as a diagnostic and a therapeutic tool because it can definitively determine the status 
of the pancreatic duct and thus guide surgical intervention (Miyano, 2006).       
     
       a)        b) 
Fig. 2. Pseudocyst of the pancreas on a thoracoabdominal CT scan of an 18 month old child. 
Note the related posterior mediastinal cyst seen on picture film a. (a, transverse section; b, 
coronal section) 
9.2.4 Treatment  
Optimal management of pancreatic pseudocysts in children remains controversial. A large 
proportion of these pseudocysts tend to resolve with medical therapy alone and have a low 
risk for recurrence. Pseudocysts less than 5 cm in diameter usually disappear without 
intervention (Mehta & Gittes, 2005). Accordingly, drainage should be performed in patients 
with pseudocysts that are more than 6 weeks old and have a diameter more than 5 cm. 
Occasionally, a demonstrable cyst wall thickening sufficient for internal drainage may 
appear on CT as early as 3-4 weeks from the onset of symptoms (Miyano, 2006). 
Approximately 60% of pancreatic pseudocysts that are caused by blunt trauma require 
surgical intervention (Hebra et al., 2009).  
Available treatment options range from conservative medical management to surgical 
drainage. Conventional management involves supportive therapy over a 6-week interval 
 
Pancreatitis – Treatment and Complications 
 
50
during which time the cyst may either resolve spontaneously or the cyst wall undergoes 
fibrous maturation, potentially allowing internal surgical drainage to the stomach or jejunum.  
Octreotide acetate, a long acting somatostatin analogue, has been shown to be successful in 
reducing exocrine function and, thereby, helps resolving pancreatic pseudocysts in children 
(Miyano, 2006; Mehta & Gittes, 2005).  
If the patient can not withstand major surgery, has an infected or an immature cyst, 
percutaneous external surgical drainage is preferred. U/S or CT guided percutaneous 
drainage is the treatment of choice for infected pseudocysts because these cysts typically 
have thin, weak walls not amenable to internal drainage. However, when compared with 
internal drainage, external drainage is generally associated with adverse consequences such 
as fistula formation and a higher recurrence rate (Miyano, 2006). 
Internal drainage, especially transgastric cysto-gastrostomy is widely used. There is 
significant evidence indicating that it is effective in the treatment of mature pancreatic 
pseudocysts (Miyano, 2006; Mehta & Gittes, 2005).  
Roux-en-Y cysto-jejunostomy is an alternative internal drainage procedure and is associated 
with less complications and recurrence rates. 
Though less commonly used than other operative procedures, contemplating cysto-
duodenostomy may be effective when a cyst is intimately adherent to the duodenum.  
Either pancreatico-duodenectomy or distal pancreatectomy, as indicated, is effective in 
treating patients with pseudocysts in selected cases. Pseudocysts in the body or tail of the 
pancreas or those involving the head and uncinate process of the pancreas that are not 
amenable to internal drainage are rare and may require distal or proximal pancreatic 
resection, respectively (Miyano, 2006).  
Minimally invasive drainage approaches to pancreatic pseudocysts were reported. Strategies 
for cysto-gastrostomy include transoesophago-gastric endoscopic cysto-gastrostomy and 
percutaneous drainage (Mehta & Gittes, 2005). The other minimally invasive technique is 
laparoscopic transgastric cysto-gastrostomy or laparoscopic cysto-jejunostomy. There are few 
reports on the use of laparoscopy in the management of pancreatic pseudocysts (Saad et al., 
2005; Sietz et al.,2006). In a multi-institutional retrospective review of 13 patients with a mean 
age of 10.4 years and mean weight of 52.1 kg who underwent laparoscopic cysto-gastrostomy 
with no conversions, the authors concluded that a laparoscopic approach to pancreatic cysto-
gastrostomy for chronic pseudocysts proved to be safe and effective. Techniques varied, but 
92% of patients had complete resolution with minimal morbidity and rapid recovery. 
Laparoscopic cysto-gastrostomy can be adopted as an appropriate first-line treatment for 
chronic pseudocysts in children (Yoder et al., 2009).  
Both endoscopic and laparoscopic drainage approaches are safe, efficient and effective, 
however, the two procedures should be performed at institutions with significant 
experience with these techniques to minimize serious potential risks.  
Treatment of persistent Pancreatic pseudocysts: 
- Internal drainage (preferred)  
- Excision (distal pseudocysts only)  
- External drainage (infected or immature cysts) 
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9.2.5 Pseudocyst complications    
Untreated pseudocysts may present with persistence of symptoms or become complicated 
with major haemorrhage, infection or cyst rupture. Haemorrhage can occur as a result of 
cyst pressure and erosion into an adjacent blood vessel and may be controlled with 
emergency angiography and embolization. For infected or ruptured pseudocysts, early 
intervention with external drainage is indicated (Miyano, 2006; Mehta & Gittes, 2005) 
9.3 Pancreatic ascites 
Pancreatic ascites is uncommon but may follow trauma or pancreatic surgery. Leakage of 
pancreatic fluid from a damaged major pancreatic duct results in ascites. Treatment is 
initially conservative and consists of bowel rest, TPN administration and use of long-acting 
somatostatin analogue. In many cases ascites resolves with this treatment. If not, ERCP or 
MRCP should be performed to determine the site of the ductal injury and, accordingly, the 
appropriate course of surgical intervention (Mehta & Gittes. 2005).  
9.4 Pleural effusion 
Occasionally, pancreatic pleural effusion may develop following severe pancreatitis. A 
significantly elevated level of pleural fluid amylase/lipase with concentrations higher than 
those obtained from patient’s serum sample, may be encountered following traumatic 
pancreatitis. Intrathoracic pancreatic pseudocyst has been reported following traumatic 
pancreatitis where, eventually, persistent pancreatic ductal leak was successfully managed 
with ERCP stenting of the pancreatic duct (Ali et al., 2010).   
9.5 Pancreatic abscess 
Infection may complicate necrotic pancreatic tissue or peripancreatic fluid collection 
resulting in pancreatic abscess. Abscess increases the mortality rate of pancreatitis threefold 
and is an absolute indication for surgical intervention. Persistence of fever and leukocytosis 
in a child with pancreatitis for more than 7 days is an indication for CT guided needle 
aspiration to differentiate pancreatic abscess from an uninfected pancreatic fluid collection. 
Dynamic CT pancreatography is a useful test in showing pancreatic necrosis which is a 
likely predisposing factor for the subsequent development of a pancreatic abscess. The 
definitive therapy for pancreatic abscess entails surgical debridement and adequate abscess 
cavity drainage (Mehta & Gittes, 2005).   
9.6 Pancreatic fistula 
Pancreatic fistula develops following surgical procedures in the pancreas. Most low output 
fistulas close spontaneously but may drain for several months. Long acting somatostatin 
analogue is beneficial in decreasing the fistula output and accelerating the rate of closure. 
Fistula closure can be facilitated by adequate nutrition, with TPN if enteral feeding results in 
high-volume output, and by ensuring that the fistula tract does not become obstructed. In 
persistent fistulas surgical Roux-en-Y jejunostomy to the leak point is recommended (Mehta 
& Gittes, 2005).  
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9.7 Hyperglycaemia 
Both hyperglycaemia and diabetes can occur in children with pancreatitis. In a recent study, 
researchers looked at 176 patients who were up to 21 years of age and who were 
hospitalized with acute pancreatitis, acute recurrent pancreatitis, and chronic pancreatitis, 
excluding those with known pre-existing diabetes or cystic fibrosis before presentation with 
pancreatitis. Severe pancreatitis was associated with hyperglycaemia, and eight patients 
developed diabetes requiring insulin by the time of discharge. The authors noted that while 
adults tend to develop diabetes after chronic pancreatitis, children can develop diabetes due 
to a single episode of acute pancreatitis (Raman et al., 2011). 
9.8 Adenocarcinoma of the pancreas 
In patients with chronic pancreatitis, it has been reported that there is a 4% life risk of 
developing pancreatic adenocarcinoma. This risk may be as high as 40% in patients with 
hereditary pancraetitis (Nydegger et al., 2006).   
10. Prognosis  
Uncomplicated acute pancreatitis in children usually have excellent prognosis. The outcome 
also depends on the co-morbid conditions (Werlin 2003). The mortality rate is approximately 
10% in mild disease and up to 90% in cases of necrotizing or haemaorrhagic pancreatitis 
(Uretsky 1999). 
11. Conclusion  
Pancreatitis in children is an uncommon event, however, it is attended with significant 
morbidity and mortality. The presentation may range from transient mild symptoms to life 
threatening, overwhelming sepsis, multiple organ system failure and death. Prompt 
institution of appropriate diagnostic and therapeutic measures is crucial to achieve good 
clinical results. Conservative management and minimally invasive surgical and endoscopic 
procedures are usually sufficient to treat most of the patients. Children rarely need surgical 
intervention for the treatment of pancreatitis and its complications. Further developments 
are anticipated in the field of research, diagnostic tools, disease severity scoring and 
therapeutic methods to improve the outcome. 
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1. Introduction 
Acute pancreatitis (AP) is a potentially lethal disorder with no specific medical treatment. 
AP is characterized by a spectrum of symptoms, ranging from a local inflammatory process 
to the more severe form (acute necrotizing pancreatitis) which is associated with a systemic 
inflammatory response and a mortality rate of 27-45%. A number of risk factors have been 
identified for AP including alcohol abuse, gallstones, abdominal surgery/injury, cigarette 
smoking, cystic fibrosis, endoscopic retrograde cholangiopancreatography, hypercalcemia, 
hyperparathyroidism, hypertriglyceridemia, infection, pancreatic cancer, and injury to the 
abdomen (Pandol et al., 2007). Alcohol abuse and the development of gallstones account for 
the majority of AP cases. In AP, inappropriate intracellular activation of digestive enzymes 
within the pancreas (e.g. trypsin, chymotrypsin, elastase) is the main initiating event. The 
development of acute necrotizing pancreatitis is usually associated with pancreatic 
glandular necrosis. Acinar cell apoptosis, the release of cytokines, activation of coagulation, 
tissue ischemia, and tissue necrosis are key factors in the progression of the condition, as 
well as in the development of associated extrapancreatic complications (Steinberg & Tenner, 
1994; McKay & Buter, 2003; Pandol et al., 2007).  
AP induces a strong inflammatory response in experimental animal models and in humans, 
and is independent of the initiating factor for acinar cell damage (Granger & Remick, 2005). 
The major inflammatory mediators in AP include tumor necrosis factor (TNF), interleukins 
1, 6, and 8, chemokines, and platelet activation factor (Makhija & Kingsnorth, 2002). Release 
of proinflammatory mediators into the circulation results in a systemic inflammatory 
response syndrome (Granger & Remick, 2005). 
Inflammatory mediators in turn can influence hemostasis. Indeed, the pathways of 
inflammation and coagulation are intimately linked. For example, pro-inflammatory 
cytokines (e.g. TNF, IL-1β) act in autocrine and paracrine loops to activate neutrophils and 
monocytes. These cytokines also activate endothelial cells by upregulating adhesion 
molecules (e.g. P- and E-selectins) and chemokines. This results in leukocyte recruitment to 
the site of injury. Activated monocytes and endothelial cells express tissue factor (TF), the 
“spark” that initiates the coagulation cascade. TF can also be expressed by cells in the 
injured pancreas. The TF/VIIa complex activates factor X to Xa (or factor XI to XIa), and the 
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factor Xa/factor Va complex converts prothrombin to thrombin. Thrombin not only forms 
the fibrin clot but is also a potent activator of protease activated receptor-1 (PAR-1). PAR-1 
activation triggers pro-inflammatory responses including secretion of cytokines and growth 
factors, and upregulation of adhesion molecules.  
In AP, coagulation abnormalities range from localized intravascular thrombosis to 
disseminated intravascular coagulation (DIC). Ultrastructural changes in the pancreas that 
accompany human AP include the infiltration of polymorphonuclear leukocytes into the 
stroma and parenchyma, intra- and extravascular accumulation of platelets, and 
microthrombi in blood vessels (Bockman et al., 1986). This chapter will provide an overview 
of the pathophysiology of acute pancreatitis with emphasis on coagulation abnormalities. 
The topics covered include dysregulation of coagulation and anticoagulant pathways, 
animal studies of AP, and the therapeutic potential of experimental interventions. 
2. Overview of hemostasis 
Hemostasis is a delicate balance between procoagulant (including platelets and clotting 
factors) and anticoagulant mechanisms (including blood flow and the production of 
anticoagulant proteins). It encompasses the vessel wall and endothelial cells, cellular 
constituents within the vessel (such as red blood cells, leukocytes, and platelets), soluble 
plasma proteins (coagulatory proteins and their moderators), as well as microparticles 
derived from leukocytes and platelets (Hoffman & Monroe, III, 2001). It is a physiologic 
process which modulates blood fluidity while also retaining the capacity to produce a 
hemostatic plug outside a damaged blood vessel. Thrombosis is a pathologic event inside 
the vessel lumen, consisting of platelet accumulation, adhesion, activation and aggregation, 
as well as tissue-factor-initiated thrombin generation and fibrin formation (Furie & Furie, 
2007). The hemostatic process is tightly regulated in a healthy individual by a system of 
anticoagulant mechanisms (Dahlback, 2000; Esmon, 2000b; Esmon, 2009). Through these 
mechanisms, the transformation of blood from a liquid to a solid state (and vice versa) is 
tightly regulated by the multiple participants of the coagulation, anticoagulation, and 
fibrinolytic pathways. The following sections describe the key components of the hemostatic 
system and their relevance to AP. Biomarkers of hemostasis in acute human pancreatitis are 
summarized in Table 1. 
3. Platelet activation in AP 
Platelet adhesion at sites of vessel injury is a multistep process involving interactions 
between various platelet receptors and subendothelial adhesive ligands (Furie & Furie, 
2007). The initial tethering of platelets to exposed subendothelial collagen is mediated by 
von Willebrand factor (VWF), a large multimeric protein secreted by endothelial cells and 
activated platelets (Furie & Furie, 2007; Lippi et al., 2009). Adherent platelets become 
activated and undergo a shape change, becoming spherical and extruding long filopodia 
that enhance platelet-platelet interactions. Activated platelets secrete ADP from their dense 
granules and synthesize and release thromboxane A2. Released ADP and thromboxane A2 
bind to distinct receptors on nearby platelets and activate them, thereby recruiting 
additional platelets to the sites of injury. Activated platelets also secrete the contents of their 
alpha granules (e.g. VWF, platelet-derived growth factor, and coagulation cofactors V and 
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VIII) (Wagner & Burger, 2003). Finally, activated platelets promote blood coagulation via the 
expression of phosphatidylserine, a negatively charged phospholipid that is normally found 
on the inside of the platelet cell membrane. Assembly of coagulation factors on the activated 
platelet surface results in an explosive generation of thrombin (described in more detail 
below). 
Evidence of increased platelet activation associated with pancreatitis has long been 
established in experimental animal models. In rabbits, administration of pancreatic fluid 
from patients with chronic pancreatitis induced platelet aggregation and activation (Prinz et 
al., 1984). In cases of acute pancreatitis, platelets have been shown to be activated, and their 
indices (mean platelet volume, platelet large cell ratio, and platelet distribution width) have 
also been shown to be elevated between onset and remission of AP (Mimidis et al., 2004). 
While a heightened platelet response is typical of patients with mild AP, a decreased platelet 
count (due to increased consumption of platelets) is observed in cases of severe AP. Low 
plasma levels of platelets in patients with AP are also associated with poor clinical outcome 
(Maeda et al., 2006). 
4. Coagulation and fibrinolysis abnormalities in AP 
Simultaneous to platelet activation, coagulation occurs in three overlapping stages: 
initiation, amplification, and propagation (Hoffman & Monroe, III, 2001). Tissue factor (TF) 
is the “spark” that initiates blood coagulation. Under normal conditions, TF is not expressed 
by cells that are in direct contact with blood (Butenas & Mann, 2004). After damage to the 
endothelial wall, however, TF is exposed to blood where it is free to bind plasma factor VIIa, 
forming TF-factor VIIa complex. TF is also expressed by macrophages and monocytes after 
stimulation by inflammatory mediators (Esmon, 1999; Nijziel et al., 2001; Bouchard & Tracy, 
2003) 
Tissue factor (TF) forms a complex with a small amount of circulating activated factor VII 
(FVIIa) and acts as a cofactor for increasing the ability of FVIIa to convert FX to FXa and FIX 
to FIXa at the cell surface (Osterud et al., 1978). FXa activates FV and together they convert a 
small amount of prothrombin to thrombin (Monroe et al., 1996). This is known as the 
initiation phase of coagulation. During the amplification phase, the small amount of 
thrombin generated initiates a positive feedback loop upon itself through further activation 
of FV, and thus, increased thrombin generation (Monroe et al., 1996). The initiation of large-
scale thrombin generation begins with the formation of the tenase complex (which consists 
of FVIIIa and FIXa) and the prothrombinase complex (consisting of FVa and FXa) on an 
anionic surface such as activated endothelial cells or platelets (Hoffman & Monroe, III, 
2001). This causes a thrombin burst, which further generates fibrin from fibrinogen. This 
rapid formation of thrombin also activates factor XIII and thrombin-activatable fibrinolysis 
inhibitor (TAFI). Factor XIIIa is then able to cross-link with fibrin strands to support and 
stabilize a fibrin meshwork, while TAFI protects the forming clot from plasmin-mediated 
fibrinolysis (Dahlback, 2000; Butenas & Mann, 2002). 
Plasma levels of TF in AP patients have been shown to be higher than those of healthy 
volunteers, though there is no statistically significant difference in the TF levels between the 
severity groups of AP (Sawa et al., 2006). Plasma levels of TF in alcoholic severe AP with 
pancreatic necrosis was significantly higher than that in alcoholic severe AP without 
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pancreatic necrosis or that in nonalcoholic severe AP with pancreatic necrosis. These 
findings suggest that an increase in plasma TF may be related to the development of 
pancreatic necrosis in alcoholic severe AP.  
Other measurements of blood coagulation are the prothrombin time (PT) and the activated 
partial thromboplastin time (APTT) which measure the extrinsic and intrinsic coagulation 
pathways, respectively. Clinical studies have shown an elevated prothrombin time in 
patients with AP (Radenkovic et al., 2009). However, there have been no reports of 
significant deviations in partial thromboplastin time (APTT) or in F1+2 levels in patients 
with AP. While these measurements suggest early hemostatic disturbances of AP, their 
usefulness in predicting patient outcome is limited. Clinical studies which measure other 
parameters (most notably d-dimer and antithrombin) have demonstrated an improved 
specificity and sensitivity in predicting outcome for these parameters, when compared to 
the utility of either PT or APTT.  
AP is also characterized by abnormalities in fibrinolysis. The fibrinolytic system counteracts 
fibrin deposition, thereby preventing excessive fibrin accumulation at sites of vascular 
injury and restoring blood flow. Plasmin, the enzyme that dissolves fibrin clots, is formed 
from plasminogen in the presence of tissue plasminogen activator (tPA) or urokinase 
plasminogen activator (uPA). Plasmin cleaves fibrin, resulting in the production of fibrin 
degradation products (e.g. D-dimer) (Adams & Bird, 2009).  
The levels of DIC parameters (low levels of platelets and AT, and high levels of D-dimer) 
and thrombin-antithrombin complex upon admission have been found to be associated with 
increased severity and poor prognosis of AP (Maeda et al., 2006). A four-fold increase in D-
dimer levels has been shown to be a marker of complicated AP (Salomone et al., 2003). In 
patients with severe AP, non-survivors have significantly higher levels of D-dimer and 
plasminogen activator inhibitor (PAI)-1 than survivors (Radenkovic et al., 2004). The high 
concentrations of D-dimer and PAI-1 in AP patients are indicative of a hypercoagulable 
state and microvascular coagulopathy which may lead to the formation of microthrombi 
and, ultimately, facilitate the progression of organ failure.  
4.1 Anticoagulant abnormalities in AP 
The potentially explosive nature of the coagulation cascade is tightly regulated by three 
natural anticoagulant systems: antithrombin (AT), the protein C (PC) pathway, and tissue 
factor pathway inhibitor (TFPI).  
4.2 Antithrombin in AP 
AT, a plasma serine protease inhibitor (serpin) synthesized and secreted by the liver, 
demonstrates broad inhibitory activity for enzymes of the coagulation cascade, particularly 
thrombin and factor Xa (Lippi et al., 2009). The rate of enzyme inhibition by AT is slow but 
is accelerated approximately 1000-fold in the presence of negatively charged 
polysaccharides such as pharmacologic heparin as well as heparan sulfate found on the 
endothelial cell surface (Bjork et al., 1992). The stimulatory effect of heparin and heparan 
sulfate is mediated by a unique pentasaccharide sequence which binds AT with high 
affinity. Binding of this pentasaccharide sequence evokes a conformational change in AT 
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that facilitates its interaction with FXa but not with thrombin. To accelerate thrombin 
inhibition by AT, heparin must bind simultaneously to AT and thrombin, a process that 
bridges the enzyme and the inhibitor together in a ternary complex (Bjork et al., 1992). AT 
also demonstrates anti-inflammatory properties through the induction of prostacyclin 
release from endothelial cells, the inhibition of leukocyte-endothelium interactions (e.g. 
rolling and adhesion), the inhibition of procoagulant cellular signaling pathways, and the 
alteration of cellular receptor expression which modulate lysosomal proteinases, interleukin 
release, and soluble intercellular adhesion molecules (Mammen, 1998; Esmon, 2005). 
In patients with AP, low levels of AT (< 69%) at admission were found to be associated with 
a poor prognosis (Maeda et al., 2006). In taurocholate-induced experimental pancreatitis in 
rats, high dose AT treatment was shown to improve survival (Bleeker et al, 1992). In 
cerulein-induced AP, AT supplementation inhibited the release of high mobility group box 1 
protein (HMGB1) as well as other proinflammatory cytokines in rats (Hagiwara et al., 2009). 
However, in a systematic review of randomized trials, AT  seems ineffective in improving 
overall mortality in critically ill patients (Afshari et al., 2007). 
4.3 The protein C pathway in AP 
The second natural anticoagulant is PC, a vitamin-K dependent glycoprotein synthesized by 
the liver. The PC pathway provides an “on site” and “on demand” anticoagulant response 
whenever thrombin is generated (Esmon, 2000c; Esmon, 2000a). Briefly, vascular injury 
initiates the coagulation cascade, ultimately resulting in thrombin generation and blood clot 
formation. Excess thrombin then binds to thrombomodulin (TM), a receptor found on the 
surface of vascular endothelial cells. The binding of thrombin to TM is critical for efficient 
protein C activation because this interaction induces a major specificity change in thrombin 
that increases its rate of protein C cleavage (ie. activation) by 1000-fold. The conversion of 
PC to APC is augmented approximately 20-fold in vivo by the endothelial cell protein C 
receptor (EPCR). EPCR binds circulating protein C and presents it to the thrombin-TM 
complex. Activated protein C (APC), in conjunction with its cofactor protein S (PS), 
degrades coagulation cofactors Va and VIIIa on the surface of negatively-charged 
phospholipids (e.g. activated platelets).  
Significant changes in protein C levels were observed in both experimental and clinical AP. 
In rabbits, a rapid decrease in PC levels was found after the induction of acute necrotizing 
pancreatitis (Ottesen et al., 1999). Serial measurements of PC in AP patients have shown a 
difference between surviving and non-surviving patients. Survivors exhibited a progressive 
normalization of PC levels in plasma, while patients who died exhibited no increase in PC 
levels (Radenkovic et al., 2004). Decreased PC levels may reflect an increased consumption 
of PC, vascular leakage, or impaired PC synthesis by the liver in the diseased state (Levi & 
ten Cate, 1999). Upregulated but insufficient generation of APC was shown to be associated 
with the development of multiorgan failure in severe AP (Lindstrom et al., 2006).  
Plasma levels of soluble TM (important for PC activation) increase throughout the course of 
AP (Ida et al., 2009). Soluble TM levels were also significantly higher in non-surviving 
patient subgroups when compared with survivors. Exhibiting a specificity of 91% in 
predicting the prognosis of AP, sTM levels may be a useful prognostic marker for early 
mortality predictions. 
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4.4 Tissue Factor Pathway Inhibitor (TFPI) in AP 
The third natural anticoagulant is tissue factor pathway inhibitor (TFPI), a Kunitz-type 
serine protease inhibitor that is produced by monocytes, macrophages, the liver, as well as 
endothelial cells (Lwaleed & Bass, 2006). It is stored mainly in three different regions of the 
body: in circulation, in the cytoplasm of platelets, and bound to the endothelium 
(DelGiudice & White, 2009). TFPI forms a quaternary complex with TF, factor FVIIa, and 
factor Xa, thereby preventing further production of factor Xa and factor IXa by the TF:VIIa 
complex and blocking additional generation of thrombin by factor Xa. 
Yasuda et al. examined the levels of TFPI in patients with AP (Yasuda et al., 2009). Plasma 
TFPI levels in patients with AP were significantly higher than those in healthy volunteers, 
and plasma TFPI levels in severe AP were greater than those in mild AP. The elevation of 
TFPI appeared to be positively correlated with the severity, degree of necrosis, as well as 
incidence of organ dysfunction. 
5. Therapeutic strategies in AP 
Modulation of hemostasis may be an attractive strategy to treat AP. Experimental animal 
models include administration of activated protein C (APC) to improve microvascular 
coagulation and inflammation. Other strategies target procoagulant factors such as platelet 
activating factor (PAF), platelets, and factor VIIa.  
5.1 Activated protein C in AP 
Recombinant human APC (rAPC; Drotrecogin alpha activated; Xigris®) is the first biological 
agent to improve survival in patients with severe sepsis , a common co-morbidity associated 
with AP (Bernard et al., 2001; Bernard et al., 2004). Studies investigating the protective 
properties associated with APC treatment in vivo and in vitro have shown that APC 
functions not only as an anticoagulant, but also as a cytoprotective signaling molecule 
involved in inflammation, apoptosis, and vascular permeability. The protective effect of 
rAPC therapy in patients with severe sepsis likely reflects its ability to modulate the 
complex changes associated with sepsis pathophysiology. 
The importance of the protein C anticoagulant pathway in AP was first studied in a rabbit 
model. Induction of severe AP caused a marked decrease in protein C activity compared to 
rabbits subjected to sham surgery (Ottesen et al., 1999), an effect that is also observed in non-
surviving patients with AP. More recently, Chen et al. elucidated the effects of APC 
treatment on coagulation mechanisms in AP. In a 5% retrograde sodium taurocholate 
infusion rat model, pretreatment with 50 ug/kg of APC versus untreated rats with AP 
resulted in significant decreases in serum TNF, serum IL-8, and pancreatic matrix 
metalloproteinase 9 (MMP-9), an enzyme which degrades a wide range of extracellular 
matrix components (e.g. collagen, fibronectin, and gelatin). Moreover, APC-treated rats had 
significantly higher levels of pancreatic EPCR and TM, receptors critical for protein C 
activation. It has been shown that endotoxins increase shedding of membrane EPCR to 
produce soluble EPCR via MMP-9 (Gu et al., 2000) which respond to an increase in 
inflammatory cytokines (Wright & Friedland, 2004). It is proposed that APC treatment 
downregulates MMP-9 expression, thus reducing the shedding of EPCR to enhance 
endothelial EPCR cell expression in the pancreas. Following this study, the therapeutic 
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effects of rAPC in AP have been demonstrated in various models of AP by different groups 
(Yamanel et al., 2005; Alsfasser et al., 2006; Chen et al., 2007) while others have shown no 
survival benefit attributed to treatment with APC (Akay et al., 2008). 
The anti-inflammatory and protective functions of APC have been documented in severity-
graded models of AP. In a 5% sodium taurocholate infusion model (via the common 
biliopancreatic duct) of acute necrotizing pancreatitis, it was found that treatment with 
recombinant human APC (bolus injection of 100 µg/kg) 6 hours following AP induction was 
associated with a decrease in pancreatic bacterial contamination as well as fewer mesenteric 
lymph nodes (Yamanel et al., 2005). APC-treated animals with AP also had significantly 
decreased amylase levels, plasma IL-6, and TNF-α by decreasing NF-ĸβ activation. 
Moreover, APC treatment resulted in improvements in pancreatic histology as reflected by 
the resolution of pancreatic edema, perivascular inflammation, acinar cell necrosis, and fat 
necrosis. This study found that APC neither worsened nor improved the hemorrhagic state 
of the pancreas in the experimental condition suggesting that the coagulation system 
remains intact despite significant pancreatic tissue injury in the early pathophysiology of 
acute necrotizing pancreatitis (Yamanel et al., 2005). 
In a rat model of mild (cerulein injection) and severe AP (intravenous cerulein injection with 
intraductal glycodeoxycholic acid infusion), treatment with recombinant human APC  at 100 
ug/kg per hour for 6 hours significantly reduced inflammation in the lungs and pancreas 
and furthermore improved survival from 38%-86% (p = 0.05) (Alsfasser et al., 2006). 
Inflammation was characterized by the presence of myeloperoxidase (MPO) in the pancreas 
and lungs of rats with severe AP, which decreased significantly with APC treatment for 6 
hours following induction of AP. MPO levels in the lungs were reduced to levels even lower 
than those in sham-operated rats, similar to levels observed in healthy mice, while MPO 
levels in the pancreas were reduced to those observed in sham-operated and healthy control 
animals, demonstrating the anti-inflammatory effect of APC (Alsfasser et al., 2006). In 
contrast, no significant changes in coagulopathy were observed in untreated rats with severe 
AP versus APC-treated rats. Coagulopathy associated with severe AP was characterized by 
significantly prolonged prothrombin and partial thromboplastin times, decreased 
fibrinogen, marked leukocytosis, and thrombocytopenia, which were not significant in 
untreated versus APC-treated rats. APC appears to offer a survival benefit by suppressing 
inflammation in the pancreas and lungs without concomitant reversal of the pancreatic 
tissue damage and coagulopathy observed in experimental severe AP (Satake et al., 1981; 
Alsfasser et al., 2006).  
Further studies aimed at elucidating the mechanism by which APC treatment improves 
outcome in AP demonstrated the involvement of mitogen-activated protein kinases 
(MAPKs) (Chen et al., 2007). MAPKs are mammalian serine/threonine protein kinases 
known to amplify signals involved in differentiation, inflammation, and apoptosis 
(Robinson & Cobb, 1997). P38 MAPK and JNK/SAPK (c-Jun N-terminal kinase/stress-
activated protein kinase) are stress-responding MAPKs which induce inflammatory 
pathways in the early pathogenesis of severe AP (Dabrowski et al., 2000; Samuel et al., 2003). 
In this study, severe AP was induced through retrograde infusion of a 5% sodium 
taurocholate solution via the pancreatic duct at 100 uL/min. Rats were pretreated before AP 
induction with a 50 ug/kg dose of APC, 10 ug/kg dose of APC, or CNI1493 (a synthetic 
molecule which significantly reduces AP severity by inhibiting MAPK phosphorylation thus 
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attenuating inflammatory pathways (Lowenberg et al., 2004; Denham et al., 2000). In rats 
with severe AP, p38 MAPK and JNK2 proteins as well as inflammatory mediators TNF and 
IL-1β were significantly elevated. These effects were reversed in rats treated with the higher 
APC dose and CNI1493 (Chen et al., 2007). Decreases in the protein expression of MAPKs 
and cytokines in both treatments were comparable to levels in the healthy control group 
(Lowenberg et al., 2004; Wang et al., 2005; Chen et al., 2007). Moreover, APC treatment at 50 
ug/kg and not CNI1493 significantly increased expression of ERK1/2 protein (Chen et al., 
2007), the activation of which is known to protect against cell injury by promoting cellular 
regeneration (Sapieha et al., 2006). 
These studies demonstrated that APC at a dose of 50 ug/kg inhibits p36 MAPK and JNK 
expression, thus reducing levels of proinflammatory cytokines like TNF and IL-1β in the 
pancreas. Additional protective effects of APC include the upregulation of ERK1/2 which 
promotes pancreatic cell regeneration and diminishes the severity of AP. 
While some studies demonstrated the therapeutic potential of APC with high bolus APC 
injections (Yamanel et al., 2005; Chen et al., 2007) and hourly infusion (Alsfasser et al., 2006) 
treatments, others have suggested that APC offers no survival benefit in early phase AP 
(Akay et al., 2008). In a 5% sodium taurocholate rat AP model, APC was given hourly at the 
same dose given in the PROWESS study which tested the therapeutic effects of APC in 
sepsis patients (Bernard et al., 2001). Akay et al. found that APC treatment at 24 ug/kg per 
hour given 4 hours after AP induction resulted in significantly reduced serum IL-6 and 
amylase levels compared to untreated rats with AP (Akay et al., 2008). However, no 
significant improvements in pancreatic histology, pancreas oxidative stress, pancreas MPO, 
or renal function were observed. It is possible that that differences observed regarding the 
therapeutic benefit of APC may be due to dosage effects and differences in experimental 
design. The use of a lower dose of APC (24 ug/kg) may have been insufficient to offer any 
therapeutic benefit compared to the previous studies using 100 ug/kg of APC bolus or 
hourly (Yamanel et al, 2005; Alsfasser et al, 2006). Furthermore, the PROWESS trials used 
the 24 ug/kg per hour dose over 96 hours versus 5 hours in the experimental AP study 
(Akay et al., 2008). As such, studies testing the therapeutic effects of APC treatment in 
animal models of AP have yielded varying results. 
5.2 Targeting Platelet Activating Factor (PAF) and platelets in AP 
Modulation of platelet activating factor (PAF) has also been studied in experimental AP. 
PAF is a receptor-binding lipid and vasodilator that activates basophils, endothelial cells, 
platelets, and neutrophils. It is the most extensively studied experimental therapy in clinical 
trials of AP. In sodium taurodeoxycholate and trypsin injection models (via the 
biliopancreatic duct), PAF is released into the peritoneal fluid, bloodstream, and lung of rats 
(Kald et al., 1993). Furthermore, inhibition of PAF via an antagonist or an enzyme 
accelerating its degradation (acetylhydrolase) decreased inflammation characterized by 
marked reductions in pro-inflammatory cytokines (Lane et al., 2001; Hofbauer et al., 1998), 
pancreatic enzyme activation (Fujimura et al., 1992), and improved survival (Leonhardt et 
al., 1992; Dabrowski et al., 1995), hemodynamics (Ais et al., 1992), and histology (Dabrowski 
et al., 1995) in caerulein- (Fujimura et al., 1992; Lane et al., 2001; Hofbauer et al., 1998), 
deoxycholate- (Ais et al., 1992), taurocholate-infusion (Leonhardt et al., 1992; Dabrowski et 
al., 1995) and murine bile duct ligation models (Hofbauer et al., 1998). 
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The therapeutic effects of reducing pro-inflammatory platelet activity while maintaining its 
hemostatic abilities have also been studied. The inflammatory role of platelets was 
demonstrated in a study where platelet supernatant administered to platelet-depleted mice 
restored normal leukocyte recruitment (Tamagawa-Mineoka et al., 2007). In a cerulein 
model of AP, platelet depletion via an antibody (anti-GP1bα) reduced many markers of 
severe AP including serum amylase levels, acinar cell necrosis, interstitial pancreatic 
hemorrhage, inflammatory infiltration by neutrophils, pancreatic MPO, pancreatic 
macrophage inflammatory protein-2 (MIP-2), and circulating leukocytes and neutrophils 
(Abdulla et al., 2011a). This study along with others showed that platelets exert a pro-
inflammatory response by invoking MIP-2 chemokine synthesis in pancreatic cells 
(macrophage and acinar cells) (Ramnath & Bhatia, 2006; Sun & Bhatia, 2007), a major signal 
for neutrophil infiltration and chemotaxis (Bhatia & Hegde, 2007; Li et al., 2004). Therefore 
targeting the inflammatory nature of platelets may have therapeutic potential in reducing 
pancreatic tissue injury and the severity of acute pancreatitis (Abdulla et al., 2011). 
Measurement Biomarker Effect Normal 
Value
AP Admission 
Value
References 
Global 
Coagulation 
PT (sec.) Increased 9.8-12.7 13.46-13.92 1,2 
APTT (sec.) NS† 21-39 32.99-33.22 1,2,3,4,5 
Platelet Count 
(10⁴/µl) 
NS† 9.2 Sur-
vivor
Non-
Survivor 
1,6 
16.2 6.8
Fibrinogen (g/L) Increased 1.8-3.5 3.7-5.39 1,2 
Procoagulant 
Activity 
D-dimer (ng/mL) Increased 0-0.39 5.5-903.50 1,3,4,7,8 
TAT (µg/L) Increased 1-16.1 11.8-25.3 3,4,6 
TF antigen 
(pg/ml)
Increased 120-140 363-721 7,9,10 
sP-selectin 
(ng/mL)
Increased 82-181 150-215 11,12,13 
Fibrinolysis 
Pathway 
Alpha-2-
Antiplasmin (%)
Decreased 80-120 73.22-105.28 1,2 
PAI-1 (U/mL) Increased 0.3-3.5 4.39-4.56 1,2,4 
Plasminogen 
(µg/mL)
Decreased 150 - 200 70.11-103.94 1,2,17 
Anticoagulant 
Activity 
AT (%) Decreased 80-120 63.47- 81.47 1,2,4,5 
PC (%) Decreased 81-173 52-84.75 1,2,4,5,8 
APC (%) Decreased 100% 76-102 2 
Protein S 
(µg/mL)
Decreased 23.8-30.6 17.3-26.9 16 
sTM (ng/mL) Increased 10.3-54 23.48-153.9 4,14,18 
TFPI (ng/mL) Increased 26.4-28.6 34.6-40.4 15 
¹Radenkovic et al. 2009; ²Radenkovic et al. 2004; ³Mavrommatis et al. 2000; ⁴Kinasewitz et al. 2004; 
⁵Collins et al. 2006; ⁶Maeda et al. 2006; ⁷Stief et al. 2007; ⁸Lindstrom et al. 2006; ⁹Sawa et al. 2006; ¹⁰Gando 
et al. 1998; ¹¹Powell et al. 2001; ¹²Ogura et al. 2001; ¹³Osmanovic et al. 2000; ¹⁴Lu et al. 2007; ¹⁵Yasuda et al. 
2009; ¹⁶Uehara et al. 2009; ¹⁷Vinazzer et al. 1988; ¹⁸Ida et al. 2009;  
†Denotes a non-significant value compared with normal controls. 
Table 1. Biomarkers of hemostasis in human acute pancreatitis. 
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5.3 Inhibition of factor VIIa in AP 
The effect of inhibiting FVIIa on experimental AP was investigated in an intraductal 
taurodeoxycholate infusion model of AP (Andersson et al., 2007). Administration of active-
site inactivated FVII (FVIIai) and N-acetylcysteine (NAC, an anti-inflammatory antioxidant) 
90 minutes prior to AP induction caused a significant reduction of MPO levels in distant 
organs like the lungs and ileum and reductions in plasma IL-6 and MIP-2 compared to 
saline controls 6 hours following AP induction (Andersson et al., 2007). This study suggests 
that coagulant mediators may potentially be therapeutic targets to decrease AP severity. 
6. Conclusions 
Coagulation abnormalities are a hallmark of AP and are related to disease severity. Results 
from experimental animal studies and human studies suggest that modulation of 
hemostasis may provide a therapeutic target for the treatment of AP. Inhibition of the 
coagulation cascade may prevent intravascular coagulation and inflammation in the 
pancreas and distant organs, thereby reducing systemic complications in patients with acute 
pancreatitis. 
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1. Introduction 
Endoscopic retrograde cholangiopancreatography (ERCP) is an essential modality for the 
diagnosis and therapy of pancreatobiliary disease. However, complications of ERCP-related 
procedures are also common. Post-ERCP pancreatitis (PEP), the most common and 
potentially serious complication of ERCP-related procedures, occurs in 1 - 9% of all 
procedures (1-16). Moreover, the PEP rate increases to 10 - 40% in cases with risk factors (1-
16). In most cases, PEP is generally mild and requires only conservative treatment. 
However, substantial complications, occasionally fatal, can occur. Therefore, it is imperative 
to establish a strategy for preventing PEP based on medical, social, and economical 
circumstances. The prevention of PEP, according to various studies, is presently based on 
the elucidation of its underlying mechanisms, the identification of its risk factors, the 
administration of pharmacological drugs, and endoscopic procedures such as pancreatic 
stenting.  
2. Mechanisms of post-ERCP pancreatitis  
Various mechanisms of PEP have been suggested (1-25), which include obstruction of the 
outflow of pancreatic juice due to papillary edema or spasm of the sphincter of Oddi after 
ERCP procedures, chemical injury due to the injection of contrast material or leakage of 
intestinal juice to the pancreatic duct, mechanical injury of the pancreatic duct caused by the 
deep cannulation of a catheter and related devices including a guidewire, hydrostatic injury 
from the rise of pressure in the pancreatic duct due to repeated pancreatography with 
contrast agents, or the infusion of water or saline solution in manometry and pancreatic 
scope procedures, and thermal injury of the pancreas causing papillary edema due to 
radiofrequency ablation (Table 1). One of the most likely mechanisms is impaired drainage 
from the pancreatic duct caused by papillary edema or spasm of the sphincter of Oddi after 
ERCP procedures (10-14,19,22,25). Another is local injury of the papilla and pancreatic duct 
as a result of ERCP procedures, or forceful and repetitive contrast injections causing local 
inflammation (1-20,26). This may lead to premature intracellular activation of proteolytic 
enzymes, consequently causing further damage and local inflammation as indicated by 
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increased levels of cytokines, and possible initiation of a systemic inflammatory response 
with multi-organ involvement (1,10,11,13). 
 
Table 1. Suggested mechanisms of post-ERCP pancreatitis 
3. Risk factors of post-ERCP pancreatitis 
PEP can be prevented by careful patient selection with full consideration of the risk factors 
for PEP. Previous researchers have reported several factors which may increase the risk of 
PEP (1-27). A meta-analysis of 15 prospective cohort studies and 52 retrospective cohort 
studies previously evaluated and elucidated the risk factors of PEP.  
Freeman et al. (1,2) reported that the high risks of PEP were associated with both patient-
related risk factors and procedure-related risk factors on multivariate analysis of prospective 
studies and meta-analyses (Table 2). In their review, they advocated special caution in 
performing ERCP-related procedures in patients with specific patient-related risk factors 
(e.g., young age, female gender, suspected sphincter of Oddi dysfunction (SOD), prior PEP, 
recurrent pancreatitis, and absence of chronic pancreatitis) and procedure-related risk 
factors (e.g., pancreatic duct injection, pancreatic sphincterotomy, balloon dilation of an 
intact biliary sphincter, difficult or failed cannulation, and pre-cut (access) sphincterotomy).  
 
Table 2. Risk factotrs of post-ERCP pancreatitis on multivariate analysis 
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Cheng et al. (3) also reported the risk factors of PEP in a large prospective multivariate 
analysis as patient-related risk factors (e.g., suspected SOD, a history of PEP, and young age 
(< 60 yrs)) and procedure-related risk factors (e.g., previous minor papilla sphincterotomy, 
pancreatic duct injections of 2 or more, and trainee involvement).  
We previously (28) identified the risk factors of PEP on multivariate analysis as procedure-
related risk factors such as initial pancreatography, non-placement of a pancreatic stent (PS) 
after ERCP procedures, procedure time of 30 min or more, pancreatic-tissue sampling by 
any method, pancreatic-intraductal ultrasonography (IDUS), and difficulty of cannulation (≥ 
15 min). Moreover, we evaluated the correlation between the number of risk factors and 
PEP. We found a statistically significant association between PEP and the number of risk 
factors (P = 0.011), and the frequency of PEP was statistically significant when there were 
more than 3 risk factors (P = 0.001).  
Special consideration should be taken for risk factors, as indicated by multivariate analysis 
and meta-analysis, in performing ERCP-related procedures, although these procedures also 
involve comparatively wide-ranging variables such as the experience of the endoscopist. 
4. Prevention attempts 
To date, there have been several attempts to prevent PEP in terms of patient selection 
considering the risk factors of PEP, pharmacological drug administration and endoscopic 
procedures.  
4.1 Pharmacological prophylaxis 
Chemoprophylaxis to reduce the synthesis and secretion of proteolytic enzymes (octreotide 
or somatostatin), protease inhibitors (gabexate mesilate, ulinastatin, nafamostat, or 
aprotinin), antibiotics, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been used 
to prevent PEP (1,29-42) (Table 3). Numerous randomized controlled trials (RCTs) and 
several meta-analyses have been performed to evaluate the efficacy of pharmacological 
drugs for preventing PEP. Freeman et al. evaluated and reviewed the results of previous 
studies (1), and found that most of these studies failed to show clearly the efficacy of 
pharmacological drugs, although some promising drugs for preventing PEP were indicated. 
However, their results should be interpreted in consideration of a lack of unified study 
design, for example, the selection of high-risk cases, mixed high-risk and non-high-risk 
cases, and a variety of criteria to define PEP. The outcomes varied and there is as yet no 
consensus on whether or not chemoprophylaxis is useful for preventing PEP.  
4.1.1 Gabexate mesilate 
Andriulli et al. (29) demonstrated that gabexate mesilate was effective for PEP evaluation. 
However, they found that the prophylactic use of gabexate mesilate did not prevent ERCP-
related pancreatic damage, even in patients at high risk for PEP in an additional study of the 
same subject group. Four other meta-analyses (29-32) of RCTs clearly showed that gabexate 
mesilate was ineffective in preventing PEP, (odds ratio [OR], 0.67; 95% confidence interval 
[CI], 0.31 – 1.47) and that it was not useful in preventing severe pancreatitis, death, 
hyperamylasemia, or abdominal pain (30). On the other hand, another meta-analysis which 
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considered the administration schedule (31) showed that the incidence of PEP after long-
term infusion (12 h) of gabexate mesilate was significantly decreased by 5.2% (95% CI, 1.1 – 
9.4, P = 0.01), although an examination of short-term infusion (within 12 h) failed to show its 
usefulness in PEP.  
 
Table 3. Pharmacologocal interventions to reduce risk of post-ERCP pancreatitis 
4.1.2 Ulinastatin 
Tsujino et al. (33) in their multicenter RCT showed that ulinastatin significantly lowered the 
incidence of PEP in the ulinastatin-administered group compared with the control group (2.9% 
vs. 7.4%, P = 0.041). Another RCT, which compared a group given a high dosage of ulinastatin 
(450,000 U) with a group given a low dosage of ulinastatin (150,000 U) and a group 
administered gabexate mesilate (900 mg) showed PEP rates of 6.5%, 8.5%, and 4.3%, 
respectively, indicating no significant differences among the groups (34). Ueki et al. conducted 
a RCT which compared a group given ulinastatin (150,000 units) and a group given gabexate 
mesilate (600 mg) and demonstrated a similar PEP rate in both groups, indicating no 
difference between the 2 groups (35). Chen at al. in their meta-analysis (36) showed that the 
incidence of PEP was significantly reduced by ulinastatin (OR, 0.53; 95% CI, 0.31 - 0.89; P = 
0.02), as well as the incidence of hyperamylasemia (OR, 0.42; 95% CI, 0.30 - 0.59; P < 0.00001); 
however, subsequent sensitivity and subgroup analyses produced conflicting results. The 
authors concluded that ulinastatin had value in preventing PEP in average-risk patients when 
administered intravenously at a dose of at least 150,000 U, given immediately before ERCP.  
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4.1.3 Somatostatin and octreotide 
A meta-analysis (32) of 9 RCTs showed a PEP rate of 7.3% in control groups and 5.3% in the 
groups administered somatostatin and octreotide (OR, 0.73, 95% CI, 0.54 – 1.006; relative 
risk [RR], 0.734, 95% CI, 0.535 – 1.006), indicating no significant difference between the 2 
groups. In contrast, a different meta-analysis (31) showed that in terms of the administration 
schedule of somatostatin, long-term infusion (12 h) was associated with a decrease in PEP 
rate by 7.7% (95% CI, 3.4 – 12.0; P < 0.0001). Short-term infusion (within 12 h) of 
somatostatin failed to show usefulness in preventing PEP. A study with bolus injections 
revealed that a bolus injection of somatostatin significantly reduced the PEP rate by 8.2% 
(95% CI, 4.4 – 12.0; P < 0.0001). A meta-analysis of the bolus injection groups in 3 other RCTs 
showed that a bolus injection of somatostatin was useful in preventing PEP (OR, 0.271, 95% 
CI, 0.138 – 0.536; difference in incidence 8.2%, 95% CI, 4.4 – 12.0; number needed to treat 
[NNT] = 12, 95% CI, 8 – 23).  
A meta-analysis of 15 RCTs involving octreotide demonstrated that the overall examination 
of 2,621 cases failed to show the usefulness of octreotide in preventing PEP (OR, 0.78; 95% 
CI, 0.57 – 1.08) (38). However, when the analysis was limited to a total of 1,714 cases 
including the cases in 5 RCTs in which more than 200 cases were studied, it was shown that 
the PEP rate was significantly decreased by octreotide (OR, 0.50; 95% CI, 0.32 – 0.79; P = 
0.003; NNT, 31). 
4.1.4 Nonsteroidal anti-inflammatory drugs 
A meta-analysis of 6 RCTs involving the administration of NSAIDs showed that the PEP 
rate was significantly lower in the NSAID-administered group (8.9% vs. 16.8%; OR, 0.46; 
95% CI, 0.32 – 0.65; P < 0.0001) (39). Of these 6 RCTs, a meta-analysis of 4 RCTs evaluating a 
rectally administered drug showed that the single use of NSAIDs just before or after ERCP 
was useful in preventing PEP (4.4% vs. 12.5%; RR, 0.36; 95% CI, 0.22 – 0.60; NNT, 15) (40). A 
subgroup analysis of the same 4 RCTs demonstrated that in the NSAID-administered group, 
there was a significant decrease in the PEP rate in both the low-risk group (RR, 0.29; 95% CI, 
0.12 – 0.71; P = 0.006) and the high-risk group (RR, 0.40; 95% CI, 0.23 – 0.72; P = 0.002) (41). 
Allopurinol, steroids, N-acetylcysteine, and mitogen-activated protein kinase inhibitors all 
failed to show a significant preventative effect in PEP (42). 
4.1.5 Endoscopic procedures 
Careful pancreatic duct injection and avoiding cannulation trauma are essential in 
performing ERCP-related procedures. Moreover, the placement of a PS with internal and 
external flanges, or a nasopancreatic drainage tube (9,10) has been performed. To prevent 
PEP, some endoscopists have inserted a naso-pancreatic drainage tube into the pancreatic 
duct (9,10) or employed a flanged PS, apparently not considering the possible advantages of 
spontaneous dislodgement (10-14,19,20). A temporary PS has recently become commercially 
available and has been reported to be effective in preventing PEP (1,15,17-20,25). PSs are 
classified into those with and without flanges on the pancreatic ductal side. The former is 
unlikely to naturally dislodge, and endoscopic removal is often necessary. As for the latter 
unflanged PS, the rate of natural dislodgement within a short period is high (1,17,25), and 
re-insertion of an endoscope for removal is generally unnecessary.  
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Several, mainly non-prospective, randomized studies (9-12,14,18-21) have evaluated 
endoscopic drainage using a PS with flanges on both sides, unlike our pancreatic duct 
spontaneous dislodgement stent (PSDS), for preventing PEP in high-risk patients (Table 4). 
The results suggested that the frequency of PEP decreased, and the PS provided a 
maintained drainage route when the papilla was blocked as a result of edema, or spasm of 
the sphincter of Oddi, or both, after the procedure.  
Recently, Freeman et al. (17) found that the insertion of a PS in high-risk patients reduced 
the frequency of PEP by 4 - 23%. In contrast, Smithline et al. (12) reported that PS insertion 
did not confer a significant beneficial effect in patients with previous biliary 
sphincterotomy.  
Sofuni et al. conducted 3 RCTs (15,28,43) to prospectively evaluate the usefulness of PSDS 
for PEP prophylaxis. In a preliminary single-center RCT (15), they evaluated PEP 
prophylaxis using the same unflanged 5-Fr PSDS in 80 consecutive patients, including those 
who underwent simple ERCP and those who received additional manipulation of the 
papilla through several stressful examinations including manometry, IDUS, and aspiration 
of pure pancreatic juice (PPJ). The trial revealed that a temporary unflanged 5-Fr PS reduced 
the frequency of PEP.  
 
Table 4. Studies of pancreatic atent for prevention of post-ERCP pancreatitis  
A multi-center RCT (43) of 6 endoscopy units based on a previous study (15) demonstrated 
that the insertion of PSDS significantly reduced the frequency of PEP (3.2% vs. 13.6%, P 
=0.019). In particular, in cases of hyperamylasemia, the placement of a PSDS significantly 
reduced the mean serum amylase level (767 vs. 1364 IU/l). This previous study clearly 
showed the efficacy of PSDS in preventing PEP.  
Finally, another RCT (28) conducted in 37 large endoscopic units evaluated whether or not 
the placement of a PSDS would prevent pancreatitis after ERCP-related procedures in 
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patients with any of the risk factors for PEP, as well as identified risk factors for PEP. The 
results demonstrated that the placement of a PSDS significantly reduced the frequency of 
PEP in the analysis, excluding invalid cases (7.9% vs. 15.2%, P = 0.021). A total of 6 risk 
factors for PEP were identified. 
Four meta-analyses (13,44-46) for prophylactic PS placement and PEP indicated that 
prophylactic temporary stent placement significantly reduces the risk of PEP.  
A meta-analysis by Andriulli et al. (44) showed that PEP developed in 16.5% of controls, and 
in 5.1% or 9.6% of the stent group on per-protocol (PP) or intention-to-treat (ITT) analyses. 
Analysis of 4 RCTs showed that PEP developed in 24.1% of controls, and in 6.1% or 12.0% of 
the stented patients on PP or ITT analyses. The risk was significantly lower in the stent 
group than in the controls (OR, 0.44; 95% CI, 0.24 - 0.81). The ORs for mild to moderate PEP 
were reduced in the stent group (OR, 0.537; 95% CI, 0.283 - 1.021), as well as those for severe 
PEP (OR, 0.123; 95% CI, 0.021 - 0.726). These trials indicated the benefits of pancreatic 
stenting in the prophylaxis of PEP; however, further randomized studies are needed before 
endorsing the routine use of this endoscopic procedure. 
Choudhary et al. (45) have recently found that PS placement decreases the risk of PEP and 
hyperamylasemia in high-risk patients. They concluded in a meta-analysis of RCTs that 
prophylactic PS placement decreased the odds of PEP (OR, 0.22; 95% CI, 0.12 - 0.38; P < 
0.01). Stents also decreased the level of hyperamylasemia (weighted mean difference, -
309.22; 95% CI, -350.95 to -267.49; P ≤ 0.01). Similar findings were also noted in other non-
randomized studies.  
Mazaki et al. (46) in their meta-analysis showed that PS placement after ERCP reduces the 
risk of PEP. They concluded that PS placement was associated with a statistically significant 
reduction in PEP (RR, 0.32; 95% CI, 0.19 - 0.52; P < 0.001). Subgroup analysis with 
stratification according to PEP severity showed that pancreatic stenting was beneficial in 
patients with mild to moderate PEP (RR, 0.36; 95% CI, 0.22 - 0.60; p < 0.001) and in patients 
with severe PEP (RR, 0.23; 95 % CI, 0.06 - 0.91; P = 0.04). Subgroup analysis according to 
patient selection demonstrated that pancreatic stenting was effective for both high-risk and 
mixed-case groups.  
Freeman et al. (1,20) also reported that unsuccessful cases of stent placement were at higher 
risk of PEP. Therefore, the PS insertion method for such risk factor cases, and for those in 
which cannulation is difficult should involve only the insertion of a guidewire before the 
main procedure. Moreover, it is occasionally difficult to place a stent in anatomic deformity 
cases. In such cases, the careful use of the Radifocus R  (Termo, Tokyo, Japan) guidewire or 
a 0.025-inch guidewire will enable successful stent placement. Taken together, PS placement 
is a strategy for preventing PEP which has been shown to be the most effective procedure 
related to prevention of PEP. 
Recently, to increase the success rate of primary deep biliary cannulation and reduce the risk 
of PEP, a wire-guided cannulation method has been proposed. However, several 
prospective studies (50-52) provided conflicting results as to whether the wire-guided 
cannulation technique reduces PEP risk compared with the standard method. Further RCTs 
are needed to confirm the effectiveness of this method. 
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4.1.6 Type of stent 
Stents with various diameters (3 - 7-Fr), lengths (2.0 - 12 cm), and with or without flanges 
have been used in previous studies of PEP. However, the optimal stent has not been 
determined (25,53).  
An internal flange is likely to make spontaneous PS dislodgment difficult, and in such cases, 
generally, the PS has to be removed 7 - 14 days after placement by additional endoscopy, 
which may not only injure the pancreatic duct, but also be an economic burden. An 
unflanged stent designed to pass spontaneously from the pancreatic duct may obviate the 
need for a second endoscopic procedure for stent retrieval. It may also reduce the overall 
cost of treatment and procedures, and the pancreatic duct is less likely to be injured by an 
internal flange when the PS dislodges spontaneously. It has been reported that 86% of 3-Fr 
stents spontaneously dislodged (25).  
Unflanged duodenal pigtail- and straight-type stents may spontaneously dislodge into the 
duodenum owing to pancreatic juice flow or friction with passing food. According to 
previous RCTs (15,43), unflanged duodenal pigtail- and straight-type stents spontaneously 
dislodge at a higher rate. The spontaneous dislodgement rates were 93.8% and 95.7%, and 
the durations until dislodgement were 2.7 and 2 days on average, respectively. The straight 
type of PS shape on the duodenal side is an important feature facilitating stent placement. 
Although the unflanged pigtail-type stent may be spontaneously dislodged at a higher rate 
due to friction with passing food and duodenal peristalsis, the handling of the short 
duodenal pigtail-type stent is slightly complicated, for example, the possible sudden 
forward movement of the stent on release, thus it requires close attention and experience. 
The straight-type PS with a flange on the duodenal side is easier to place than the pigtail-
type PS. 
Long-term PS retention is a significant risk factor with respect to chronic pancreatitis (1,25-
28). Rashdan et al. (25) reported that 3 - 4-Fr stents are more effective than traditionally used 
stents for preventing PEP, and that 5 - 6-Fr stents cause more significant stent-induced 
pancreatic duct changes than 3 - 4-Fr stents. However, 3 - 4-Fr stents require a small-caliber 
guidewire (0.018 - 0.025 inches), and the use of a small-caliber guidewire is difficult and 
requires a high level of experience (1,25-27). In contrast, the 0.035-inch guidewire used with 
the 5-Fr PS is relatively easy to use for stent placement.  
5. Conclusion 
PEP is the most common and potentially serious complication of ERCP-related procedures. 
The current optimal strategy for preventing PEP is considered to include the elucidation of 
its underlying mechanisms, identification of risk factors, administration of pharmacological 
drugs, and endoscopic procedures such as pancreatic stenting. The placement of a PS 
currently remains the most effective strategy for preventing PEP. 
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1. Introduction 
The nosological definition of inflammatory pancreatic diseases appears rather difficult and 
uncertain, as proved by the great number of classifications which have been proposed in the 
last few decades, showing that the definition and classification of this disease is still under 
critical review. The reason is the reduced availability or, in the majority of the cases, the 
absence of histological findings which can be connected to a clinical picture that moreover is 
often subject to evolutions. A not negligible role in generating uncertainties is played by the 
very diversified territorial distribution of the various forms of pancreatitis: this provides to 
the different observers different and often hardly reconcilable experiences. Therefore, the 
succeeding classifications are based exclusively on clinical or laboratory data or on imaging 
exams. We can consider as stable references the basic anatomo-clinical correspondences. It is 
preliminarily acquired that the parenchymal phlogistic process recognizes its origin in the 
self-digestive effect of the same pancreatic proteolytic enzymes. Self-limiting parenchymal 
inflammation characterizes mild and moderate acute pancreatitis. Self-digestive processes of 
serious entity with parenchymal necrosis and peripancreatic fluid collections manifest 
themselves as severe acute pancreatitis (SAP). Finally, chronic pancreatitis is histologically 
characterized by fibrosis, sclerosis and calcifications. Historically, the rigorous and well-
defined distinction between acute and chronic pancreatitis has represented for a long time 
the basis of classifications in which acute and chronic pancreatitis were substantially 
considered two different diseases but, in the course of time, important modifications have 
taken place. In fact, currently this distinction is in discussion due to the imaging of the main 
bile duct and of the duct of Wirsung and above all due to the more comprehensive, 
prolonged and detailed clinical observations which allow to estimate the sometimes long 
evolution of pancreatitis. These observations show that acute and chronic forms overlap 
(Bassi & Butturini , 2007). The onset and/or the acute manifestations of chronic pancreatitis 
are considered and also the acute pancreatitis which, because of the repeated acute episodes, 
evolve anatomo-clinically towards chronicity. Recurrent acute pancreatitis is characterized 
by several acute episodes which follow the first attack. On the whole, the risk of recurrence 
for pancreatitis with different etiology is contained (20-30%). On the contrary the patients 
who present a second attack have a much higher risk of further recurrences and therefore 
require a rigorous diagnostic investigation. Biliary lithiasis and excessive alcohol 
consumption are the more frequent causes of pancreatitis, reaching as a whole the total 
incidence of 80% (Barthet, 2001; Gullo et al, 2002). However, the frequency rate between 
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biliary and alcoholic etiology is subject to great variations in relation to geographic 
distribution. Moreover, even if with much contained frequency, numerous other causes of 
pancreatitis are recognized which may manifest as recurrent and which, on the whole, 
represent 20% of the total (Ferec & Maire, 2005; Hastier, 2005) : hereditary, metabolic 
pancreatitis (hyperlipidemia, hypercalcaemia, steroids), from neoplastic ductal obstruction 
(intraductal papillary mucinous neoplasms (IPMN), periampullary tumors,etc), from 
congenital anomalies (pancreas divisum, annular pancreas, anomalies of the biliopancreatic 
junction), from dysfunction of the sphincter of Oddi, from drugs and toxic substances, 
trauma and infections and finally post-endoscopic retrograde cholangiopancreatography 
(ERCP) pancreatitis. Among all the various forms of recurrent pancreatitis, the conditions 
based on the obstruction of the flow of pancreatic secretions amenable to endoscopic 
treatment (ERCP-Endoscopic Sphincterotomy (ES)) are in evidence: biliary pancreatitis, 
dysfunction of the sphincter of Oddi, pancreas divisum. The object of our interest is the 
anatomo-clinical condition of recurrent pancreatitis. Pancreatic inflammatory diseases may 
evolve towards chronicity because of either the episodic increase of the phlogistic response 
and/or the recurrence of acute attacks. In pancreatitis with different etiopathogenesis it is 
useful to examine which are the possible different pathogenetic modalities of pancreatitis 
recurrence and its possible evolution. On the basis of the clinical presentation, acute 
pancreatitis, in particular those of biliary etiology, can be subdivided in mild, moderate and 
severe: the former, which include clinical forms of different relevance and extension, 
represent the majority of acute pancreatitis (75%). Severe forms constitute the remaining 
25%. Among these an ulterior 20% is represented by forms of particular and sudden severity 
(early severe acute pancreatitis (ESAP)) (Beger & Rau , 2007). Pancreatitis incidence increases 
stably with the increase of the average age of population and with the increased incidence of 
biliary lithiasis and alcohol consumption. Unlike in chronic pancreatitis in which fibrosis 
does not revert and there is no total recovery with restoration of the original condition, 
patients with an attack of acute pancreatitis, particularly in mild/moderate forms, show an 
almost complete anatomical and functional recovery. However, there remains still the 
possibility of other recurrent attacks. The reason of this possible evolution can be recognized 
in at least two circumstances: either the initial and effective cause persists or it is not 
completely removed by the therapeutic intervention: biliary lithiasis or biliary sludge, 
cholelithiasis, inflammatory papillary stenosis, invariated alcohol consumption, tumors 
obstructing the main pancreatic duct. Also severe pancreatitis with extended necrotic 
parenchymal areas can evolve into chronic pancreatitis for successive stenosis of the main 
pancreatic duct. The possibility of the evolution of an acute inflammatory process into a 
chronic phlogistic condition returns therefore in evidence. The distinction between acute 
and chronic pancreatitis is based on the natural history, the characteristics of the clinical 
picture and the anatomo-pathological alterations. Acute pancreatitis starts out in patients 
with no history of related illness and with the possibility of a complete resolution especially 
in mild/moderate forms. On the contrary, the anatomical and functional recovery in severe 
forms can be compromised. Moreover in SAP with severe impairment of the general clinical 
conditions and important structural alterations, the prognosis is serious. In chronic 
pancreatitis the organ impairment and the persistence of painful symptomatology of 
moderate severity characterize the intervals between the acute attacks. However, the acute 
attack, both in acute and chronic pancreatitis, is characterized by acute onset and by very 
 
Recurrent Pancreatitis 
 
87 
similar symptoms. Therefore, in the absence of an histological exam and of prolonged 
observation, the distinction between the two forms may be difficult. Regarding this point, 
SAP and ESAP often with biliary etiopathogenesis and with impairment of clinical 
conditions, must be considered with attention. In fact, the acute onset in chronic pancreatitis 
and severe acute pancreatitis may be distinguished for the presence in the latter of a severe 
impairment of clinical conditions which impairs the prognosis. All these considerations 
contribute to establish a connection between acute and chronic forms. The inflammatory 
process underlying acute pancreatitis can resolve if the recurrence of acute episodes is 
interrupted in the early stages. But, if the conditions which determine the recurrence of the 
acute attacks persist, like for example papillary sclerosis or obstruction with reflux in the 
duct of Wirsung, then inflammation will be able to evolve into fibrosis and acute 
pancreatitis will evolve anatomically and clinically into chronic pancreatitis. Therefore, 
recurrent pancreatitis may be considered the clinical condition which constitutes the bridge 
between acute and chronic pancreatitis. In fact, pancreatic inflammation may show a chronic 
evolution through the recurrence of acute episodes. Thus it is important to establish through 
which anatomical alterations and how in the pancreatitis of various etiologies this evolution 
is determined. 
2. Biliary pancreatitis 
Pathogenetic modalities of recurrent pancreatitis are well evident in biliary pancreatitis. 
Recurrent acute biliary pancreatitis is caused by obstacle in the papillary patency with 
abnormal biliopancreatic flow. Papillary obstacle, caused by gallstones, biliary sludge, 
cholesterol cristals, sclerosis or edema, determines biliopancreatic reflux in the pancreatic 
duct with consequent pancreatitis. Therefore, restoring the normal transpapillary flow and 
cleaning the common bile duct (CBD) can prevent pancreatitis recurrences. This 
pathogenetic pattern of acute biliary pancreatitis (ABP) is by now widely documented 
(Frossard et al.,2008; Lee et al, 1992; Opie, 1901; Pandol SJ, 2006; Wang et al, 2009). The 
incidence of recurrent biliary pancreatitis is reported to widely vary between 30% and 60% 
in patients who did not undergo cholecystectomy and ES, often with a short interval 
between the first and the second attack: 4-6 weeks (Heider et al, 2006; Van Geenen et al, 
2009). Our purpose is to evaluate the possibility and the means to prevent recurrent acute 
biliary pancreatitis. Detailed examination of an homogeneous series contributes to clarify 
the anatomo-clinical details. The study evaluated the patients with ABP admitted to our 
hospital in the period September 1997 - December 2010. We collected a total of 261 cases, 
mean age 49 (20-86), M 112 – F 149, including 203 (77,7%) mild/moderate and 58 (22,3%) 
severe pancreatitis (Tab 1). Among moderate pancreatitis, we recognized 31 (15,7%) 
moderate/severe pancreatitis, characterized by extensive pancreatic and peripancreatic 
inflammation with fluid collections and mild necrosis, without however impairment of the 
general clinical conditions (Heider et al, 2006; Nealon et al, 2004). We selected, through the 
medical records, the patients who had a first attack of ABP, distinguishing them from the 
ones who had previously suffered from one or more episodes of ABP. The patients with a 
first attack of onset were on the whole 188 (72,3%), while those with previous repeated 
episodes were 73 (28%). Among the 73 recurrent pancreatitis, 12 (16,4%) were severe and 61 
(83,6%) moderate/mild (Tab. 2). 
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MEAN 
AGE 
SEX Dir. 
BIL. 
< 2 
mg/dl
Dir. 
Bil. 
2-5 
mg/dl
AST/ALT 
x3 iU/l 
gamma-
GT 
>200 
iU/l 
ALP 
>150 
iU/l 
CBD 
size 
(US)> 8 
mm 
Cholecystic 
Lithiasis 
49 
(20-86) 
F 149 
M 112
60.4% 39.6% 
 
26.8% 59.9% 53.6% 40.7% 100% 
EDEMATOUS 187 71.64% 
NECROTIZING 74 28.36% 
PERIPANCREATIC FLUID 
COLLECTION 
95/261 36.39% 
Table 1. Demographic data, percentage incidence of biliary lithiasis and cholestasis tests, 
pancreatitis morphology (US/CT) in 261 acute biliary pancreatitis at the admission in our 
Hospital. 
 
MEAN 
AGE 
SEX Dir. 
Bil. 
< 2 
mg/dl
Dir. 
Bil. 
2-5 
mg/dl
AST/ALT
x3 iU/l 
gamma-
GT 
>200 
iU/l 
ALP 
>150 
iU/l 
CBD size 
(US)>8mm 
Cholecystic 
Lithiasis 
54 
(28-76) 
F 44 
M 29 
47.2% 52.8%
 
31.2% 64.3% 59.4% 48.2% 100% 
EDEMATOUS 54 73.97% 
NECROTIZING 19 26.03% 
PERIPANCREATIC 
FLUID 
COLLECTION 
33/73 45.20% 
Table 2. Demographic data, percentage incidence of biliary lithiasis and cholestasis tests, 
pancreatitis morphology (US/CT) in 73 recurrent acute pancreatitis at the admission in our 
Hospital. 
The acute episode of pancreatitis was defined by the presence of abdominal epi-mesogastric 
pain radiating through to the back and by increased serum amylase and lipase levels. To 
establish the gallstone etiology of pancreatitis, we searched, in all patients, on 
ultrasonography, gallbladder lithiasis and/or gallstones, sludge, microlithiasis etc. in the 
CBD or also a dilatation of the CBD (>8 mm). Laboratory cholestasis tests were on average 
positive in 40% of patients: direct bilirubin between 2 and 5 mg/l, alkaline phosphatase 
>150 U/l and gamma-GT >200 U/l. Alcohol consumption in these patients had also been 
excluded. The severity of pancreatic involvement was assessed with abdominal ultrasound 
(US) at the admission and with computed tomography (CT) (Balthazar criteria)(Balthazar et 
al, 1990) after 48-72-hours. The patients with previous attacks of recurrent acute pancreatitis 
have not been submitted, during the previous hospitalizations, to any specific therapy for 
pancreatitis (ERCP/ES, cholecystectomy), but only to simple supportive therapy. In this 
group, with recurrent pancreatitis, control of gallstone etiology, laboratory cholestasis tests 
and the CT pancreatic involvement were not dissimilar compared to all patients. All patients 
underwent the complete treatment for ABP, adjusted according to the degree of severity of 
the disease: intensive therapy, clinical and instrumental monitoring of papillary patency, 
 
Recurrent Pancreatitis 
 
89 
ERCP/ES (209/261=80%) within 72 hours from the onset in all severe pancreatitis (58) (in 3 
cases this procedure was unsuccessful and in 7 cases it was delayed for 10 days), in all 
recurrent pancreatitis (73), in all moderate/severe pancreatitis (31) with extensive 
inflammatory pancreatic and peripancreatic involvement, fluid collection and mild 
pancreatic necrosis (as shown by CT), but without organ failure and finally in 
moderate/mild pancreatitis with laboratory cholestasis tests and instrumental (US/MRCP) 
confirmation of papillary obstacle (lithiasis, microlithiasis, sludge in CBD, papillary edema, 
stenosis, etc.) (59/203, 29%). The treatment was completed with laparoscopic 
cholecystectomy: 254 video-laparocholecystectomies (VLC) and 7 open cholecystectomies. 
The timing of cholecystectomy varied according to the severity of pancreatitis; generally, we 
waited for the stabilization of the pancreatic and peripancreatic phlogosis/necrosis and of 
the patient’s clinical conditions. After the treatment and the discharge, all the patients were 
introduced in a follow-up program (clinical and instrumental control after 90 and 180 days). 
The 73 patients with recurrent pancreatitis, after the standard therapeutic program and the 
discharge, entered a follow-up program with clinical and instrumental controls at 90 and 
180 days. Forty-two (57,5%) patients were monitored (31 patients could not be reached): the 
results of the follow-up showed, beside the absence of critical episodes, the stable 
normalization of laboratory and instrumental cholestasis tests at the first (90 days) and at 
the second control (180 days) (Tab 3). A further recurrence has occurred only in 2 patients 
(2/42 = 2,7%) with a moderate/mild pancreatitis at the 145th day from the discharge. Once 
the persistence of the papillary obstacle for incomplete sphincterotomy had been assessed, 
the resolution was obtained with medical therapy and a new ES. 
 
Tot. Bil. 
 
ALP 
 
AST/ALT 
 
Amylase
 
Lipase 
 
gamma-
GT 
 
CBD 
size 
(US) 
Recurrence 
0.80 
mg/dl 
115 
iU/l 
24/50 
iU/l 
220  
iU/l 
110 
iU/l 
38 
iU/l 
6 
mm 
2 (2.7%) 
Table 3. Recurrent acute biliary pancreatitis 42/73 (57.5%) : follow-up (180 days)  
Cholestasis tests were on average normal. 
The same controls in 88 patients (88/188 = 46,8%) with a first attack of acute pancreatitis, at 
90 and 180 days from the discharge resulted normal, in the absence of new acute episodes 
(Tab 4).  
 
Tot. Bil. 
 
ALP 
 
AST/ALT 
 
Amylase 
 
Lipase 
 
gamma-
GT 
 
CBD 
size 
(US) 
Recurrence 
0.90 
mg/dl 
112 
iU/l 
28/40 
iU/l 
95 
iU/l 
158 
iU/l 
54 
iU/l 
5 
mm 
_ 
Table 4. Acute biliary pancreatitis 88/188 (46,4%) : follow-up (180 days)  
Cholestasis tests were on average normal. 
We believe that ES has a control role in the therapy of ABP. Biliary pancreatitis presents 
clinical findings of different severity. Signs and symptoms of reference, always present, 
consist in epigastric pain with acute onset and characteristic radiation to the back and 
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evident increase of serum amylase and lipase levels. Moderate/mild pancreatitis, with 
pancreatic or peripancreatic edema, is not accompanied by impairment of the patient’s 
general clinical conditions, requires only supportive therapy and generally evolves towards 
a spontaneous recovery. In these patients cholecystectomy is indicated and is performed, as 
a general rule, while the patient is still hospitalized. In moderate/mild pancreatitis ES is not 
generally indicated because the papillary obstacle is transient and probably incomplete. In 
the cases showing clinical and laboratory signs or ultrasound evidence of cholestasis, 
instrumental control of the bile duct with magnetic resonance cholangiopancreatography 
(MRCP) is proposed. ERCP/ES is used as therapy only in case of lithiasic obstacles or biliary 
sludge in the CBD or papillary stenosis. Moreover the advisability of an instrumental 
control of the bile duct with MRCP is discussed in patients with mild acute pancreatitis who 
do not show any clinical or instrumental sign of cholestasis, as an additional exam beside 
the routine abdominal ultrasonography before cholecystectomy. The incidence of gallstones 
in the population of western countries is about 15% and among these patients about 10-15% 
have choledocholithiasis (Tazuma, 2006). The literature data show that a very variable range 
(45-75%) of patients with acute biliary pancreatitis has stones in the CBD (Barro et al,2005; 
Young et al,2003). The cases with acute biliary pancreatitis include mild/moderate self-
limiting forms with transient papillary obstacle, which are not accompanied by clinical, 
laboratory or instrumental signs of cholestasis. For these mild/moderate forms of acute 
pancreatitis the use of invasive procedures to explore the CBD is not advisable, while it is 
necessary to demonstrate the absence of stones in the CBD. For these reasons in patients 
with mild/moderate acute biliary pancreatitis without increase of cholestasis indexes and in 
the absence of dilatation of intra and extra-hepatic biliary ducts, it is useful to know if 
obstacles are present in the CBD. These patients should undergo a MRCP to determine the 
conditions of the CBD before cholecystectomy. In these cases, in fact, the extensive use of 
MRCP can be useful for a significant reduction of the number of non-therapeutic ERCP/ES 
and their associated complications. The clinical scenario is, in 20-30% of cases, a severe 
pancreatitis characterized by extensive pancreatic and peripancreatic necrosis, fluid 
collections at risk of infection, possible systemic inflammatory response syndrome (SIRS) 
with impairment of the patient’s clinical conditions which always requires starting 
immediately intensive therapy. Besides, 20% of SAP show an early severity – ESAP - with 
development within 72 hours of multiple organ failure and within 2 weeks of infection of 
the pancreatic and peripancreatic necrotic collections with high mortality (40-60%). Thus, in 
all severe pancreatitis it is necessary a prolonged control of the pancreatic and 
peripancreatic necrotic collections which are exposed to infectious complications. Early 
(within 72 hours) ES has proved to be successful to maintain and to control the evolution of 
the inflammatory process and also safe to prevent close inflammatory-necrotic recurrences, 
which are caused by the persistence of the papillary obstacle and of the biliary reflux in the 
pancreatic duct (Folsch et al, 1997; Heider et al, 2006; Hernandez et al, 2004; Kimura et al, 
2006; Neoptolemos et al, 1988; Sungler et al, 2007 ; Van Geenen et al, 2009). Cholecystectomy 
is definitely indicated, but should be programmed once the patient’s clinical conditions are 
stable. Another clinical manifestation of biliary pancreatitis is the moderate form. Its 
nosological definition is rather difficult and uncertain, placed between the much better 
identifiable mild and severe forms. Among the moderate forms it is significant, to 
therapeutic goals, to identify the moderate/severe forms (Heider et al,2006) which are 
characterized by pancreatic necrosis, not exceeding 30% of the parenchyma at the CT control, 
edema and phlogosis of the retroperitoneal peripancreatic lodge with possible fluid 
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collections. In these forms impairment of the patient’s clinical conditions with multi-organ 
dysfunction is absent. Also, infection of the fluid collections occurs rarely. The resolution of 
symptoms occurs in a relatively short time, 10 days on average; return to normality of serum 
amylase and lipase levels is slower and so is the resolution of the pancreatic and 
peripancreatic phlogosis/necrosis and the fluid collections reabsorption. Also in these cases 
early (within 72 hours) ES is effective to reduce the risk of an often even earlier recurrence of 
pancreatitis. Cholecystectomy can be performed when the patient’s clinical conditions are 
restored, almost always during the same hospitalization. The pathogenesis of acute biliary 
pancreatitis is based on the alteration of transpapillary flow caused by edema and/or 
mechanical obstacle which determines the pancreatic intra-ductal reflux. Thus ES by 
normalizing the biliopancreatic transpapillary flow removes the morphofunctional 
alteration and reduces the risk of pancreatitis recurrences, which present themselves 
sometimes with acute close episodes. Besides, ERCP/ES allow at the same time to clean the 
CBD in case of sludge, microlithiasis or stones. Once the initial pathogenesis has been 
defined, it remains to establish which patients with acute biliary pancreatitis should 
undergo ES. ES is indicated in severe and in moderate/severe pancreatitis, and, of course, in 
acute recurrent pancreatitis, irrespective of the presence of laboratory, clinical and 
instrumental signs of cholestasis or of a lithiasic obstacle in the CBD which, if present, 
constitute further motive for ES. On the contrary, moderate/mild pancreatitis does not 
require endoscopic treatment unless cholestasis is present. In patients with recurrent 
pancreatitis, according to the pathogenetic sequence papillary obstacle / biliopancreatic 
reflux, the necessity to restore the papillary patency with ES is assumed. In our experience 
recurrent pancreatitis is present in 30% of acute biliary pancreatitis treated. Recurrent 
pancreatitis occupies a nosographic place which presents a special interest because it can 
represent the connection between acute pancreatitis and chronic pancreatitis. A relevant 
contribution to the definition of the therapeutic choice and of the possible nosological 
organization which may clarify the possible evolutions of acute pancreatitis (ex: recurrent 
acute pancreatitis evolving to chronification of the phlogistic lesions) may come from the 
careful and extended clinical observation integrated with repeated instrumental 
verifications: US-CT-MRCP. In fact, ever since its onset, we can consider pancreatitis as a 
difficult disease to classify, whose possibilities of evolution can be influenced by numerous 
etiopathogenetic factors and which should be subject to a dynamic follow- up. Acute 
pancreatitis can evolve into the chronic form as the result of recurrences of repeated 
episodes of papillary obstruction secondary to edema and to sclerotic evolution of the 
inflammatory reaction of the sphincter of Oddi. Biliary lithiasis, with passage of stones, 
biliary sludge, microstones or with persistent lithiasic obstacle of the papilla, plays a 
considerable role in the genesis of the sclerosis of the sphincter of Oddi. In this light, ES in 
the treatment of recurrent acute biliary pancreatitis may have a role of prevention against an 
hypothesized papillary fibrotic evolution of the phlogosis with consequent chronification. 
The process that brings to pancreatic fibrotic alterations corresponds clinically to repeated 
episodes of typical abdominal pains and increased levels of serum amylase and lipase which 
are caused by recurrences of acute pancreatitis. The episodes of parenchymal inflammation 
evolve towards the self-limitation of the phlogosis without sequels, as an alternative to the 
evolution towards chronification. The recurrent pancreatitis presents itself with the 
anatomopathological substrate of an acute inflammatory focus during the course of chronic 
pancreatitis. In a general picture, the possible evolutions of the pancreatic inflammations are 
self-limitation, progression with self-digestion and extensive necrosis of the parenchyma 
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and of the surrounding tissues, or an evolution with predominance of fibrosis and 
calcifications which characterize chronic phogosis. Finally, ES plays a double preventive 
role, interrupting the recurrence of acute attacks and the possible chronification of the 
phlogistic process. Recurrent acute biliary pancreatitis has been caused, in patients 
discharged from the hospital without additional treatment, by persistent papillary obstacle 
(small stones, sludge, microlithiasis, cholesterol crystals). Therefore we confirm the 
therapeutic validity of instrumental control (US/MRCP) and the possible treatment 
(ERCP/ES) of papillary or biliary lithiasic obstacle for the prevention of recurrent acute 
biliary pancreatitis. ES plays an important role in the treatment of ABP and a most 
important role in recurrent pancreatitis because of the persistent papillary obstacle. In 
severe, moderate/severe and recurrent pancreatitis, instrumental confirmation of 
papillary obstacle is not necessary because this is persistent. On the contrary, in 
mild/moderate pancreatitis laboratory, US and MRCP confirmation of papillary or CBD 
lithiasic obstacle is useful prior to ERCP/ES because the papillary obstacle is transient. 
Patients with mild/moderate pancreatitis without cholestasis indexes should undergo 
instrumental control with MRCP for lithiasic obstacles in the CBD prior VLC because in a 
very variable range (45-75%) of acute biliary pancreatitis stones are present in the CBD. 
The results of these evaluations show the efficacy of the therapeutic program with 
ERCP/ES in the prevention of recurrent acute biliary pancreatitis with mini-invasive 
approach. The pathogenetic modalities of recurrent pancreatitis are well defined and 
obvious in the forms with biliary aetiology. However there are recurrent pancreatitis also 
among pancreatitis with different aetiology: these are less frequent pancreatitis for which 
a smaller number of observations is available and therefore with a somewhat uncertain 
characterization. 
3. Alcoholic pancreatitis 
The diagnosis of alcoholic pancreatitis is based on the definition of alcohol consumption and 
on the presence of anatomopatological alterations assessed with morphological 
examinations (X-rays, CT, EUS, wirsungraphy): parenchymal anomalies and of the excretory 
ducts with or without calcifications. In the course of alcoholic pancreatitis, recurrent 
episodes of acute pancreatitis can evolve into chronic pancreatitis and the effective and 
determining way of the recurrence of acute attacks can be evidenced (Gorelick, 2003; 
Spanier et al,2008; Whitcomb, 2005). In fact, most observers currently believe that chronic 
pancreatitis which follows prolonged ethanol abuse reflects repeated but subclinical, 
episodes of acute pancreatic injury. These repeated episodes of pancreatic injury with 
necrosis lead to fibrosis which characterizes chronic pancreatitis (Kloppel,1999). There are 
numerous theories since long presented in literature which propose an explanation of the 
lesive action of alcohol on pancreatic parenchyma but none of them is completely acquired. 
Alcohol would cause hypertriglyceridemia, fat acid and ethyl esters formation, that is 
formation of oxygen free radicals, causing pancreatic phlogistic damage. According to 
another hypothesis, alcohol alters the composition of pancreatic secretions with reduction of 
inhibiting enzymes and proteins precipitation forming intraductal plugs. Ductal obstruction 
causes increase in endoluminal pressure and consequent phlogosis with multiple foci of 
pancreatitis. Also the spasm of the sphincter of Oddi has been attributed to the action of 
alcohol. 
 
Recurrent Pancreatitis 
 
93 
4. Processes obstructing the flow of pancreatic juice, pancreas divisum 
Obstructions of various nature of the main pancreatic excretory duct can cause pancreatitis 
too, in the parenchymal territory proximal to the obstruction. The obstacle can be a ductal 
neoplasia (IPMN) (Fazel et al ,2005) or a papillary alteration (periampullary diverticula, 
duodenal ulcer, duodenal Crohn, post-traumatic stenosis of the duct of Wirsung), or 
pancreas divisum (Arya et al, 2006; Gelrud et al, 2004). Pancreas divisum can cause acute 
pancreatitis for the small-caliber of the minor papilla which represents an obstacle to 
pancreatic flow. The endoscopic control of pressure in the pancreatic duct shows values 
more elevated than in normal patients. This hypothesis is at the basis of the therapeutic 
procedure of sphincterotomy of the pancreatic minor papilla. Therapeutic success reaches 
80% (Bradley & Stephan,1996). The pancreatitis from ductal obstruction can present itself 
with an acute attack, orienting clinically to an acute form involving all the gland, but the 
histological characteristics are attributable to a chronic phlogosis which is limited to the 
portion of gland proximal to the obstruction. Also in this case, the evolution of the anatomo-
pathological lesion is characterized by the sequence phlogosis-proteolisis-necrosis-fibrosis. 
In advanced stages of chronic pancreatitis ductal stenoses and gallstones can be the base of 
acute attacks of pancreatitis. However, recurrent acute attacks are documented also in the 
early stages of alcoholic chronic pancreatitis (Garg et al,2007). In summary, it is not well 
established whether initial chronic pancreatitis is the cause of recurrent acute pancreatitis or 
whether, on the contrary, acute recurrent attacks of pancreatitis evolve into chronic 
pancreatitis. In general, for pancreatitis caused by an obstacle to the flow of pancreatic 
secretions, the treatment consists in the removal of the obstacle. However, the specific 
treatment is deeply diversified according to the nature of the obstacle: ampullary and 
periampullary tumors and intraductal neoplastic stenoses must be removed surgically; 
small pancreatic stones or phlogistic stenosis can be treated with endoscopical procedures. 
5. Hereditary pancreatitis 
In hereditary pancreatitis (Ferec & Maire,2005; Whitcomb, 1999), the intraparenchymal 
activated trypsinogen is not inhibited by the antienzymes which are inactive for genetic 
causes, that is because it is present trypsin rendered genetically resistant to antitrypsin. The 
effect is a series of recurrent episodes of pancreatitis which induce parenchymal chronic 
alterations with fibrosis, calcifications and sclerosis. 
6. Autoimmunitary pancreatitis 
The autoimmunitary phlogistic process in pancreatitis is characterized by a sclerotic effect 
(Hamano et al, 2001) with conspicuous lymphoplasmacellular infiltrates. In these cases, 
phlogosis is delimited sometimes in a mass which, if in the pancreatic head, can  
cause biliopancreatic ductal obstruction, simulating a neoplastic lesion (autoimmune 
lymphoplasmacellular pancreatitis or eosinophilic pancreatitis).  
7. Metabolic pancreatitis 
Possible recurrences of acute attacks with phlogosis which evolve into fibrosis and  
chronic sclerosis occur for hypercalcaemia and hyperlipidemia. Hypercalcaemia (in 
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hyperparathyroidism) causes pancreatitis for the increased activation of proteolytic 
digestive enzymes. Hyperlipidemia causes pancreatitis because chylomicrons and free fat 
acids in excess interfere with pancreatic microcirculation. The circulatory alteration is the 
base of ductal obstructions of fibrous origin (obstructive mechanism).  
8. Pancreatitis in celiac disease 
Celiac disease (CD) is an immune mediated enteropathy caused by permanent insensivity to 
gluten in genetically susceptible individuals. Some recent reports have shown an association 
between acute pancreatitis and CD. A recent epidemiological study has shown that patients 
with CD have a higher risk than the general population for development of acute 
pancreatitis with epigastric pain and biochemical and radiographic confirmation 
(Ludvigsson et al, 2007). There are in the literature many pathogenetic mechanisms to 
explain the development of pancreatitis in patients with CD. T helper cell class 1 (TH1) 
cytokine up-regulation in CD may be predisposing factor for acute pancreatitis (Ludvigsson 
et al,2007). Another hyphotesis suggests that malnutrition can cause pancreatitis 
(Ludvigsson et al, 2007). However there is no evidence to show improvement of pancreatitis 
after correction for malnutrition. The mechanism for recurrent pancreatitis in CD may be 
papillary stenosis resulting from localized duodenal inflammation (Patel et al, 1999; Sood et 
al, 2007). The ES is the possible treatment. On the other hand it is also postulated that the 
improvement of recurrent episody of pancreatitis is a result of gluten restriction (Patel et al, 
1999)). 
9. Idiopathic pancreatitis 
Idiopathic pancreatitis, that is with undefined etiology, represent approximately 20% of all 
cases. Among them, however, an important number can be ascribed to biliary forms with 
microstones or biliary sand of which there is no sure confirmation, that is they are caused by 
dysfunction of the sphincter of Oddi , generally of difficult demonstration. 
10. Sphincter of Oddi dysfunction  
Sphincter of Oddi dysfunction (SOD) can be due to stenosis or dyskinesia. Stenosis is a 
structural alteration due to inflammation and consequent stenosis (ex. passage of stones). 
Dyskinesia, instead, is a functional disorder with hypertonia. Stenosis or dyskinesia can 
involve the biliary sphincter, the pancreatic sphincter or the common sphincter. The 
clinical pictures may be slightly different if the alteration involves the biliary sphincter 
(pain of biliary type, biliary enzymes increase) or the pancreatic sphincter (pain of 
pancreatic type, recurrent attacks of pancreatitis). In summary, the phlogistic process is 
due to the obstruction and to the increased pressure in the pancreatic excretory system. 
The therapeutic indication in SOD is endoscopic sphincterotomy. Criteria for this 
diagnosis are represented by dilatation (> 8 milimeter) of the common bile duct, delayed 
emptying (more than 45 ') after ERCP, increased levels of alkaline phosphatase and 
gamma-GT during the episodes of pain. Certainty of diagnosis is based on finding, on 
manometry during ERCP, elevated pressure in the sphincter of Oddi (> 40 mmHG). Tc-
99m iminodiacetic acid (IDA) cholescintigraphy is helpful for the diagnosis. It is moreover 
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possible that the dysfunction of the sphincter of Oddi be present also in patients who did 
not undergo cholecistectomy. Three levels of diagnostic certainty are distinguished. In 
type 1 SOD the three clinical criteria above mentioned are present and manometry of the 
sphincter is superfluous. In type 2 SOD two clinical criteria are present or or only one but 
this one must not be pain. In this case manometry of the sphincter of Oddi is necessary 
and is pathological in half of the cases. Lastly in type 3 SOD only pain is present in the 
right hypochondriac region. Manometry of the sphincter is necessary. Moreover, in these 
cases of uncertain assessment the answer to the sphincterotomy is not sure (Vassiliou & 
Laycock,2008). In fact endoscopic sphincterotomy, in particular of pancreatic sphincter, 
can prevent the recurrence of dysfunction of the sphincter of Oddi in 60% of cases (Elta, 
2008). 
In conclusion, the sequence of physiopathologic events which underlies pancreatic 
parenchymal phlogosis has overlapping characteristics in acute and chronic pancreatitis. 
The inflammatory process, caused by ductal obstruction or for cleansing, by the biliary 
reflux, of the mucosa of the main pancreatic duct, is determined by the action, in the 
acinar cells of pancreas, of the same proteolytic enzymes produced there. Chronic 
pancreatitis is caused by repeated episodes of subclinic acute pancreatitis with 
parenchymal necrosis evolving into fibrosis. Therefore, the hypotheses to consider are the 
activation of proteolytic enzymes and of trypsinogen in the same acinar cells or the 
reduced inhibitory action of antienzymes that is, in the end, the activated 
intraparenchymal diffusion of the pancreatic secretions activated in the lumen of the 
excretory duct for the alteration of its mucous barrier. Recurrent, also subclinical, episodes 
of acute pancreatitis with phlogosis and necrosis evolve into the fibrosis and the sclerosis 
of chronic pancreatitis. It must still be explained how the obstruction of the main 
pancreatic duct or of smaller ducts can induce the intracellular activation of proteolytic 
enzymes. Steer (Steer,1998) has advanced the hypothesis of the colocalization. According 
to this hypothesis, based on experimental data, enzymes like trypsinogen and lyisosomial 
hydrolase as catepsin B are localized together in the cytoplasmic vacuoli. In these 
conditions catepsin B can activate trypsinogen into trypsin which with its proteolytic 
action causes self-digestion and intraparenchymal phlogosis. The intensity of the 
inflammatory response can regulate the severity of pancreatitis. 
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USA 
1. Introduction  
Acute pancreatitis is the third most common gastrointestinal disease diagnosis at hospital 
discharge. (Browse 2003) Although many etiologies exist, the most common causes 
worldwide are gallstone disease and excessive alcohol consumption. However, one-third of 
pancreatitis cases have no association with alcohol, no associated biliary tract disease, and 
no pancreatic duct obstruction, and are thus labelled idiopathic. Despite a documented 
increase in the overall incidence of acute pancreatitis in several countries, disease related 
mortality has progressively declined over the years. This improvement is in part due to 
advances in disease management, including better diagnostics and treatment modalities. 
(Baron 2001) 
Acute pancreatitis is a pathological condition in which activated pancreatic enzymes leak 
into the substance of the pancreas and initiate  auto-digestion of the gland. Most episodes of 
acute pancreatitis are mild and self-limiting and do not require aggressive intervention. In 
marked contrast, approximately one fifth of patients develop severe acute pancreatitis 
which is associated with a mortality rate that can exceed 30%. (Bradley and Dexter 2010).  
Pancreatitis occurs with equal frequency in men and women, despite the common 
association of gallstones  with female gender. Although the peak incidence of pancreatitis is 
in the fourth and fifth decades of life, it  can occur at any age.  
2. Signs and symptoms 
The most common presenting symptom of acute pancreatitis is pain. Typically the 
discomfort begins suddenly, high in the epigastrium, and steadily increases in severity until 
movement is intentionally limited and respiratory excursion is reduced. It is often 
unrelenting and may radiate through to the back, classically just to left of mid-line. 
Frequently, a complex of nausea, vomiting and retching accompanies the abdominal pain. 
Although many acute abdominal conditions can cause nausea, and vomiting, pancreatitis is 
often associated with a specific pattern of persistent nausea between cyclical bouts of emesis 
without nausea prior to initiation of the pain. (Mergener and Baillie 1998) 
Many patients report having eaten an unusually large meal or drunk alcohol an hour or so 
before the pain began (Mergener and Baillie 1998). When the pain is severe, any movement 
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of the lower chest wall and abdomen exacerbates the discomfort, often resulting in  rapid 
shallow breathing and a sensation of dyspnea. In advanced cases, patients may develop 
tetanic muscle twitches, cramps and spasms related to associated hypocalcemia associated 
with the development of intra-abdominal fat necrosis. (Browse 2003) 
As the condition progresses, retroperitoneal inflammation and trans-capillary leak reduce 
intravascular volume resulting in tachycardia with peripheral vasoconstriction generating a 
pale skin tone and diaphoresis. A paralytic intestinal ileus may develop, resulting in 
abdominal distension, a quiet abdomen to auscultation, and aggravation of nausea. 
Advanced cases may be associated with retroperitoneal haemorrhage, causing bruising and 
discoloration in the left flank (Grey Turner’s sign) and around the umbilicus (Cullen’s sign); 
both are late signs of extensive inflammatory destruction of the pancreas and peri-pancreatic 
tissues. (Dickson et al 1984) 
Physical findings often consist of tenderness to palpation in the upper abdomen and 
abdominal distension, with severe cases producing diffuse abdominal guarding with 
discrete epigastric fullness secondary inflammatory exudate present in the lesser sac. Over 
time, this collection can organize, resulting in the formation of a pancreatic pseudocyst or 
lesser sac abscess. (Browse 2003) 
3. Laboratory assessment, risk assessment and prognostic systems 
Multiple risk assessment and classification systems have been developed over the years to 
assist in the clinical assessment of patients presenting with acute pancreatitis. These systems 
have been formulated in an attempt to predict the severity of a given episode of pancreatitis, 
and therefore aid in directing disease- appropriate management plans. Notable tools include 
the Atlanta Classification, Ranson’s Criteria, the Acute Physiology and Chronic Health 
Evaluation (APACHE) II systems, and the Balthazar CT Severity Index (CTSI). (Brisinda, 
Vanella et al. 2011) 
3.1 Biochemical values used for prognostication 
Biochemical markers, including serum amylase and lipase, have been traditionally utilized 
in the diagnosis of acute pancreatitis. Newer indices have been reported to yield higher 
correlations with the presence of pancreatitis and have demonstrated improved prognostic 
value. (Gates 1999) 
3.1.1 Serum amylase and lipase 
Serum amylase and lipase levels are the most commonly obtained biochemical markers of 
pancreatic disease, particularly for evaluation of the presence of acute pancreatitis. However, 
the utility of these enzyme markers is complicated by significant limitations, including low 
sensitivity and specificity (Young 1989). In aggregate, there are many causes of elevated serum 
amylase levels, and amylase levels may only be moderately elevated or even normal in proven 
cases of acute pancreatitis of all degrees of severity (Clavien et al. 1989).  
While an amylase level of three times the upper limit of normal is often recommended to 
support a clinical diagnosis of acute pancreatitis, the magnitude of the observed 
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hyperamylasemia has limited direct correlation with disease severity (Clavien et al. 1989). 
Furthermore, after reaching a peak serum concentration, the subsequent return of amylase 
levels to previously normal levels does not necessarily correlate with resolution of clinical 
illness, limiting the value of serial measurements (Young 1989). If hyperamylasemia 
temporally persists in conjunction with clinical symptoms, consideration should be given to 
the presence of a pseudocyst or peri-pancreatic abscess. Clinical studies have demonstrated 
that serum amylase levels can be normal in one-fifth of diseased patients, elevated in one-
quarter of well patients, and that the magnitude of serum elevation has poor statistical 
correlation with disease severity or ultimate prognosis. (Vissers, Abu-Laban et al. 1999) 
Serum lipase is the acinar enzyme most often recommended to replace or supplement 
amylase levels for the diagnosis of acute pancreatitis. At a cut-off of five times the upper 
limit of normal, an elevated lipase is virtually diagnostic for pancreatitis, approaching 100% 
specificity; however, its sensitivity is limited to 60% (Kazmierczak et al. 1993). Given these 
considerations, using a multiple of twice the upper limit of normal may offer high specificity 
without significantly compromising sensitivity. Although few studies have examined the 
prognostic value of elevated lipase levels in acute pancreatitis, most suggest poor correlation 
with disease severity, similar to amylase. (Vissers, Abu-Laban et al. 1999) 
Simultaneous measurements of both serum lipase and amylase have not been shown to 
improve diagnostic accuracy, and no advantage has been demonstrated over assaying lipase 
alone (Viel et al. 1990). While serum lipase measurements are comparable to amylase in 
terms of speed, cost, and availability, evidence suggests that lipase is the more accurate 
assay for acute pancreatitis (Clave et al. 1995). As a result, in institutions where both tests 
are available, it is recommended that lipase replace amylase as the initial enzymatic test for 
acute pancreatitis. Regardless of the marker employed, it is important to appreciate that the 
absolute levels of neither amylase nor lipase have prognostic value in established disease. 
(Vissers, Abu-Laban et al. 1999) 
3.1.2 Blood Urea Nitrogen (BUN) 
Some studies have demonstrated that an elevated Blood Urea Nitrogen (BUN) level at 
admission and subsequent temporal increases in BUN levels during the initial 24 hours of 
hospitalization are independent risk factors for mortality in acute pancreatitis (Wu et al. 
2009). Serial BUN measurements have also been shown to provide prognostic accuracy 
comparable to the more complex APACHE II score for early prediction of in-hospital mortality 
(Papachristou et al. 2010). Among patients with an elevated BUN value at admission (>20 
mg/dL), a decrease of at least 5 mg/dL at 24 hours is associated with a reduced risk of in-
hospital death. In contrast, among patients with a normal BUN value at admission, even 
modest increases in the BUN level (≥ 2mg/dL) are associated with an increased risk of 
mortality (Wu, Bakker et al. 2011). Due to its correlation with outcome, an algorithm based on 
early changes in BUN level has been developed to aid clinicians in evaluating patient 
responses to early resuscitation efforts in pancreatitis. (Wu, Bakker et al. 2011) 
3.1.3 Coagulation parameters: D-dimer and tissue factor 
Coagulation disorders are known to occur in the early phase of severe acute pancreatitis and 
the D-dimer of fibrinogen is a commonly used clinical parameter to assess the hemostatic 
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system (Salomone et al. 2003). Studies have demonstrated that serum D-dimer levels 
significantly differ between pancreatitis patients with and without key clinical 
differentiators such as the progression to multiple organ dysfunction syndromes, the 
eventual need for surgical intervention, and the development of both pancreatic and 
secondary infection (Radenkovic et al. 2009). Furthermore, serum D-dimer levels have been 
demonstrated to correlate well with two traditional markers of severity in acute pancreatitis, 
namely the APACHE II score and C-reactive protein serum levels (Papachristou, Whitcomb 
2004). As such, the D-dimer assay may be a useful, easy, and inexpensive early prognostic 
marker of the evolution and complications of acute pancreatitis. (Ke, Ni et al. 2011) Several 
studies have demonstrated elevated levels of circulating Tissue factor (TF) to be present in 
patients presenting with acute pancreatitis (Yasuda et al. 2009). Furthermore, a weak 
statistical correlation between assayed serum TF levels and disease severity has been 
observed (Yasuda et al. 2009).  Further studies will be required to characterize this 
relationship. (Andersson, Axelsson et al. 2010)  
3.1.4 C-reactive protein (CRP) 
C-reactive protein (CRP) is an acute phase reactant that is elevated in several inflammatory 
conditions and serves as a non-specific marker for inflammation (Wilson et al 1989). In acute 
pancreatitis, CRP levels commonly peak on the 3rd or 4th day after symptom onset, with 48-
hour values of 150 mg/dL often accepted as a predictor of subsequent disease severity 
(Dervenis et al. 1999). It has been demonstrated that peak CRP levels of ≥210 mg/dL can 
differentiate severe acute pancreatitis from milder forms with a sensitivity of 83-84% and a 
specificity of 74-85%. (Wilson et al. 1989) Similar studies have shown that high CRP levels 
have an overall accuracy of 93% in detecting pancreatic necrosis. CRP levels are easy to 
measure, widely available, and relatively inexpensive to perform. One disadvantage of CRP 
is its delayed serum peak (48-72 hours), although this delay is also inherent in other 
methods used for severity assessment in acute pancreatitis such as the Ranson criteria. 
(Yadav, Agarwal et al. 2002) 
3.1.5 Hemoconcentration 
Recently, hemoconcentration has been identified as a strong risk factor and an early marker 
for the develpment of necrotizing pancreatitis and organ failure (Baillargeon, Ramagopal et 
al. 1998). Admission hematocrit (Hct)  ≥ 47 and failure of admission Hct to decrease by 24 h 
represent strong risk factors for the development of severe pancreatitis. (Yadav, Agarwal et 
al. 2002). The sensitivity of hematocrit as a marker for necrotizing pancreatitis is 72% at 
admission and increases to 94% at 24 hours; specificity is 83 and 69%, respectively. 
(Baillargeon, Ramagopal et al. 1998) 
The relationship between hemoconcentration and the development of pancreatic necrosis 
has been studied extensively in experimental animal models (Hotz et al. 1995). These studies 
have shown that early hemoconcentration in acute pancreatitis contributes significantly to 
the impairment of the pancreatic microcirculation and to the subsequent progression to 
pancreatic necrosis (Hotz et al. 1995). Patients presenting with an elevated admission 
hematocrit or those demonstrating an admission hematocrit that does not decrease by 24 
hours are at high risk for complications (Brown, Orav et al. 2000). Consideration in this 
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patient cohort should be given to early intensive care unit admission for vigorous fluid 
resuscitation, supportive care, and continous hemodynamic monitorring. In contrast, 
patients who do not exhibit these criteria may have a lower likelihood of developing severe 
pancreatitis and could represent a group that requires less intensive care. (Brown, Orav et al. 
2000) 
3.1.6 Interleukins and procalcitonin 
Interleukins, particularly IL-6 and IL-8, have been identified as serum markers of disease 
severity in acute pancreatitis (Heath et al. 1993 and Rau et al 1997). Although predictive 
accuracies have varied in several clinical studies, meta-analyses performed to assess their 
utility in predicting severe acute pancreatitis have demonstrated promising correlations. 
(Gregoric, Sijacki et al. 2010) 
IL-6 is a cytokine produced by a wide variety of cell types, including macrophages (Xing et 
al 1994). It drives the hepatic acute phase response and as such may be one biochemical step 
closer than CRP to the underlying inflammatory process in acute pancreatitis. Serum levels 
of IL-6 in patents with severe pancreatitis can be elevated as early as five hours after 
admission; pooled sensitivities range between 81.0% and 83.6%, specificities between 75.6 
and 85.3%, and odds ratios of between 3. 43 and 4.90 in predicting disease severity (Aoun, 
Chen et al. 2009). IL-8 serum levels also have been found to correlate with pancreatitis, with 
pooled sensitivities identified between 65.8 and 70.9% and specificities of 66.5% and 91.3% 
for days 1 and 2 of disease presentation. (Aoun, Chen et al. 2009) 
Procalcitonin (PCT) is the inactive propeptide of the hormone calcitonin, which is involved 
in calcium homeostasis (Assicot et al. 1993). In patients with acute pancreatitis, PCT has 
been shown to predict the subsequent development of infected pancreatic necrosis and has 
been demonstrated to be a predictor of severity and organ failure in patients with acute 
pancreatitis (Riche et al. 2003). Sensitivity analyses performed on multiple studies have 
demonstrated that a serum PCT value greater than 0.5 ng/mL is an accurate predictor of 
severe acute pancreatitis (Mofidi, Suttie et al. 2009). In studies where daily serum PCT levels 
were measured, it was noted that patients who subsequently developed infected pancreatic 
necrosis had a sustained increase in serum PCT levels and that the degree of PCT increase 
reflected the severity of systemic inflammation and progresion to multiorgan dysfunction 
(Rau et al. 1997). Furthermore, it has been observed that serum PCT levels tend to decrease 
with clinical improvment (Rau et al. 1997).  
The identification of pancreatic necrosis is clinically important because patients with sterile 
pancreatic necrosis are often treated with supportive care only, whereas infected pancreatic 
necrosis generally requires surgical or radiologic intervention (Büchler et al. 2000). Infected 
pancreatic necrosis is classically diagnosed by microbial culture of material obtained using 
image-guided FNA of pancreatic tissue. Unlike FNA, the measurement of PCT is non-
invasive and is not hindered by the potential for image-directed sampling error. 
Furthermore, PCT levels are not affected by antifungal and antimicrobial systemic coverage, 
and remain elevated in infected pancreatic necrosis (Rau et al. 1997). However, it is 
important to note that PCT is a nonspecific marker of infectious complications in critically ill 
patients, and as a result other infective foci need to be excluded carefully when interpreting 
PCT measurements in pancreatitis.. (Mofidi, Suttie et al. 2009) 
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3.2 Systems based risk models 
3.2.1 Atlanta classification 
Most recent attempt to standardize severity criteria in acute pancreatitis The 1992 Atlanta 
Symposium was convened to standardize severity criteria and nomenclature in acute 
pancreatitis (Bradley 1993). A major step forward at the time was the establishment of a 
universal definition of severe pancreatitis. Objective criteria of severity and outcome were 
defined by both local and systemic parameters (Table 1.) In addition, universal standards to 
define “predicted severe” pancreatitis were adopted based on the two most popular scoring 
systems, namely the Ranson criteria and the Acute Physiology and Chronic Health 
Evaluation II (APACHE II) criteria. “Predicted severe” pancreatitis was defined as either a 
score of three or more in Ranson criteria, or eight or more in APACHE-II criteria.  
(Gates 1999)  
Severity Criteria  Definitions 
  
Organ Failure  
Cardiovascular Systolic blood pressure < 90 mm Hg ( after resuscitation ) 
Respiratory PaO2 < 60mmHg ( 8 kPa ) 
Renal Serum creatinine > 177 µmol/l ( 2mg/dl ) after resuscitation 
Gastrointestinal 
Haemorrhage 
>500 ml/ 24h 
  
Systemic 
Complications 
 
Coagulation 
System 
Platelet count < 100 × 109/l  
 Fibrinogen level < 1g/l 
 Fibrin split products >80µg/mL 
Metabolic Corrected serum calcium < 1.85 mmol/l ( 7.5 mg/dl)  
serum lactate levels > 5mmol/l 
  
Local Complications  
Acute fluid 
collections 
Occur early in the natural history of acute pancreatitis and lack a 
fibrous capsule 
Pseudocyst Occurs at least 4 weeks after the onset of symptoms and has a fibrous 
capsule 
Pancreatic abscess A localised collection of pus containing little or no necrotic pancreatic 
material  
Pancreatic necrosis Pathological features : diffuse or focal area of nonviable pancreas that 
maybe associated with peripancreatic fat necrosis CT features : an 
area of non-enhancing pancreas measuring > 3 cm in diameter or 30% 
of pancreatic tissue  
Table 1. Atlanta Classification for Severe Pancreatitis 
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Threshold scores for assignment of “predicted severe” pancreatitis 
≥ 3 Ranson criteria 
≥ 8 APACHE II criteria 
Although the Atlanta Classification has proven useful, a more thorough classification 
system could incorporate assessment of clinical severity with more objective measurements 
of anatomic pathology in and around the pancreas. In addition, the Atlanta Classification 
fails to differentiate between the two discrete peaks in mortality (early and late) observed 
with pancreatitis. (Brisinda, Vanella et al. 2011) 
3.2.2 Ranson criteria 
Ranson proposed the first numerical grading system for acute pancreatitis in 1974, focusing 
on several commonly observed clinical and hematochemical variables (Ranson et al. 1974). 
With an increased number of risk factors present, there is a corresponding increase in 
mortality rate (Ranson et al. 1974). In patients with less than three positive signs no 
significant associated mortality is observed, whereas in patients with at least six signs the 
mortality rate is over 50% (Ranson 1995). Furthermore, individuals with a score greater than 
six often develop necrotising pancreatitis (Ranson 1995). This system is particularly useful at 
the two extremes of the scale, with less discriminating power between; correlation with 
severity of disease or the eventual development of necrosis in patients with a score of 3-5 is 
deficient. (Brisinda, Vanella et al. 2011) 
 
At admission During initial 48 hours 
Age > 55 years Hematocrit decrease > 10% 
White blood cell count > 16000/µl Blood urea nitrogen increase >5mg/dl  
( >1.8 mmol/l) 
Serum glucose level > 200 mg/dl  
(>11.1 mmol/l) 
Calcium < 8 mg/dl (<2 mmol/l) 
Serum lactate dehydrogenase > 350 IU/l PaO2 < 60 mmHg 
Aspartate Aminotransferase > 250 IU/l Base deficit > 4 mEq/l 
 Fluid sequestration > 6 l 
Table 2. Ranson criteria for non- gallstone pancreatitis 
 
At admission During initial 48 hours 
Age > 70 years Hematocrit decrease > 10% 
White blood cell count > 18000/µl Blood urea nitrogen increase >5mg/dl  
( >1.8 mmol/l) 
Serum glucose level > 220 mg/dl  
(>12.2 mmol/l) 
Calcium < 8 mg/dl (<2 mmol/l) 
Serum lactate dehydrogenase > 400 IU/l PaO2 < 60 mmHg 
Aspartate Aminotransferase > 250 IU/l Base deficit > 5 mEq/l 
 Fluid sequestration > 4 l 
Table 3. Ranson criteria for gallstone pancreatitis 
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The Ranson scoring system was derived from statistical analysis of multiple clinical and 
laboratory parameters from consecutive patients who were tested for significant correlation 
with disease outcome (Ranson et al. 1974). The result was an 11-point conglomerate of 
predictive factors, five of which were to be obtained on admission and the remaining six 
within 48 hours of presentation. Because the first group of patients analysed had a 
preponderance of alcohol-associated disease, a second analysis was later performed with 
patients manifesting gallstone pancreatitis. (Ranson et al. 1974) Thus, two separate Ranson 
criteria currently exist for gallstone and non-gallstone pancreatitis, as illustrated above. 
The Ranson scoring system has important merits, along with some deficits. Clear benefits 
include its ease of use and its clinical correlation, with an estimated sensitivity of 72%, 
specificity of 76%, positive predictive value of 51%, and negative predictive value of 89. 
(Gates 1999) 
However, many physicians inappropriately apply the non-gallstone criteria to patients with 
gallstone pancreatitis, which accounts for a third of all cases of acute pancreatitis. 
Furthermore, patients are often incorrectly classified as having “predicted mild” pancreatitis 
before 48 hours; using the Ranson criteria, patients may only be classified as “predicted 
severe” or “pending” pancreatitis before the 48 hour mark. Importantly, the Ranson criteria 
have not been validated for continued temporal monitoring of the patient’s condition. A 
repeat assessment with the criteria at say, 72 hours, cannot be accurately interpreted with 
the tool. It is also important to note that the Ranson criteria have not been validated for used 
in children. (Gates 1999) 
3.2.3 Glasgow criteria 
The Glasgow criteria (Imrie) were originally introduced in the late 1970’s and early 
1980’sand have since been modified three times. (Imrie et al. 1978). The original Glasgow, or 
modified system, has been used for the prediction of mortality, and like the Ranson, 
performs well. It yields an estimated sensitivity of 63%, specificity of 84%, positive 
predictive value of 52%, and negative predictive value of 89% (Steinberg 1990). When  
Variables for the Glasgow Scoring System 
Age > 55 years 
White blood cell count > 15000 /µl 
PaO2 < 60 mmHg (8 kPa) 
Serum lactate dehydrogenase > 600 units/l 
Serum aspartate aminotransferase > 200 units/la 
Serum albumin < 32g/l 
Serum calcium < 2 mmol/l 
Serum glucose > 10 mmol/l 
Serum urea > 16 mmol/l 
a Removed from revised Glasgow outcome score.  
Each variable has a binary score of 0 or 1. The outcome score is derived from the sum of all variables at 
48 hours after presentation.  
Table 4. Glasgow (Imrie) severity scoring system for acute pancreatitis  
 
Acute Pancreatitis: Presentation and Risk Assessment 
 
109 
 
Table 5. Continued  
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compared to Ranson, it may be less sensitive while adding increased specificity. Any 
Glasgow data point may be scored at any time during the first 48 hours of presentation, but 
like Ranson, the Glasgow system is not valid for repeat measurements beyond 48 hours and 
cannot be applied to children (Gates 199). During the initial 48 hours, a patient may be 
classified only as having “severe” or “pending” pancreatitis. (Gates 1999) 
3.2.4 Acute Physiology and Chronic Health Evaluation II (APACHE-II) 
The Acute Physiology and Chronic Health Evaluation II (APACHE-II) assessment has 
become popular more recently. The system is comparatively complex and more difficult to 
perform because 12 different physiologic measurements are used (Larvin 1989). The higher 
the total score, the more severe the episode of acute pancreatitis, which corresponds to an 
increase in predicted morbidity and mortality (Wilson et al. 1990). One major advantage of 
the APACHE-II numeric system compared with other systems is that it can be used 
throughout the patient’s hospital course, aiding evaluation and monitoring of response to 
therapy. (Knaus, Draper et al. 1985) 
The APACHE-II system was developed as a general measure of disease severity and not 
specifically as a tool for describing acute pancreatitis. Each physiologic parameter is 
weighted from 0 to 4, and an aggregate score is tabulated (Knaus, Draper et al. 1985). Unlike 
the Ranson and Glasgow criteria, APACHE-II can provide a valid prediction of mild 
pancreatitis on admission. The APACHE-II is valid for repeated measures throughout 
hospitalization and it represents a universal measurement of disease severity, obviating the 
need for a separate score for acute pancreatitis. The APACHE II performs very well as a 
prognostic tool, with sensitivity and specificity rates of 75% and 92% respectively (Wilson et 
al. 1990).  
3.2.5 Bedside Index for Severity in Acute Pancreatitis (BISAP) 
A newer prognostic scoring system, the Bedside Index for Severity in Acute Pancreatitis 
(BISAP) has been proposed as an accurate method for early identification of patients at risk 
for in-hospital mortality (Wu, Johannes et al. 2008). The BISAP combines findings of 
physical examination, vital signs, routine laboratory data, and imaging studies to derive a 
five-point score (Wu, Johannes et al. 2008).  
Individual Components of the BISAP Scoring System 
BUN > 25mg/dl 
Impaired mental status (Glasgow Coma Scale Score < 15) 
Age > 60 years 
Pleural effusion detected on imaging 
SIRS, ≥ 2 or more of the following: 
Temperature <36°C or >38°C 
Respiratory Rate >20 breaths/min or PaCO2 <32 mmHg 
Pulse > 90 beats/min 
WBC count > 12,000 or <4,000 cells/mm3 or >10% immature neutrophils (bands 
Adapted from Gut 57(12): 1698-1703 (Wu, Johannes et al. 2008) 
Table 6. BISAP Scoring System 
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The BISAP uses five ordinal points: urea nitrogen (BUN) >25 mg/dl, impaired mental status 
as defined by evidence of disorientation or alteration in mental status, presence of Systemic 
Inflammatory Response Syndrome (SIRS), age > 60 years, and the presence or absence of 
pleural effusions (Singh, Wu et al. 2009).  
SIRS is defined by the presence of ≥ 2 of the following criteria:  
Pulse >90 beats/min, respirations >20/min or PaCO2 <32 mmHg, temperature >38°C of 
<36°C, WBC count > 12,000 or <4,000 cells/mm3 or >10% immature neutrophils (bands). 
The presence of each variable contributes one point to a total 5-point score, and is obtained 
within 24 hours of admission; there is no requirement for additional computation, and the 
assessment of mental status is the only subjective parameter involved. It should be noted, 
however, that the SIRS criterion is a composite parameter that involves four separate but 
related criteria. Essentially, the BISAP is an eight-variable system cumulatively applied to 
calculate five points. (Wu, Johannes et al. 2008) 
Studies have demonstrated that the BISAP score can predict mortality risk (Wu, Johannes et 
al. 2008). Studies have demonstrated that a BISAP score ≥ 3 is associated with higher 
mortality when compared to scores < 3; high specificity and negative predictive values were 
observed using these ordinal values (Wu, Johannes et al. 2008). Furthermore, it has been 
shown that BISAP scores ≥ 3 predict the development of organ failure, persistent organ 
failure, and the evolution of pancreatic necrosis. (Singh, Wu et al. 2009) 
The key advantages of the BISAP include its relative ease of use and application of 
parameters that are commonly obtained either at presentation or within 24 hours of 
presentation (Wu, Johannes et al. 2008). The score appears generalizable, having been 
initially formulated and validated using a large number of patients across 389 hospitals, 
reflecting a broad spectrum of health-care delivery. (Singh, Wu et al. 2009) 
The BISAP score cannot readily distinguish transient organ dysfunction from more 
persistent organ dysfunction at 24 hours (sensitivity of 38%, specificity 92%, PPV 58%, and 
NPV 84%), an important clinical distinction since the latter group suffers the majority of 
morbidity and mortality in acute pancreatitis (Zimmerman et al. 1994). The BISAP score 
may prove more useful in the triage of patients to levels of care intensity on initial 
evaluation rather than being used to predict the development of persistent organ failure and 
its consequences. (Papachristou, Muddana et al. 2010) 
In summary, the BISAP score is a reliable prognostic tool enabling classification of patients 
with acute pancreatitis into mild or severe groups, and its components are clinically relevant 
and easy to obtain. It is important to recognize that an inherent limitation of all such scoring 
systems is their conversion of continuous variables into binary values of equal weight and 
thus fail to capture synergistic or multiplicative effects based on interactions of 
interdependent systems.  
3.3 Imaging based risk models 
3.3.1 Ultrasonography 
Ultrasonography (US) may be useful in the early assessment of acute pancreatitis to evaluate 
the biliary system for the presence of gallstones or common bile ductal stones. However, US 
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use is often technically limited to applications in the early staging of acute pancreatitis due 
to the presence of overlying bowel gas secondary to paralytic intestinal ileus. In aggregate, 
abnormal US findings are seen in 33-90% of patients with acute pancreatitis; a diffusely 
enlarged and hypoechoic gland is consistent with interstitial edema, while extrapancreatic 
fluid collections (e.g., lesser sac, anterior pararenal space) can be detected in patients with 
severe disease. (Balthazar 2002) 
3.3.2 Computed Tomography (CT) 
Most of the clinical and laboratory parameters discussed thus far are applied to evaluate the 
systemic effects of pancreatitis, and only indirectly infer the presence and degree of 
pancreatic damage. The use of Computed Tomography (CT) in acute pancreatitis has 
increased in the last decade as it offers improved anatomic visualization, direct assessment 
of the extent of parenchymal injury, and identification of local complications (Dervenis et al. 
1999). The CT Severity Index (CTSI) derived by Balthazar et al. has become the standard 
objective assessment for the description of CT findings in acute pancreatitis. (Balthazar 2002)  
The first described CT grading index was based on radiographic images obtained without 
the addition of intravenous (IV) contrast (Hill et al. 1982). Using the scoring system, it was 
demonstrated that patients with high grade pancreatic damage (grades D or E) had a 
mortality rate of 14% and a morbidity rate of 54%, as compared with no mortality and a 
morbidity rate of only 4% in lesser affected patients (groups A, B or C.) Due to the lack of IV 
contrast, its main drawback was an inability to reliably depict pancreatic necrosis (Balthazar, 
Robinson et al. 1990).  
A major significant improvement has been achieved in early CT grading systems with the 
introduction of an incremental contrast bolus CT technique (Kivisaari et al. 1983). Contrast-
enhanced CT has been used effectively to directly characterize and quantify pancreatic 
parenchymal injury. Investigators have shown that the attenuation values of pancreatic 
parenchyma during an intravenous contrast bolus study can be used as an indicator of 
pancreatic necrosis and as a predictor of disease severity (Dervenis et al. 1999).  
Patients with mild interstitial pancreatitis have an intact but vasodilated capillary network 
and therefore exhibit uniform enhancement of the pancreatic gland (Balthazar 2002). To the 
contrary, areas of diminished or no enhancement are indicative of decreased blood flow and 
reveal pancreatic zones of ischemia or necrosis (Balthazar 2002). An excellent correlation has 
been documented between necrosis, length of hospitalization, development of 
complications, and death. Furthermore, the extent of pancreatic necrosis has also been 
proven to be of clinical importance with prognostic and therapeutic implications (Vitellas et 
al. 1999). Studies have shown that patients with less than 30% necrosis exhibited no 
mortality and a 48% morbidity rate, while larger areas of necrosis (30-50% and >50%) were 
associated with morbidity rates of 75-100% and mortality rates of 11-25% (Balthazar, 
Robinson et al. 1990). 
The CT Severity Index (CTSI) was designed to improve the early prognostic value of CT in 
cases of acute pancreatitis and is based on IV contrast-enhanced imaging (Balthazar, 
Robinson et al. 1990). The grading and allocation of points takes into consideration the CT 
grade as well as the extent of necrosis and is illustrated in the table below. It has been 
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demonstrated that a statistically significant correlation exists between morbidity and 
mortality and the CTSI score (Balthazar, Robinson et al. 1990). Studies have shown that 
patients with a severity index of 0 or 1 exhibit a 0% mortality rate and no morbidity, while 
patients with a severity index of 2 had no mortality and a 4% morbidity rate (Balthazar, 
Robinson et al. 1990). In contrast, a severity index of 7-10 yields a 17% mortality rate and a 
92% complication rate. (Balthazar, Robinson et al. 1990) In a clinical study comparing BISAP, 
Ranson criteria, APACHE-II, and CTSI, CTSI was the most accurate in predicting pancreatic 
necrosis. (Papachristou, Muddana et al. 2010) 
CT grade Grade
Points
Necrosis  
(in percentage)
Necrosis 
Points 
CT severity 
indexb 
Normal ( A )  0 0 0 0 
Focal, diffuse enlargement, contour 
irregularity, inhomogenous attenuation 
( B ) 
1 0 0 1 
B + peripancreatic haziness/strand 
densities ( C ) 
2 < 30 2 4 
B + C + one ill-defined peripancreatic 
fluid collection ( D ) 
3 30 - 50 4 7 
B + C + two ill-defined peripancreatic 
fluid collections ( E ) 
4 < 50 6 10 
a Balthazar 
b Grade points are added to points assigned for percentage of necrosis. 
Table 7. Computed Tomography Severity Indexa 
Adapted from Eur J Gastroenterol Hepatol 23(7): 541-551 (Brisinda, Vanella et al. 2011) of 
presentation may show only equivocal findings of pancreatitis, and that CT scans 
obtained 3 days after clinical onset yield higher accuracy in the depiction of pancreatic 
necrosis (Vitellas et al. 1999). Thus, it is recommended that when the clinical diagnosis of 
pancreatitis is in doubt, an initial early CT be used to confirm the clinical suspicion or to 
help detect alternative acute abdominal conditions that mimic acute pancreatitis. For 
staging, however, more reliable results are obtained with the use of intravenous bolus 
contrast-enhanced CT performed 48-72 hours after the onset of an acute attack of 
pancreatitis. (Balthazar 2002) 
It appears that the CTSI is an anatomically oriented scoring system that aids in identifying 
local complications from pancreatitis, while clinical scores, such as the APACHE-II, may be 
superior for predicting associated organ failure and systemic complications (Lankisch et al. 
2000). In patients with predicted severe disease or those manifesting a severe clinical course 
within the first 48 hours of presentation, the CTSI appears superior to other scoring systems 
in predicting overall pancreatitis severity and pancreatic necrosis. (Chatzicostas, 
Roussomoustakaki et al. 2003) At present, it appears that clinical scores are the best way to 
stratify the immediate management of acute pancreatitis, particularly the requirement for 
intensive care, and that the value of CT is greater in evaluating intermediate term 
management. (Alhajeri and Erwin 2008)  
 
Acute Pancreatitis: Presentation and Risk Assessment 
 
115 
3.3.3 Magnetic Resonance Imaging (MRI) 
The development of high field strength magnetic resonance imaging (MRI), rapid gradient-
echo breath hold techniques, and fat suppression methodologies has made MR imaging an 
excellent alternative imaging modality to aid in the evaluation of patients with acute 
pancreatitis (Lecesne et al. 1999). It is particularly useful in patients who cannot receive 
iodinated contrast material due to allergic reactions or renal insufficiency. Gadolinium-
enhanced T1 weighted gradient-echo MR images can depict pancreatic necrosis as areas of 
non-enhanced parenchyma (Fulcher, Turner 1999). Fat-suppression images are also helpful 
in defining subtle, diffuse, or focal parenchymal abnormalities. T2 weighted images can 
accurately depict fluid collections, pseudocysts, and areas of haemorrhage. (Balthazar 2002) 
4. Conclusion  
Acute pancreatitis is a dynamic entity with varying degrees of severity. Most episodes of 
acute pancreatitis are generally mild, but up to a third of cases may progress to severe 
pancreatitis. This is associated with a significant increase in associated mortality and 
complications. The key to effectively managing the patient with an episode of acute 
pancreatitis is early identification and diagnosis, followed by an appropriate assessment of 
severity. Appropriate evaluation of severity and prognosis is of great help in aiding the 
clinician in administering appropriate care. The clinician needs to be able to determine 
which patients will benefit from invasive intervention or transfer to a critical care  unit, with 
the availability of its attendant intensive laboratory and cardiorespiratory monitoring.  
A variety of prognostication systems for acute pancreatitis have been developed over the 
years to better categorize disease severity and predict clinical outcomes. There are three 
commonly employed types of predictors of the severity of acute pancreatitis: individual 
biological markers, multi-parameter scorings systems, and imaging-based systems. Within 
each category there are several individual systems, each with unique advantages and 
disadvantages. Given the currently available tools, the majority of patients presenting with 
acute pancreatitis will benefit from a rational and informed combination of these 
complimentary but distinct systems. In an era where intensive and invasive techniques are 
available to manage the local and systemic complications of pancreatitis, the ability to 
appropriately identify patients who will benefit from these interventions in a timely fashion 
is an important adjunct to their care. 
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Imaging Appearances of  
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1. Introduction 
Autoimmune pancreatitis (AIP) is a rare disorder of presumed autoimmune etiology with 
specific pathologic features, and is an increasingly recognized clinical condition. AIP is 
characterized histologically by fibrosis with dense infiltration of T lymphocytes and IgG4-
positive plasma cells in the peripancreatic and interlobular area of the pancreas (1-4). 
Patients with AIP usually have serum markers of autoimmune disorders, such as increased 
IgG4 and antinuclear antibodies. Although clinical features and symptoms are nonspecific, 
association with many other autoimmune disorders have also been reported (5-10). 
Therefore AIP should be considered in differential diagnosis when a patient with another 
autoimmune condition presents with symptoms related to the pancreas and biliary tract.  
AIP has been described in literature to respond well to steroid therapy. Also, imaging 
appearances of AIP improve with steroid therapy, so imaging can be used in evaluation of 
treatment (11-16). Correct diagnosis is essential for appropriate treatment planning and to 
avoid unnecessary surgery. In particular, differentiation of AIP from pancreatic 
malignancies is very important, and several characteristic imaging features have been 
reported (16-18). 
This article presents imaging appearances of AIP described in several radiological publications.  
2. Imaging findings of AIP 
AIP is mainly indicated by an imaging procedure such as contrast enhanced computed 
tomography (CT) or magnetic resonance imaging (MRI) (16, 18-22). 
The classic finding of contrast enhanced CT that is diagnostic or highly suggestive of AIP is 
the diffuse sausage shaped enlargement of the entire pancreas with homogeneous 
attenuation, moderate enhancement and featureless, pencil sharp borders, absent of the 
normal pancreatic clefts (Figure1-4). The pancreas is covered with a thin capsular-like low 
density rim that possibly represents inflammatory exudates (Fig 1ab). Usually there is no 
calcification, peripancreatic fluid collection or vascular involvement. Though the diffuse 
form is most commonly reported in literature, focal forms have been reported, and the 
involved segment may mimic a pancreatic tumor, consequently most patients with focal 
forms of AIP underwent surgery, because of preoperative diagnoses of pancreatic carcinoma 
(Figure 4)(16-18, 23, 24).  
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A 
 
B 
A, Contrast enhanced axial CT scan shows diffuse enlargement of the pancreas with sharp borders and 
minimal peripancreatic stranding (arrow), B, MRI shows diffuse pancreatic enlargement with minimal 
high signal intensity on T2-weighted MR images. 
Fig. 1. (A,B) Images obtained in 58-year-old man with diffuse form of AIP who had jaundice 
and abdominal pain at presentation.  
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C 
 
D 
Endoscopic retrograde cholangiopancreatographic (ERCP) image shows diffuse narrowing of 
pancreatic duct with irregular walls (C; arrrows), and focal stricture in distal common bile duct (D; 
arrrow). 
Fig. 1. (C,D) Images obtained in 58-year-old man with diffuse form of AIP who had jaundice 
and abdominal pain at presentation.  
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E 
E, Axial CT scan shows that enlargement of the pancreas diminished after steroid therapy. 
Fig. 1. (E) Images obtained in 58-year-old man with diffuse form of AIP who had jaundice 
and abdominal pain at presentation.  
A diffusely enlarged pancreas can be also seen in diffuse infiltrative pancreatic carcinoma, 
malignant lymphoma, plasmacytoma, or metastases. However, in most of these conditions, 
imaging features are usually different from those observed in AIP. 
Compared with normal pancreatic parenchyma, diffuse or localized enlargement of the 
pancreas is seen as low intensity on T1-weighted MR images and high intensity on T2-
weighted images (Figure1b). Diffusion-weighted MR images (DWI) are considered useful for 
detecting AIP and for evaluating the effect of steroid therapy. AIP is seen as high signal 
intensity on DWI (Figure4c), which improved after steroid treatment. Apparent diffusion 
coefficients (ADCs) also reflected disease activity (Fiure4d). Thus, DWI is considered a 
valuable tool for detecting AIP, determining the affected area, and evaluating the effect of 
treatment (25, 26). In many cases, ADC values are lower in AIP than in pancreatic cancer, so an 
ADC cut off value is potentially useful for distinguishing AIP from pancreatic cancer (26).  
Magnetic resonance cholangiopancreatography (MRCP) is a non-invasive method to 
evaluate the pancreatic duct and biliary tract, and recently, the imaging quality has 
increased to almost the equivalent of endoscopic retrograde cholangiopancreatography 
(ERCP). ERCP is thought to be the most accurate diagnostic modality for AIP, especially 
when evaluating the pancreatic duct (27). Both MRCP and ERCP show characteristic diffuse 
narrowing with irregularities or serration along various segments of the main pancreatic 
duct (Figure1c, 3d). Sometimes, there may be a focal stricture. The intrapancreatic segment 
of the common bile duct may be focally or segmentally narrowed resulting in dilatation of 
the proximal bile duct (Figure1d, 3d). 
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Axial CT scan obtained at the level of the proximal portion of superior mesenteric artery shows 
circumferential thickening of periarterial soft tissue (arrow) consistent with sclerosing messenteritis. 
Fig. 2. 52-year-old man with diffuse form of AIP.  
 
A 
A, Contrast enhanced axial CT scan shows diffuse enlargement of the pancreas with sharp borders and 
minimal peripancreatic stranding (arrow). 
Fig. 3. (A) 54-year-old man with diffuse form of AIP. 
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B 
 
C 
B, Swelling of the pancreatic head is also seen (arrow)., C, Transabdominal transverse US image shows 
enlargement of the pancreatic head with minimal decreased echotexture of pancreas (arrows). 
Fig. 3. (B,C) 54-year-old man with diffuse form of AIP. 
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D 
 
E 
D, MRCP image also shows the narrowing of the main pancreatic duct with irregular walls and focal 
stricture in the distal common bile duct (arrrow),.E, Axial CT scan obtained after steroid therapy shows 
a normal-appearing pancreas, and enlargement of the pancreas is diminished.  
Fig. 3. (D,E) 54-year-old man with diffuse form of AIP. 
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A 
 
B 
Contrast enhanced CT scan shows focal enlargement in the pancreatic body and tail with sharp borders 
and a thin capsular-like rim. The lesion appears as a relatively low attenuation area compared to normal 
pancreatic parenchyma on early phase (A), and as an almost iso-attenuation area compared to normal 
pancreatic parenchyma on delayed phase (B) (arrows). Hydronephrosis on the left is also seen due to 
concurrent retroperitoneal fibrosis. 
Fig. 4. (A,B) 62-year-old man with focal form of AIP. 
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C 
 
D 
C, Diffusion-weighted MR image shows a focal high-intensity area on the pancreatic body and tail 
(arrow) (b=800mm2/s). D, ADC map shows low ADC value  (1.014×10-3mm2/sec) on the pancreatic body 
and tail (arrow) . 
Fig. 4. (C,D) 62-year-old man with focal form of AIP. 
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E 
E, Combined PET/CT scan shows strong FDG uptake at the pancreatic body and tail (arrow). 
Fig. 4. (E) 62-year-old man with focal form of AIP. 
FDG-PET/CT is useful for detecting AIP and associated extrapancreatic autoimmune 
lesions and for monitoring their disease activity. AIP can cause intense FDG uptake in the 
pancreas (Figure4e). AIP should always be considered when making a diagnosis with FDG-
PET in patients with pancreatic disorders. In many cases, differentiation of AIP from 
pancreatic malignancies is thought to be difficult by PET/CT (28-30). Lee et al reported that 
in difficult cases, on PET/CT imaging, the presence of diffuse uptake of FDG by the 
pancreas or concomitant extrapancreatic uptake by the salivary glands may aid in 
differentiation of autoimmune pancreatitis and pancreatic cancer (29). 
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1. Introduction 
Diagnostic accuracy in regard to biliary and pancreatic diseases has improved markedly 
since the introduction of computed tomography (CT) and magnetic resonance 
cholangiopancreatography (MRCP)(1,2), but detection of small bile duct cancers and small 
pancreatic cancers is difficult even by those modalities. Endoscopic retrograde 
cholangiopancreatography (ERCP) remains the most accurate and reliable procedure for 
cytodiagnosis and precise staging of biliary and pancreatic neoplasms, and it is 
indispensable to the endoscopic treatment of biliary and pancreatic diseases. 
Pancreatitis remains the most common complication of ERCP and results in substantial 
morbidity and, occasionally, in death (3-5). The mechanisms responsible for the 
development of post-ERCP pancreatitis are not fully understood, but they are thought to be 
multifactorial. A number of specific risk factors have been proposed as predictors of post-
ERCP pancreatitis (6-15), and they include patient-, endoscopist-, and procedure-related 
factors. We therefore think that clear identification of risk factors is facilitated by analyzing 
the data for diagnostic ERCP and therapeutic ERCP separately. 
Early identification of patients who are likely to develop post-procedure pancreatitis is 
highly desirable in terms of planning long-term follow-up in the hospital and an early 
therapeutic approach. Hyperamylasemia is common after ERCP, and amylase values have 
been found to peak between 90 min and 4 h post-ERCP (16,17). Testoni et al. (18) concluded 
that the serum amylase level measured 4 h after endoscopic sphincterotomy was the most 
reliable predictor of post-ERCP pancreatitis, and Thomas et al.(19) showed that the 4-h post-
procedure amylase level is clinically significant as a predictor of post-ERCP pancreatitis. We 
therefore hypothesized that the 4-h amylase level is the most accurate amylase value for 
predicting subsequent pancreatitis. 
Several studies (20-24) have demonstrated that the serum lipase level is more sensitive 
indicator than the serum amylase level for diagnosing other forms of acute pancreatitis, but 
only a few studies (25-27) have compared measurements of various pancreatic enzymes as a 
means of predicting post-ERCP pancreatitis. Moreover, it is still unclear whether there are 
differences in the diagnostic accuracy of pancreatic enzyme levels for predicting post-ERCP 
pancreatitis according to the procedures, in other words, whether the ERCP is diagnostic or 
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therapeutic. In the present study we evaluated the 4-h post-ERCP serum amylase level and 
serum lipase level as predictors of pancreatitis, with special focus on comparison of the two 
as a means of predicting post-ERCP pancreatitis, in a retrospective single-center design in 
Japan. 
2. Patients and methods 
We conducted a retrospective study in a single center by reviewing the 1631 consecutive 
cases in which ERCP was performed between January 1999 and December 2004 and 
(male:female ratio= 974:657 (1.48/1) ; age range 8-97 years old, median 67 years old). 
Diagnostic ERCP had been performed in 910 cases (male:female ratio=518:392 (1.32/1); age 
range 8-90 years old, median 63 years old), and therapeutic ERCP in 721 cases (male: female 
ratio=456:265 (160/1); age range 19-97 years old, median 67 years old). All patients were 
enrolled in this study, and there were no exclusion criteria. Diagnostic ERCP included 
brushing cytology (biliary tract, pancreatic duct) and intraductal ultrasonography (IDUS). 
Therapeutic ERCP included endoscopic papillary balloon dilatation (EPBD), endoscopic 
sphicterotomy (EST), stone removal, and bile duct drainage. 
All ERCP patients were intravenously infused over 4 hours with one of the following 
protease inhibitor solutions beginning 30 minutes before the ERCP examination: Gabexate 
mesilate 200 mg in 0.9% saline, 500 ml, Nafamostat mesilate 20 mg in 0.9 % saline, 500 ml; or 
Ulinastatin 50,000 U in 0.9 % saline, 500 ml. The choice of inhibitor was at the discretion of 
the chief physician responsible for the patient’s care. 
All patients remained in the hospital for at least 24 hours after the procedure to monitor 
them for clinical manifestations of pancreatitis. Serum amylase and lipase levels were 
measured before and 4 and 16-18 hours (the next morning) after ERCP. We evaluated 23 
variables, including patient-related factors, an endoscopist-related factor, and procedure-
related factors that could be analyzed in detail based on information in the patients’ charts. 
We also evaluated and compared the 4-h post-ERCP serum amylase level and serum lipase 
level as predictors of pancreatitis based on receiver-operator characteristic (ROC) curves. To 
compare the ROC curves, we analyzed only the data from cases in which both amylase and 
lipase could be measured, in other words, we made a matched pair comparison. We 
analyzed the data of a total of 1267 patients, consisting of 65 pancreatitis patients and 1202 
non-pancreatitis patients. A total of 688 patients, consisting of 39 pancreatitis patients and 
649 non-pancreatitis patients had undergone diagnostic ERCP, and a total of 579 patients, 
consisting of 26 pancreatitis patients and 553 non-pancreatitis patients, had gone therapeutic 
ERCP.  
Data related to the procedures were gathered in a prospective manner, but the global 
analysis was performed in a retrospective manner. 
2.1 Endoscopists 
The 1631 ERCP procedures were performed by 11 different endoscopists (median: 57 
procedures per endoscopist, range: 8-423). Four of the endoscopists performed about 84% of 
the procedures, and each of the 4 had performed more than 200 ERCPs before the study. The 
other 7 endoscopists had performed fewer than 200 ERCPs each before the study. 
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2.2 Definition 
High levels of emzymes was defined as an amylase level (normal range: 40-125 IU/l) and 
/or lipase level (normal range 13-49 IU/l) above the upper limit of the normal range. The 
criteria for the diagnosis of post-ERCP pancreatitis were: (1) abdominal pain that persisted 
for at least 24 hours; (2) a serum amylase level and/or lipase level measured 16-18 hours 
after the procedure (next morning) that was more than three times the upper limit of the 
normal range; (3) pancreatic swelling with or without fluid collection on an abdominal US 
and/or CT examination the next morning. Fulfillment of criterion 1 plus criterion 2 and/or 3 
was required to make the diagnosis. Pancreatitis was graded as follows according to the 
scoring system proposed by the Ministry of Health, Labour and Welfare of Japan (JPN 
score) (28,29): mild (0 points); moderate (1 point); severe (2 points or more). 
The injection pressure of contrast medium into the pancreatic duct was scored as follows 
based on the degree of pancreatic duct visualization, according to a modification of the 
criteria proposed by Tsujino et al. (30): 0, no pancreatic duct visualization; 1, visualization of 
the main pancreatic duct alone; 2, 1 and visualization of primary branches; 3, 2 and 
visualization of secondary branches; and 4, 3 and/or visualization of acini (acinarization). 
2.3 Statistical analysis 
In the first step, a univariate analysis was performed by the chi-square method for each of 
the potential risk factors. In the second step, factors with a p value <0.2 according to the chi-
square analysis were included in a multivariate (logistic regression) analysis performed 
using Statview 5.0 software. A p value <0.05 was considered statistically significant. The 
odds ratios are reported with their 95% confidence limits. 
ROC curve analyses for the serum amylase and lipase values were performed using 
Medcalc software. We assessed whether the difference in area under two ROC curves was 
significant based on the methods proposed by Hanley JA et al (31). In short, the difference in 
area under two ROC curves derived from the same set of patients is calculated as a critical 
ratio z by using the formula: 
z= (A1-A2)/√(SE12+SE22-2rSE1SE2),  
where A1 is the observed area and SE1 is estimated error of the ROC area associated with 
modality 1, A2 and SE2 are the corresponding values for modality 2, and r is a constant 
calculated from (A1+A2)/2 and (rn+ra)/2, where rn is the coefficient for the correlation 
between modality 1 and modality 2 in the control group (non-pancreatitis group in this 
study), and ra is the coefficient for the correlation between modality 1 and modality 2 in the 
diseased group (pancreatitis group in this study). This quantity z is then referred to tables of 
the normal distribution and values of z above a certain cutoff are taken as evidence of a 
difference between the ‘true’ ROC areas. 
We selected optimal cutoff values for the serum amylase and lipase values as predictors of 
post-ERCP pancreatitis based on their sensitivity and specificity and especially their positive 
predictive value (PPV) and negative predictive value (NPV), by using a prior probability 
value for post-ERCP pancreatitis of 4.2% (incidence rate among the cases in this study as a 
whole). 
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3. Results 
3.1 Incidence of post-ERCP pancreatitis 
Pancreatitis developed after 67 (4.2%) of the 1631 ERCP procedures. According to the JPN 
scores the pancreatitis was mild after 60 (3.7 %) of the procedures, moderate after 5 (0.3%), 
and severe after 4 (0.2%). There were no deaths in our series. Pancreatitis developed after 40 
(4.4%) of the 910 diagnostic ERCPs, and after 29 (4.0%) of the 721 therapeutic ERCPs. The 
difference between the incidence of post-ERCP pancreatitis after diagnostic ERCP and after 
therapeutic ERCP was not statistically significant.  
The incidence of post-ERCP pancreatitis after diagnostic ERCP in the Gabexate mesilate 
group, Nafamostat mesilate group, and Ulinastatin group was 4.7% (31/666), 3.8% (7/184), 
and 3.3% (2/66), respectively, and there were no statistically significant differences in the 
incidence of post-ERCP pancreatitis between the three groups. The incidence of post-ERCP 
pancreatitis after therapeutic ERCP in the Gabexate mesilate group, Nafamostat mesilate 
group, and Ulinastatin group was 4.4% (19/428), 3.4% (7/209), and 3.6% (3/84), 
respectively, and there were no statistically significant differences in the incidence of post-
ERCP pancreatitis between the three groups. 
3.2 Risk factors for post-ERCP pancreatitis 
3.2.1 Diagnostic ERCP 
3.2.1.1 Univariate analysis  
The univariate analysis revealed statistically significant associationss between an increased 
risk of post-ERCP pancreatitis and 4 of the13 patient-related factors and 4 of the 9 
procedure-related factors (Tables 1 and 2). The patient-related factors that significantly 
increased the risk of pancreatitis were: age 65 years or over, presence of hyperamylasemia 
and/or hyperlipasemia before ERCP, past or present pancreatitis and IPMN. The significant 
procedure-related risk factors according to the univariate analysis were: injection of contrast 
medium into the pancreatic duct score >= 3, brushing cytology in the pancreatic duct, IDUS, 
and endoscopic nasobiliary drainage (ENBD).  
3.2.1.2 Multivariate analysis 
Five risk factors were significant according to the multivariate analysis. Two were patient-
related factors, age (OR=1.043/1 yr increase in age) and presence of hyperamylasemia 
and/or hyperlipasemia before ERCP (OR=2.291), and the other three were procedure-
related factors, high contrast medium injection pressure into the pancreatic duct (OR=2.406/ 
1 point increase), brushing cytology in the pancreatic duct (OR=4.135), and IDUS 
(OR=4.373). The R-square value was 0.204. 
3.2.2 Therapeutic ERCP 
3.2.2.1 Univariate analysis  
The univariate analysis revealed a statistically significant association between an increased 
risk of post-ERCP pancreatitis and only one endoscopist-related factor: inexperienced 
endoscopist (Tables 3 and 4).  
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IPMN, intraductal papillary mucinous neoplasia 
ERCP: Patient-related Factors (ref 34)) 
Table 1. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Diagnostic 
 
ERCP: An Endocopist-related Factor and Procedure-related Factors (ref 34)) 
IDUS, intraductal ultrasonography; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary 
balloon dilation; ENBD, endoscopic nasobiliary drainage 
Table 2 Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Diagnostic 
Patient-related factors Pancreatitis Non-pancreatitis p value
(n=40) (n=870)
Significant
   Age (>=65years/<65years)    26/14     378/492 <0.001
   Hyperamylasemia and/or       
      hyperlipasemia (yes/no)    18/22    184/686 <0.001
   Past or present
      pancreatitis (yes/no) 9/31 76/773 0.004
  IPMN  12/28 131/739 0.011
Not significant
   Gender (male/female)     17/23    501/369 0.062
   Past-post ERCP
      pancreatitis(yes/no)     1/39       6/864 0.200
   Past or presenting
     cholangitis (yes/no)     1/39       79/791 0.151
   Periamupullary 
     diverticulum (yes/no)     3/37     66/804 0.984
   Chronic pancreatitis (yes/no)     5/35      97/773 0.791
   Pancreatic cancer (yes/no)      2/38      108/762 0.160
   Pancreas divisum (yes/no)      1/39       30/840 0.746
   Anomalous pancreatic-          
     biliary junction (yes/no)      2/38       25/845 0.438
   Bile duct stone (yes/no)      1/39      40/830 0.532
Endoscopist-related factor and Pancreatitis Non-pancreatitis p value
Procedure-related factors (n=40) (n=870)
Significant
   Injection pressure of contrast
     medium into the pancreatic
    duct (score 3,4/0-2)    29/11    348/522 <0.001
   Brushing cytology in the
     pancreatic duct (yes/no)   11/29     69/801 <0.001
   IDUS (yes/no)    8/32   55/815 <0.001
   ENBD (yes/no) 1/39 3/867 0.040
Not significant
   Endoscopist experience
  (<=200 ERCPs/>200 ERCPs) 9/31 125/745 0.156
   EST (yes/no)   0/40     1/869 0.830
   EPBD (yes/no)    0/40    0/870 N.E.
   Bile duct stone exploration
     (yes/no)   0/40     0/840 N.E.
   Brushing cytology in the         
     bile duct (yes/no)     1/39     44/826 0.466
   Biliary stenting (yes/no)     0/40     0/870 N.E.
 
Pancreatitis – Treatment and Complications 
 
136 
 
IPMN, intraductal papillary mucinous neoplasia 
Table 3. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Therapeutic 
ERCP: Patient-related Factors (ref34)) 
 
ERCP: An Endocopist-related Factor and Procedure-related Factors (ref34)) 
IDUS, intraductal ultrasonography; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary 
balloon dilation; ENBD, endoscopic nasobiliary drainage 
Table 4. Univariate Analysis of Risk Factors for Post-ERCP Pancreatitis after Therapeutic  
Patient-related factors Pancreatitis Non-pancreatitis p value
(n=29) (n=692)
Not Significant
   Age (>=65years/<65years)    19/10     391/301 0.337
  Gender (male/female)  21/8     435/257 0.300
   Hyperamylasemia and/or       
   hyperlipasemia (yes/no)    8/21     207/485 0.788
   Past or present
      pancreatitis(yes/no)     1/28    49/643 0.450
   Past-post ERCP
      pancreatitis(yes/no)     1/39        6/864 0.200
   Past or presenting
     cholangitis (yes/no)     13/16       313/379 0.966
   Periamupullary 
     diverticulum (yes/no)     8/21     115/577 0.123
   Chronic pancreatitis (yes/no)      1/28      18/674 0.780
   Pancreatic cancer (yes/no)     3/26      112/580 0.400
   Pancreas divisum (yes/no)      0/29       1/691 0.838
   IPMN(yes/no)    0/29     2/690 0.772
   Anomalous pancreatic-          
     biliary junction (yes/no)      1/28      6/686 0.165
   Bile duct stone (yes/no)      14/15      350/342 0.808
Endoscopist-related factor and Pancreatitis Non-pancreatitis p value
Procedure-related factors (n=29) (n=692)
Significant
   Endoscopist experience
     (<=200 ERCPs/>200 ERCPs)   8/21   62/630 <0.001
Not significant
   Injection pressure of contrast
     medium into the pancreatic
    duct (score 3,4/0-2)    5/24    59/633 0.106
   Brushing cytology in the
     pancreatic duct (yes/no)   0/29     10/682 0.514
   IDUS (yes/no)    0/29    6/686 615
   EST (yes/no)    5/24     98/594 0.642
   EPBD (yes/no)    8/21     114/578 0.118
   Bile duct stone exploration
     (yes/no)    7/22     156/536 0.841
   Brushing cytology in the         
     bile duct (yes/no)    1/28     20/672 0.861
   Biliary stenting (yes/no)     4/25     120/572 0.620
   ENBD (yes/no)     5/24    231/461 0.070
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3.2.2.2 Multivariate analysis 
Two risk factors were significant according to the multivariate analysis. One was an 
endoscopist-related factor, inexperienced endoscopist (OR=4.407), and the other was a 
procedure-related factor, high contrast medium injection pressure into the pancreatic duct 
(OR=1.693/ 1 point increase). The R-square value was 0.073. 
3.2.2.3 Multivariate analysis of the cases as a whole 
Six risk factors were significant according to the multivariate analysis for whole cases. Two 
were patient-related factors, age (OR=1.038/1 yr increase in age) and presence of 
hyperamylasemia and/or hyperlipasemia before ERCP (OR=1.807). One was an 
endoscopist-related factor, inexperienced endoscopist (OR=2.645), and the other three were 
procedure-related factors, high contrast medium injection into the pancreatic duct 
(OR=1.608/1 point increase), brushing cytology in the pancreatic duct (OR=2.605), and 
IDUS (OR=2.602). R-square value was 0.114. 
3.2.3 Prediction of pancreatitis following ERCP by the 4-h post-procedure serum 
amylase level and lipase level 
3.2.3.1 Diagnostic ERCP 
The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level 
after diagnostic ERCP showed good test performance, with an area under the curve of  
0.88 (95% CI: 0.85-0.91) and 0.94 (95% CI: 0.92-0.96), respectively (Figure 1). The 4-h  
  
The area under the curve of the amylase levels was 0.88 (95% CI: 0.85-0.91).  
The area under the curve of the lipase levels was 0.94 (95% CI: 0.92-0.96).  
Fig. 1. ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after 
diagnostic ERCP. 
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post-procedure serum lipase level was a more effective predictor of post–ERCP pancreatitis 
than the amylase level based on the areas under the ROC curves (p=0.025). 
3.2.3.2 Therapeutic ERCP 
The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level 
after therapeutic ERCP showed good test performance, with an area under the curve of 0.92 
(95% CI: 0.90-0.93) and 0.96 (95% CI: 0.94-0.97), respectively (Figure 2). The 4-h post-
procedure serum lipase level was a more effective predictor of post–ERCP pancreatitis than 
the amylase level, based on the area under the ROC curves (p=0.035). 
 
 
 
 
The area under the curve of the amylase levels was 0.92 (95% CI: 0.90-0.93).  
The area under the curve of the lipase levels was 0.96 (95% CI: 0.94-0.97).  
Fig. 2. ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after 
therapeutic ERCP. 
3.2.3.3 ERCP cases as a whole 
The receiver-operating characteristics (ROCs) of both the 4-h amylase level and lipase level 
after ERCP for the cases as a whole showed good test performance, with an area under the 
curve of 0.91 (95% CI: 0.89-0.92) and 0.96 (95% CI: 0.94-0.97), respectively (Figures 3).  
The 4-h post-procedure serum lipase level was a more effective predictor of  
post–ERCP pancreatitis than the amylase level based on the areas under the ROC curves 
(p=0.007). 
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The area under the curve of the amylase levels was 0.91 (95% CI: 0.89-0.92). 
The area under the curve of the lipase levels was 0.96 (95% CI: 0.94-0.97).  
Fig. 3. ROC curve of the 4-h post-procedure serum amylase levels and lipase levels after 
ERCP in the cases as a whole. 
3.2.3.4 Optimal cutoff values for amylase and lipase 
The optimal cutoff values for amylase were five times (625 IU/l) the upper limit of the 
normal range in the diagnostic ERCP cases, therapeutic ERCP cases, and ERCP cases as a 
whole based on their sensitivity and specificity and especially on their PPV and NPV  
(Table 5). 
 
Post-ERCP pancreatitis (ref34)). PPV, positive predictive value; NPV, negative predictive value. 
Table 5. Diagnostic Accuracy of Various Amylase Cutoff Levels for Predicting  
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The optimal cutoff values for lipase were ten times (490 IU/l) the upper limit of the normal 
range in diagnostic ERCP cases, therapeutic ERCP cases, and ERCP cases as a whole based 
on their sensitivity and specificity and especially on their PPV and NPV (Table 6).  
 
Table 6. Diagnostic Accuracy of Various Lipase Cut-off Levels for Predicting Post-ERCP 
pancreatitis (ref34)). PPV, positive predictive value; NPV, negative predictive value.. 
4. Discussion 
Pancreatitis remains the most common complication of ERCP, occurring after 1% to 30% of 
procedures (4-15), and its reported incidence has varied with the thoroughness of follow-up, 
the definition used, factors related to patient susceptibility, case mix, types of maneuvers 
performed, and the endoscopist. Rates of pancreatitis of 2% to 9% have been typical in 
unselected large prospective series (6-14). The subjects of the present study were consecutive 
patients who underwent diagnostic or therapeutic ERCP, and the incidence rate of pancreatitis 
was 4.2% in the subjects as a whole, 4.4 % in the diagnostic ERCP group, 4.0 %. In therapeutic 
ERCP group. These figures are comparable to those reported in recent prospective studies in 
which the definition and study population were similar to those in our study. 
A number of specific risk factors, acting independently or in concert, have been proposed as 
predictors of post-ERCP pancreatitis (6-14). The present study assessed 23 risk factors that 
included patient-related, procedure-related, and endoscopist-related variables. The results 
of the multivariate analysis showed that older age, hyperamylasemia and/or 
hyperlipasemia before ERCP, endoscopist experience with fewer than 200 ERCPs, high 
contrast medium injection pressure into the pancreatic duct, brushing cytology in the 
pancreatic duct, and IDUS each increased risk independently. The results of this study also 
demonstrated that the risk of post-ERCP pancreatitis is as much related to patient 
characteristics as to endoscopic technique and/or maneuvers, as previously reported (6-
10,14). However, the limitation of the present study is that it was a retrospective study. In 
spite of the fact that data were obtained from consecutive ERCP cases, minimal bias must be 
taken into account. 
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Previous studies have suggested that early hyperamylasemia is useful as a predictor of post-
ERCP pancreatitis (18,19,32,33). Thomas et al. (19) found that a 4-h amylase level threefold 
higher than normal was a useful predictor of pancreatitis and had a sensitivity and specificity 
of 70% and 95.3%, respectively. Testoni et al. (18) reported that a serum amylase level fivefold 
higher than normal 4 h after the procedure is a reliable predictor of post-procedure 
pancreatitis, with a sensitivity of 68.4%. In the present study the ROC of both the 4-h amylase 
level and the 4-h lipase level after diagnostic ERCP showed good test performance, with an 
area under the curve of 0.88 and 0.94, respectively, and the ROC of both the 4-h amylase level 
and the 4-h lipase level after therapeutic ERCP also showed good test performance, with an 
area under the curve of 0.92 and 0.96, respectively. In addition, the ROC of both the 4-h 
amylase and the 4-h lipase level after ERCP in the cases as a whole showed good test 
performance, with an area under the curve of 0.91 and 0.96, respectively. The optimal cutoff 
values for the amylase level after diagnostic ERCP, therapeutic ERCP, and ERCP as a whole 
were 5 times (625 IU/l) the upper limit of the normal range, and the sensitivity and specificity 
of the cutoff value for the as a whole cases was 78.0% and 85.8%, respectively. The optimal 
cutoff values for the lipase level after diagnostic ERCP, therapeutic ERCP, and ERCP as a 
whole cases were 10 times (490 IU/l) the upper limit of the normal range, and their sensitivity 
and specificity in the cases as a whole were 94.9% and 86.4%. The results of this study 
confirmed that the 4-h post-procedure serum amylase and lipase level are good predictors of 
pancreatitis both after diagnostic ERCP and after therapeutic ERCP.  
Comparisons of measurements of various pancreatic enzymes as a means of detecting of acute 
pancreatitis other than post-ERCP pancreatitis have shown that the blood lipase level is almost 
as sensitive as the total blood amylase level and has better specificity (20). Other studies (21-23) 
have demonstrated that the blood lipase level is more sensitive than the blood amylase level, 
and still another study concluded that the blood lipase level is an important diagnostic 
indicator for acute pancreatitis and that measuring it should be given top priority (24). By 
contrast, few studies have compared measurements of various pancreatic enzymes as a means 
of diagnosing post-procedure pancreatitis (25-27). Panteghini et al. (25) found that the serum 
lipase level increased faster than the levels of the other enzymes measured and that the 
average peak in lipase level was the highest in post-procedure pancreatitis. Doppl et al. (26) 
concluded that serum lipase measurement is the most sensitive diagnostic test for post-ERCP 
pancreatitis. The results of the present large retrospective study demonstrated that serum 
lipase was a more effective marker than amylase for predicting post-ERCP pancreatitis both 
after diagnostic ERCP and after therapeutic ERCP, based on the area under the ROC curves. A 
further prospective study should be performed to confirm the superiority of serum lipase over 
amylase as a predictor of post-ERCP pancreatitis. 
In conclusion, the 4-h post-ERCP serum amylase level and the 4-h post-ERCP lipase level, in 
particular, were found to be a useful means of predicting pancreatitis both after diagnostic 
ERCP and after therapeutic ERCP in a large retrospective study in a single center. A 
prospective study should be undertaken to confirm the usefulness of the 4-h post-ERCP 
amylase and lipase levels as predictors of post-ERCP pancreatitis. 
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1. Introduction 
Gallstone disease is one of the most common causes of acute pancreatitis. There are two 
accepted mechanisms regarding its pathogenesis: reflux of bile into the pancreatic duct and 
transient ampullary obstruction in the ampulla 1.  
Although most episodes are mild and resolve spontaneously, severe pancreatitis with local 
and systemic complications may lead to death 2. It is uncertain whether gallstones initiate or 
also maintain biliary pancreatitis 3.  
Since the advent of endoscopic retrograde cholangiopancreatography (ERCP) in 1974, it has 
replaced conventional surgery with the T-tube as the treatment of choice for common bile 
duct stones, reducing complications and shortening recovery time. 
It is also used to treat a variety of pancreaticobiliary diseases such as biliary strictures, stone 
removal, and biliary leaks.  
This chapter will review the role of endoscopy in acute gallstone pancreatitis and some of its 
complications. 
2. The role of endoscopy in acute gallstone pancreatitis 
2.1 Technique  
ERCP is performed with a side-viewing duodenoscope, reaching the ampulla of Vater. The 
bile duct is cannulated selectively under fluoroscopic guidance. There are different 
cannulation techniques, such as the use of a standard catheter or sphincterotome (Cotton-
Cannulatatome II PC Double Lumen Sphincterotome Cook-Medical), guidewire assistance, 
or a needle knife.  
2.2 ERCP in acute gallstone pancreatitis 
The management of acute gallstone pancreatitis has been controversial and the major debate 
has been whether the endoscopic treatment of acute gallstone pancreatitis ameliorates or 
exacerbates the disease.4 
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One of the most discussed issues in the investigation of acute pancreatitis has been whether 
enrolled patients would benefit from ERCP, with or without sphincterotomy, and whether it 
is possible to determine in which cases it would be beneficial.  
Increases in serum bilirubin, alkaline phosphatase and/or gamma-glutamyl transferase, and 
persistent dilatation of the common bile duct 5, suggest that gallstones are the cause of the 
pancreatic inflammation.  
In the majority of patients with mild biliary pancreatitis, bile duct stones have already 
passed to the duodenum by the time cholangiography is considered, so routine ERCP 
would be unnecessary 6; the prevalence of residual choledocholithiasis is less than 30% 7.  
Thus, patients with resolving mild acute pancreatitis can undergo laparoscopic 
cholecystectomy with intraoperative cholangiography, and any remaining bile duct stones 
can be dealt with by postoperative or intraoperative ERCP 8 . During the last years, several 
studies have reported that the indication for ERCP has changed from being a diagnostic tool 
to a therapeutic procedure 9 10, avoiding the risk of complications.  
Abdominal ultrasound, magnetic resonance (MR) and endosonography are the imaging 
techniques of choice.  
Although the value of ultrasound is limited due to its low sensitivity, its specificity is high. 
Dilation of the common bile duct alone is neither sensitive nor specific for the detection of 
common bile duct stones 8.  
MR is known to miss small gallstones 6 mm 1. The latter are the most frequent cause of acute 
pancreatitis. Limitations of magnetic resonance imaging include the difficulty in performing 
this procedure in critically ill or uncooperative patients, and its contraindications such as the 
presence of pacemakers 8. In these cases it is advisable to perform a biliary endosonography, 
with a positive predictive value of 91% to 100% in detecting bile duct stones 7.  
EUS is generally considered to be the most accurate method.  
Persistent biliary obstruction worsens the outcome and increases the severity of acute 
pancreatitis. When tests clearly show an alteration in liver function, with images compatible 
with common bile duct stones, it is undoubtedly advisable to perform endoscopic 
sphincterotomy and stone removal. Biliary drainage is necessary when bile drainage is 
incomplete because cholestasis predisposes the patient to cholangitis 9 11.  
Routine ERCP should be avoided in patients with low to intermediate suspicion of retained 
bile duct stones and who are planned to have cholecystectomy 8.  
2.3 Acute gallstone pancreatitis at the time of admission 
Wirsung duct hypertension and the migration gallstone theory 
One of the most prominent theories on the pathophysiology of acute pancreatitis is the 
common pathway and gallstone migration 12. In 1974 Acosta et al demonstrated the 
association between gallstone disease and acute pancreatitis. Gallstones were found in the 
feces of 34 out of 36 patients with pancreatitis 13. Transient obstruction of the ampulla of 
Vater increases pancreatic duct pressure and activates digestive enzymes 11.  
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Currently, most authors agree that transient obstruction by a migrating gallstone initiates 
pancreatitis. There is no consensus on the effects that follow stone impaction and the 
development of pancreatic inflammation. Some studies have questioned the relationship 
between duration of obstruction and severity of pancreatitis. A randomized trial in 61 
patients reported by Acosta et al in 2006 demonstrated that duration of ductal obstruction is 
a critical factor in determining severity. 14. 
2.4 Early descompression of the wirsung duct – ERCP 
As a result of the theories proposed for the onset of acute pancreatitis, different studies have 
questioned the benefit of early decompression of the ampulla of Vater.  
There are several randomized studies that compare patients receiving either early 
endoscopic intervention (EEI) within 72 hours after admission or early conservative 
management (ECM) 15 14, and which show contradictory conclusions 16 17 3.  
A study conducted in Hong Kong by Fan et al included 195 patients with acute pancreatitis: 
97 patients underwent ERCP within 24 hours after admission, and 98 received initial 
conservative treatment. Complications occurred in 18% of patients receiving early ERCP 
and in 29% of those receiving conservative treatment. The authors concluded that early 
ERCP is safe and effective in reducing the incidence of biliary sepsis, but removal of stones 
from the ampulla or from the common bile duct does not completely reverse the damage 
already done to the pancreas during the first hours or days of the illness 17. Fan et al and 
Neoptolemos et al demonstrated a significantly lower rate of complications in patients who 
had predicted severe pancreatitis and underwent early ERCP 16 17.  
In a study performed in Germany in 1997, Folsch et al randomized 126 patients to early 
ERCP and 112 to conservative treatment. This was a 22-institution multicenter prospective 
trial, which excluded patients with jaundice or cholangitis. Complications were similar in 
the two compared groups, but patients in the ERCP group had more respiratory failure. 
Because the authors found no explanation for this difference, they concluded that early 
ERCP and papillotomy were not beneficial 3. 
A meta-analysis carried out in the USA in 1999 by Sharman and Colin reported statistically 
significantly fewer overall complications and reduced mortality in patients with acute 
pancreatitis treated with ERCP + sphincterotomy compared with those treated 
conservatively. The role of ERCP + ES in patients with mild gallstone pancreatitis should be 
further evaluated in a large prospective RCT. ERCP + ES should be recommended for all 
patients with acute biliary pancreatitis and may be particularly beneficial in those with 
severe disease. 
ERCP may not be necessary or beneficial in patients with low likelihood of biliary 
obstruction 18.  
In 2006, Oria et al randomized 103 patients to receive either EEI (n =51) or ECM (n = 52). 
Their study failed to provide evidence that EEI benefits patients with acute gallstone 
pancreatitis.  
In 2008, Petrov et al conducted a meta-analysis in 450 patients. The results showed that early 
ERCP in patients with predicted mild and predicted severe ABP without acute cholangitis 
did not lead to a significant reduction in the risk of overall complications and mortality 1. 
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One of the most important points is proper patient selection. Larger prospective studies are 
needed to determine the correct value of ERCP in acute gallstone pancreatitis. Finally, there 
is no consensus as to which patients should be treated within 72 hours or later. In 
conclusion, ERCP in acute gallstone pancreatitis is still controversial, except when there is 
associated cholangitis. 
  
Stone removal with a Dormia Basket.  
Figs. 1 – 2. ERCP in acute gallstone pancreatitis  
2.5 Cholangitis and acute gallstone pancreatitis 
Biliary drainage is indicated within 24h of admission for patients with cholangitis (fever, 
abdominal pain and jaundice, the classic Charcot’s triad) 8. 
Clinical presentation ranges from a mild, self-limited process to a serious, life-threatening 
condition 19 . The most frequent symptoms are fever in 90%, jaundice in 60% and abdominal 
pain in 70% of cases. It can be associated with hypotension and altered mental status, the so-
called Reynold’s Pentad Syndrome 20.  
Historically, surgery was the treatment of choice.  
Currently, endoscopic retrograde cholangiopancreatography is the gold standard treatment.  
There are several methods to perform ERCP endoscopy, sphyncterotomy with or without 
stent placement, or nasobiliary drainage placement. The latter has advantages in that it can 
be washed and bile culture can be done, but has the disadvantage of patient discomfort 21.  
Biliary obstruction promotes bacterial colonization and infection. The most common 
organisms are E. coli, Enterococcus and Klebsiella. Biliary obstruction is necessary but not 
sufficient to cause cholangitis. Partial obstruction is associated with a higher rate of infection 
than complete obstruction.  
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It is essential to perform early diagnosis and deliver prompt treatment 19, which should 
initially include medical therapy, antibiotics and supportive medical care, followed by 
biliary decompression. The delay or failure in early recognition of cholangitis may be fatal. 
An endoscopic biliary stent should be placed if bile duct stones cannot be removed, so as to 
ensure proper drainage of the bile duct.  
Twenty to 40 ml of bile should be aspirated to provide a sample of bile for microbiologic 
analysis, and adopt the most suitable antibiotic therapy. Endoscopic treatment can only 
involve stone removal with or without biliary stents, or with a nasobiliary catheter. Stents 
can be placed in different sizes, from 8.5 to 10 French, and their length shall depend on the 
length of the bile duct. Several studies have demonstrated no difference in treatment 
outcomes between biliary stenting and nasobiliary catheter drainage 22 23.  
Biliary stents are temporary and are removed after 30 days. 
2.5.1 Post ERCP pancreatitis  
ERCP complications are pancreatitis, hemorrhage, perforation, cholangitis and cholecystitis. 
The overall rate of complications is 9.8% 24. The most frequent is pancreatitis. Young age, a 
history of pancreatitis, and sphincter of Oddi dysfunction, are risk factors. Thus, the 
technique and the experience of the endoscopist are important. The mechanisms underlying 
pancreatitis include intraductal pressure due to overinjection and papillary edema. 25.  
Criteria to define ERCP pancreatitis are: acute pain and tenderness in the upper abdomen, 
elevated pancreatic enzyme levels in blood, and radiologic abnormalities characteristic of 
acute pancreatitis.  
Pancreatitis post ERCP should be classified according to Cotton’s staging 6 .  
Although there has been controversy regarding the use of pre-cut sphincterotomy, a recent 
meta-analysis by Cenname et al showed that pre-cut implementation reduces post-ERCP 
pancreatitis risk 26.  
3. Endoscopic treatment of pancreatic pseudocyst  
3.1 Introduction 
Pancreatic pseudocysts are organized collections of enzyme-rich fluid after an acute 
pancreatitis, an exacerbation of chronic pancreatitis, or pancreatic trauma 27. They can be 
associated with necrotizing pancreatitis in between 2% and 50% of cases 28.  
Spontaneous resolution rate is 30% to 50% after a period of 6 weeks.  
Pseudocysts larger than 6 cm and persistent more than 6 weeks should be drained.  
Two thirds are located in the head of the pancreas 28.  
Infection of the pseudocyst results in a pancreatic abscess that can progress to sepsis, so 
early recognition and prompt intervention are necessary. 27. 
Surgical management is performed by internal drainage by cystenteric anastomosis, either 
in the form of a cystgastrostomy, cystduodenostomy, or cystjejunostomy 29. 
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The major advantage of endoscopic drainage over surgical drainage is minimal 
invasiveness, which reduces the duration of hospital stay and improves patient tolerance 30. 
Endoscopic transmural drainage is a minimally invasive alternative to surgery 31. The 
approach is to create a fistula between the pancreatic collection and the digestive tract. It is a 
proven treatment and can be performed via a transpapillary and/or transmural approach. 
The transgastric route is the most preferred. 
The risk of perforation is high when luminal compression is not visible at endoscopy 31. 
The introduction of endoscopic ultrasonography has allowed a proper selection of the 
puncture sites, avoiding major gastric vessels and adjacent structures 32.  
Morbidity mainly consists of bleeding, infection, and perforation.  
Bleeding is the most frequent complication 28  
3.2 Technique 
It is very important that the pseudocyst be in close approximation to the enteric wall (less 
than 1 cm).  
The first step is to search for a luminal compression in the stomach or in the duodenum by 
using the duodenoscope. 
When the cyst is not found to bulge, which occurs in almost 50% of cases, endoscopic 
ultrasound may be used for localization and evaluation of the distance between the two 
structures and identification of interposed vessels 29.  
When a luminal compression is identified, a needle-knife catheter is used to puncture and 
access the pseudocyst. After access, a 0.035-inch guidewire (Tracer Metro Direct Wilson-
Cook Medical) is coiled within the pseudocyst and dilation of the fistula is performed using 
a 15 mm balloon dilator (CRE balloon; Microvasive) under fluoroscopic guidance. 
There are several devices that are used to puncture the gastric or duodenal wall to enter into 
the cyst cavity30. Once inside the pseudocyst, the pancreatic necrosis is removed with a 
Dormia Basket (Cook Medical WEB-2X4-2X6).  
In a randomized trial, Varadarajulu et al demonstrated that success rate of transmural 
drainage of pancreatic pseudocysts was higher when performed under endosonography 
guidance. The authors concluded it should be considered as the first-line treatment. 
4. Percutaneous approach in necrotizing biliary pancreatitis 
4.1 Introduction 
About 20% of patients with acute pancreatitis develop pancreatic necrosis associated or not 
with peri pancreatic necrosis 33. This is one of the most feared complications of acute 
pancreatitis due to its high morbidity and mortality. Infection of pancreatic necrosis 
naturally develops during the second phase of the disease (most commonly in the 2nd and 
3rd week after the onset of symptoms) and has been reported in as many as 40–70% of 
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patients with necrotizing pancreatitis. The risk of infection increases with the extent of intra- 
and extra-pancreatic necrosis 34. It is crucial to know whether the necrosis is infected or not, 
since this will determine which treatment is to be performed. 
When fever, leukocytosis, and unexpected deterioration appear, infection is suspected11.  
Infected pancreatic necrosis necessitates surgical debridement, while sterile necrosis is 
managed best non-operativelly (Fig 3.) Infected necrosis constitutes an absolute indication 
for prompt intervention. 
 
 
  (A) Image on admission             (B) 7 days post-admission 
 
 (C) One month post-admission.       (D) At 4 months, without treatment. 
 
Fig. 3. Conservative treatment. 
Until recently, the first-choice intervention in infected necrotizing pancreatitis was surgical 
necrosectomy by laparotomy. This approach is associated with considerable morbidity (34–
95%) and mortality (11–39%) 33. 
In 1998, Freeny et al published a series of patients who were treated primarily with imaging-
guided percutaneous catheter drainage.  
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Since Van Sonnenberg and D'agostino et al’s first reports, intervention strategies in acute 
pancreatitis have been used for over fifteen years in patients not amenable to surgical 
treatment. 
There are various techniques of necrosectomy: surgical, endoscopic and endoscopic 
necrosectomy. Treatments are multidisciplinary and tend to be conservative. 
Retroperitoneoscopy, endoscopy and laparoscopy are minimally invasive techniques and 
have prompted the use of mini-invasive or step-up treatment strategies.  
Both surgical and percutaneous drainage are associated with a significant risk of 
pancreatico-cutaneous fistula formation35.  
This chapter will address only percutaneous necrosectomy 
Percutaneous treatments for resolution of the complications of acute pancreatitis 
 Ultrasound-guided diagnostic puncture. 
 CT-guided diagnostic puncture. 
 Single or multiple percutaneous drainage under ultrasound guidance. 
 Single or multiple percutaneous drainage with CT guidance. 
 Replacement of catheters up to 30 Fr with fluoroscopic guidance. 
 Retroperitoneal lavage under fluoroscopic guidance. 
 Retroperitoneoscopy under fluoroscopic guidance. 
 Catheter replacement under fluoroscopic guidance. 
Infected pancreatic necrosis is uniformly fatal if untreated and even after aggressive surgical 
intervention 36 
The time point for surgical or interventional procedures has changed in the last years. 
Mortality rate of patients undergoing early surgical necrosectomy reached 65%. Ideally, 
necrosectomy should be performed on day 30 after onset of symptoms. Delayed 
necrosectomy allows demarcation of the necrotic tissue 37. One of the most difficult tasks is 
choosing the right time for intervention. 
The evolution and advances in radiologic imaging and new developments of interventional 
radiology have demonstrated the advantages of mini-invasive treatment. 
Percutaneous treatment in severe acute pancreatitis is directed at addressing local 
complications, such as abscesses, peripancreatic collections and infected necrosis, to 
postpone surgical intervention or even to obviate the need for surgical necrosectomy33. 
Percutaneous endoscopic necrosectomy requires insertion of a catheter under CT guidance 
into the necrotic retroperitoneal collection. The drain tract is dilated to 28 to 30 F to allow 
piecemeal necrosectomy at multiple endoscopic sessions with acceptable success and 
mortality rates 38.  
The procedure is best suited for the stable patient but can be attempted in the critically ill 
patient as well 39.  
In addition to catheter debridement, these patients also require care from a multidisciplinary 
team involving collaboration by internists and surgeons, as well as interventional 
radiologists, to manage their complex clinical picture 36. 
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4.2 Fine needle aspiration 
Elevations in white blood count and temperature occur in both sterile and infected necrosis. 
Hence, it is not possible to distinguish these conditions clinically unless CT scan shows 
evidence of air in the retroperitoneum, but this is a rare findings 40 41 42 . 
The use of FNA is controversial. It has been the practice of some authors to advocate early 
FNA to identify infection and determine which patients will benefit from necrosectomy. 
Treatment strategies based on the presence of infection have led to the widespread advocacy 
for early fine needle aspiration (FNA) of the necrotic pancreas 37,41,43. 
FNA can be guided by either computed tomography or ultrasonography and should be 
performed in patients who develop significant pancreatic necrosis and clinical signs of sepsis.  
Bacterial tests including gram staining and culture of the aspiration material have a 
diagnostic sensitivity and specificity of 88 and 90%, respectively. 
It is important that only those patients who develop clinical signs of sepsis should undergo 
FNA, since the procedure bears a potential risk of secondary infection 34,37,44  
Haney, Pappas et al. consider that clinical presentation is sufficient to make an operative 
determination. They argue that to examine the appropriate role of FNA, one must consider 
the timing of surgical intervention. Although early necrosectomy was once advocated, 
numerous more recent studies have confirmed that delayed surgical intervention is 
associated with better outcomes. The current consensus is for delayed surgical intervention, 
even in the setting of infected necrosis 37,41. 
The critical argument against routine FNA, then, is that during this delay, the clinical course 
of the patient will readily predict who will need debridement and who will not 41. 
4.3 Ultrasound – Guided puncture 
This procedure is performed in patients in poor general condition in intensive care units 
with progressive deterioration of their general condition and suspected infected collection.  
The puncture approach depends on the ultrasound, and should be performed using the best 
acoustic window possible. The needles used in the procedure are thin because they are only 
for diagnostic purposes.  
When the puncture yields purulent fluid percutaneous drainage can be placed following the 
Seldinger technique. 
4.4 CT guided puncture 
It is performed in patients with progressive deterioration of general condition and suspected 
infected pancreatic fluid collection. An advantage of CT guided puncture is that it can be 
performed by different approaches: anterior, posterior, right or left lateral, or transgastric, 
according to the location of collections.  
It is the method of choice in the presence of abdominal distention and deep fluid collection. 
The aim of the procedure is to extract as much necrotic tissue as possible. 
 
Pancreatitis – Treatment and Complications 
 
156 
Catheters are removed when cavity size is small at fluoroscopy, no collection is noted on 
scan tomography, and catheter output has decreased to 15-30 mL per day.  
4.5 Placement of drains 
The placement of drains with ultrasound or CT guidance depends on the usage and customs 
of each operator. Undoubtedly, in the presence of abdominal distention and deep fluid 
collection the method of choice is computer-tomography guided puncture.  
Indication for the procedure is the presence of infection in the collection that has been 
confirmed either by the presence of pus or a positive culture from the puncture. 
Drainage site selection depends on the location of the infected collections; this decision can 
be made at the time of drainage or during the course of treatment. The size and number of 
catheters depends on the consistency of content and its location. Eight Fr or 8.5 Fr catheters 
can be used initially and be replaced with catheters up to 30 Fr; this replacement can be 
performed with fluoroscopic guidance. 
  
                (A) Right lateral drainage                       (B) Left lateral drainage  
Fig. 4.  
4.6 Replacement of catheters up to 30 Fr with fluoroscopic guidance 
It is important to assess the effectiveness of drainage catheters. When there are poor 
drainage areas, larger caliber drainage catheters up to 30 Fr can be placed under 
fluoroscopic guidance. They should be examined constantly according to the patient's 
clinical course and washed with saline when necessary. Performing a sonogram is useful. 
Dye is injected through the catheter; drainage catheters are considered sufficiently effective 
if the dye is evacuated completely leaving no residue.  
When debris or poor drainage persists, the procedure should be attempted using catheters 
of increasing caliber, to reach 30 Fr diameter. A rigid Amplatz-type guidewire is placed 
through the existing catheter using the set of Amplatz dilators up to 30 Fr. The catheters are 
then fixed following the regular technique and can be flushed with saline solution when 
necessary. 
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  (A) CT on admission.                (B) 17 days post-admission 
  
  (C) Drainage at 34 days               (D) 8.5 Fr Catheter 
  
    (E) At 58 days    (F) 30 Fr Catheter 
Fig. 5.  
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4.7 Multiple percutaneous Catheter Technique 
Multiple catheters are often used simultaneously (Fig 5). One to five 10 to 16 Fr catheters are 
inserted under CT guidance into the pancreatic necrotic tissue. Aggressive irrigation is 
performed with saline when necessary, while the debris is removed by syringe suction. 
Lavage fluid is injected to fill the cavity and aspirated until all fluid is removed. When the 
catheter becomes occluded, it is removed under syringe suction 36 . 
Stone baskets are used to remove large pieces of debris. This is repeated until the fluid 
becomes clear. Finally, a self-retaining catheter is left in the drainage cavity. The session is 
repeated 2 to 3 times per week 39. The aim of the procedure is to extract as much necrotic 
tissue as possible. 
All patients receive intravenous antibiotics appropriate to the organism grown in culture of 
the pancreatic fluid. 
Catheters are removed when cavity size is small at fluoroscopy, no collection is noted on 
scan tomography, and catheter output has decreased to 15-30 mL per day.  
 
Fig. 6. Multiple drainage performed under CT scan guidance  
4.8 Retroperitoneoscopy under fluoroscopic guidance  
When collection persists after drainage, catheters can be replaced under fluoroscopic 
guidance. The procedure is performed under sedation following the Seldinger technique. A 
nephroscope equipped with two channels for viewing the inside the pancreatic collection is 
used. It is placed with a video camera connected to a monitor, and tweezers are inserted 
through the working-channel to remove necrotic and devitalized tissue. The major risk is 
hemorrhage. It is useful to perform the procedure under direct vision and fluoroscopic 
guidance, to view how far the ureterescope has reached. On completion of the session, the 
necrotic cavity is flushed and a 30Fr catheter is inserted.  
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Fig. 7.  
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Intra-Abdominal Hypertension and  
Abdominal Compartment Syndrome  
in Critically Ill Surgical Patients  
(Special Findings in Severe Acute Pancreatitis) 
Zsolt Bodnár 
Department of General Surgery, Hospital de Torrevieja,  
Spain 
 „…a clinical entity that had been ignored for far too long”   
(Ivatury RR-Sugerman HJ) 
1. Introduction 
Intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS) are very 
frequent findings in patients with severe acute pancreatitis. The causing factors are the 
retroperitoneal inflammation, paralytic ileus, ascites and the serious visceral edema due to 
massive fluid resuscitation, which leads to increased intra-abdominal pressure (IAP), early 
organ disfunction with IAH and finally ACS. Several publications conclude that this clinical 
entity can appear in high-risk surgical patients (severe acute pancreatitis) within the first 12 
hours of the admission to intensive care unit. In these cases the mortality rate is extremely 
high. That is why we have to pay attention to make the correct and early diagnosis, 
treatment and follow-up of the severe acute pancreatitis (1-2). 
The ACS is a rediscovered life threatening clinical entity. The aim of this chapter is to show 
the definitions, ethiology, pathophysiology, diagnosis and treatment of this serious, not only 
surgical problem. 
The mortality due to the abdominal compartment syndrome is extremely high (38-71%). It 
can be defined as adverse physiologic consequences that occur as a result of an acute 
increase in the IAP. The most common causes are retroperitoneal haemorrhage, visceral 
oedema, pancreatitis, bowel obstruction, tense ascites, peritonitis, tumor. The affected 
systems are cardiovascular, pulmonary, renal, central nervous systems and splanchnic 
organs. The gold standard diagnostic method is the continuous intra-abdominal pressure 
monitoring. The fundamental ways of the treatment are the adequate fluid resuscitation and 
surgical decompression (1-2).  
Finally we would like to show the special findings of the IAH and ACS according to the 
problem of severe acute pancreatitis. 
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2. Historical highlights 
There are three big eras in the history of ACS. 
The first is the evolution in the understanding of the pathophysiology of the compartment 
syndrome in general. (The first case of the muscular compartment syndrome was described 
by Hamilton in 1850.)  
The second was the era of the experimental studies for measure the IAP. (different devices 
and techniques by different locations, for example through the bladder (uterus or rectum).  
The third is the era of the understanding and management of the basic problem which was 
started with the work of Sir Heneage Ogilvie who performed the first laparostomies and 
described the beneficial effect of this process in the management of giant abdominal war 
wounds (3). 
The real story of ACS started in the second part of the XIX. century (4-5). First, in 1863 
Marey published his experiences about the increased abdominal pressure's effects. In 1865 
the first intra-abdominal pressure measurement via rectum was performed in Germany. 
Between 1870 and 1900 numerous attempts were carried out to measure IAP and to study its 
influence to vital functions (Bert, Schroeder, Schatz, Wendt, Quinke, Heinricius). 
In 1911 Emerson published his article titled "The intra-abdominal pressure" (6). In 1940 the 
first laparostomy was performed to reduce the increased IAP (Ogilvie). The first description 
of the importance of staged abdominal closure was published in 1948. (Gross). In 1951 
Baggot claimed that abdominal closure in case of distension can cause death. 
In the 70's several teams carried out investigations on laparoscopy and effects of 
pneumoperitoneum on IAP. In 1982 Harman and his team proved the harmful effects of IAP 
on renal function and significance of decompression in these cases. In 1984 Kron was the 
first who described the compartment syndrome but didn't use the definition itself (4). Also he 
used the method of pressure measurement via urinary catheter that became commonly used in 
1989 though the base of this method was described by Oderbrecht 100 years earlier. Later this 
technique was developed by several scientists (Iberti, Sugrue, Malbrain, Balogh and their 
colleagues) (7-11). In 1989 terminus technicus "abdominal compartment syndrome" was 
created by Fietsam and his team (5). The two articles that had opened the decade of ACS were 
published in 1995 and 1996 (12-13). In the previous ten years several teams started to 
investigate the monitoring techniques of intra-abdominal pressure. The first worldwide 
conference was organized 6-8 December 2004, in Noosa (Queensland) in Australia and 
WSACS (World Society of Abdominal Compartment Syndrome) was established at the same 
time. This society now counts numerous members from all over the world. 
3. Definitions 
3.1 Consensus definitions  
To understand perfectly the question of the ACS it is very important to make clear of the 
basic concepts. The below mentioned consensus definitions were made by the 2004 
International ACS Consensus Definitions Conference of the WSACS firstly in December of 
2004 in Noosa (Australia) and they were rediscussed in 2007 in the Antwerp (Belgium) 
during the Third World Congress of the Abdominal Compartment Syndrome (WCACS):  
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Intra-abdominal pressure (IAP): is the steady-state pressure concealed within the 
abdominal cavity. (14-15) 
Intra-abdominal hypertension (IAH): is defined by a sustained or repeated pathological 
elevation in IAP ≥ 12 mmHg. (14-15) 
Abdominal Compartment Syndrome (ACS): is defined as a sustained IAP > 20 mmHg 
(with or without an APP < 60 mmHg, where APP = MAP - IAP and APP = abdominal 
perfusion pressure; MAP = mean arterial pressure) that is associated with new organ 
dysfunction / failure. (14-15) 
(The normal range of the IAP is between the 0 and 5 mmHg, and it significantly depends on 
Body Mass Index (BMI) (9,16).) 
3.2 Classification 
IAH is graded as follows:  
- grade I. 12-15 mm Hg 
- grade II. 16-20 mm Hg 
- grade III. 21-25 mm Hg 
- grade IV. IAP > 25 mm Hg 
(IAP may be defined with several units. To avoid misunderstanding IAP is measured in 
mmHg according to the international consensus (1 mmHg = 1.36 H20cm = 0.13 kPa)). (1-2) 
3.3 Etiopathogenesis 
Primary ACS: is a condition associated with injury or disease in the abdominopelvic region 
that frequently requiers early surgical or radiological intervention. ( for example: peritonitis, 
pancreatitis, bowel obstruction, haemorrhage, trauma, etc.) (1-2) 
Secundary ACS: conditions that do not originate from the abdominal cavity, generaly 
caused by surgical activity (for example: abdominal closure under distension, extremely 
large abdominal hernias, operation of bowel obstruction). (1-2) 
The incidency of IAH is 2-30% and of the ACS is 1-16% in general surgical syndromes and in 
the ethiopathogenesis are acute and chronic causes: 
Acute (1-2): 
- spontaneous: peritonitis, abdominal abscess, bowel obstruction, ruptured aortic 
aneurysm, tension pneumoperitoneum, acute pancreatitis, mesenteric thrombosis 
- postoperative: peritonitis, abscessus, bowel obstruction, intra-abdominal haemorrhage 
- trauma: intraperitoneal and retroperitoneal haemorrhage, visceral oedema after 
cardiopulmonary resuscitation 
- iatrogenic: laparoscopy, abdominal closure under distension 
Chronic (1-2): 
ascites, enlarged intra-abdominal cyst, long term peritoneal dialysis, pregnancy, extreme 
obesity 
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Chronic and slow increasing of IAP can be compensated by the human organism and the 
abdomen adaptates for increased load, so ACS won't develop in this case. 
Incidency 
Incidency of IAH is 2 – 30 % (10,18) in general surgical syndromes and the incidency of ACS 
is 1 – 16 % (17-19). If intensive care unit (ICU) treatment is necessary, the development of 
ACS is expectable in the first 12 hours (11,18). 
Risk factors for IAH / ACS (14-15) 
Diminished abdominal wall compliance:  
- acute respiratory failure, especially with elevated intrathoracic pressure 
- abdominal surgery with primary fascial or tight closure 
- major trauma / burns 
- prone positioning, head of bed > 30 degrees 
- high body mass index (BMI), central obesity 
Increased intra-luminal contents: 
- gastroparesis 
- ileus 
- colonic pseudo-obstruction 
Increased abdominal contents: 
- hemoperitoneum / pneumoperitoneum 
- ascites / liver dysfunction 
Capillary leak / fluid resuscitation: 
- acidosis (pH < 7.2) 
- hypotension 
- hypothermia (core temperature < 33 Co) 
- polytransfusion (> 10 units of blood / 24 h) 
- coagulopathy (platelets < 55000 / mm3 or prothrombin time (PT) > 15 seconds or partial 
thromboplastin time (PTT) > 2 times normal or international standardised ratio (INR) > 1.5)  
- massive fluid resuscitation (> 5 l / 24 h) 
- pancreatitis 
- oliguria 
- sepsis 
- major trauma /burns 
- damage control laparotomy 
4. Pathophysiological changes during the increased IAP 
IAH can cause serious complications in any organ (Table 1). Without effective therapy / 
intervention it can occurr multi organ failure (MOF) by affected cardiovascular, respiratory, 
central nervous system and renal function. De Waele and his colleagues published that there 
was a 94% incidence of respiratory, 94% cardiovascular and 89% of renal failure among 
patients with IAH (where IAP > 12 mmHg). (1,2,12,13,16,18): 
Intra-Abdominal Hypertension and Abdominal Compartment Syndrome in  
Critically Ill Surgical Patients (Special Findings in Severe Acute Pancreatitis) 167 
Cardiovascular system 
The increased IAP reduces the cardiac functions. The increased pressure lowers the end-
diastolic volume as well as the venous return from the inferior caval vein, portal vein and 
superior caval vein. The systemic vascular resistency increases because of the compressed 
capillary system and the afterload will be consequently elevated. All of these effects result 
cardiac insufficiency and compensatoric tachycardia (19,20). 
IAP = 0-9 
mmHg 
IAP = 10-15 
mmHg 
IAP = 16-25  
mmHg 
IAP = 26-40  
mmHg 
cytokines 
release  
circulation of 
the abdominal 
wall decreases 
with 42% 
significant reduction of 
splanchnic circulation 
and venous return 
„hemodinamic collapse” 
increased 
capillary 
permeability 
significant 
reduction in the 
circulation of 
other abdominal 
organs 
increase in systemic 
vascular resistance 
(SVR), central venous 
pressure (CVP), peak 
airway pressure (PAWP)
fatal acidosis
fluid content 
of the „third 
space” 
expands 
local acidosis total respiratory capacity 
(TRC), vital capacity 
(VC) lowered due to 
pulmonary compression
hypoxia
hypercapnia 
decreased 
venous return 
as well as 
preload 
free radical 
release 
hypoxia
hypercapnia 
anuria
early effects 
on the central 
nervous 
system  
bacterial 
translocation 
throught 
intestinal 
mucosa 
circulation of intestinal 
mucosa decreases with 
61% 
circulation of coeliac artery is 
reduced to 58% 
  increasing acidosis circulation of superior 
mesenteric artery is reduced to 
39% 
  renal failure: oliguria, 
anuria 
circulation of renal artery is 
reduced to 30% 
  disturbance of central 
nervous system 
circulation of abdominal muscles 
lowered with 80% (infection, 
wound-healing disturbances) 
Table 1. Physiological changes during increased IAP (Wolfe, 2005) 
Respiratory system 
Due to the increased IAP the diaphragm will be shifted to cranial direction on both sides 
causing the reduction of pulmonary volume and cardiac function. Without intervention 
acidosis and hypoxia will occur (12,19,20). 
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Renal function 
The renal perfusion decreases related to the reduced cardiac function and direct 
compression of renal arteries and kidneys, with consequent oligo- and anuria. IAP 15 - 20 
mmHg results in oliguria, and above 30 mmHg it causes anuria (13,19,20,21). 
Splanchnic circu1ation 
The splanchnic, mesenteric and hepatic perfusion decreases above 15 mmHg of IAP. It is a 
well-known and proved fact that splanchnic and hepatic circulation has an autoregulation. 
The basis of this autoregulation is the renin-angiotensin system, the HABR (hepatic arterial 
buffer response) and vasopressin. Though numerous clinical studies proved that this 
complex system could compensate the consequencies of insuffient arterial circulation, 
venous return, decreased preload due to the increased IAP only for few hours. When it 
worns out it causes irreversible destruction of the intestinal mucosa and the liver. This is 
why decompression is essential in the ACS's therapy! The reduced circulation results in a 
mucosal ischaemia and bacterial translocations. Intestinal bacteria and their toxic products 
result sepsis and multiple organ failure (MOF) (22-24) (Figure 1). Endotoxins or exotoxins 
cause a chain reaction of mediators that can damage either the pathogen and the human 
organism and if it becomes irreversible can cause death. This progressive clinical syndrome 
is a manifestation of multiple organic dysfunction or failure (ARDS - Adult Respiratory 
Distress Syndrome, renal failure, DIC -Disseminant Intravascular Coagulation). If it 
progresses the symptoms of multiple organ failure and septic shock with hypotonia will 
appear. Since this phenomenon occurs as a consequence of not only infections but 
pancreatitis, burning and ACS, the definition of SIRS (Systemic Inflammatory Response 
Syndrome) was introduced in the 90's (22). 
 
Fig. 1. Effects of increased intra-abdominal pressure on the splanchnic circulation (IAH = 
intra-abdominal hypertension, ACS = abdominal compartment syndrome) 
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Abdominal wall circulation 
The reduced abdominal wall circulation results in insufficient wound-healing, higher 
possibility of inflammation and dehiscency (25). 
Central Nervous System 
The increased IAP lowers the intracranial pressure secondarily due to the compression of 
jugular venous system and of the thoracic region (26).  
5. Laboratory changes of inflammatory markers during the increased IAP in 
patients with acute pancreatitis 
The technique of IAP measurement is accurate, precise, reproducible and cost-effective. 
However laboratory measures for monitoring of IAH have not been defined. The 
immunological changes were examined in a study group of 65 patients with acute 
pancreatitis (IAP > 12 mmHg) in one of our studies. Serum adenosine, IL-1β, IL-2, IL-4, 
IL-10, TNFα and IFNγ were measured. Significant correlations were found among IAP-
adenosine values and IAP-IL-10 values providing new tools for the laboratory 
monitoring of IAH as well as further understanding of the pathomechanism contributing 
to ACS.  
We present here the historical diagram (Figure 2) from one of our preliminary studies which 
shows the very important correlation between IAP and adenosine: 
 
 
Fig. 2. Significant correlations between IAP and adenosine level 
The pathophysiology of IAP is still poorly understood, including the contributions of 
adenosine and cytokines (27). Adenosine contributes to the maintenance of hepatosplachnic 
blood flow (28) and hypoxia results in increased serum adenosine concentrations (22,29). 
Such alterations may result in enlargement of the abdominal organ blood volume and 
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potentially contribute to the pathology associated with increased IAP and ACS. In addition 
to its contribution to maintenance of hepatosplanchnic blood flow, adenosine is an 
endogenous regulator of cellular functions including neurotransmission (30), local 
circulation (31) and the modulation of inflammation (32-35).  
Previous studies in porcine and rabbit models demonstrated that increased IAP was 
associated with reduced gastric intramucosal pH (36) and increased levels of IL-1β, IL-6, 
TNFα, and CRP (37).  
In our own studies, we investigated the associations of serum levels of adenosine, C-reactive 
protein (CRP) and various cytokines (interleukin 1β [IL-1β], IL-2, IL-4, IL-10, tumour 
necrosis factor α [TNFα] and interferon γ [IFNγ]) with IAP in surgical patients with or 
without elevated IAP. 
Our observations derive from surgical patients being treated in an intensive care unit and 
therefore, likely represents the greater degree of individual variation expected in human 
populations as compared to homogeneous experimental models. Thus, while cytokines such 
as IL-1β, IL-6, TNFα and CRP may have been significantly associated with IAP in animal 
models (37), they were not significantly related in our study. On the other hand, our results 
showed a highly significant relationship of both IL-10 and adenosine with IAP in a 
heterogeneous human population, suggesting that they may be better indicators of IAP in 
this case.  
We found a robust linear correlation between IAP ≥15 mmHg and serum levels of adenosine 
and IL-10. While we believe that this relationship may be helpful in monitoring the effects of 
IAP lowering therapies, we also believe that the increase in serum adenosine level may 
directly contribute to the development and maintenance of IAH-ACS.  
We propose that a strong relationship may exist between the advancement of hypoxia and 
splanchnic ischemia, inducing the release of adenosine from the hypoxaemic tissues of the 
gut (22,28,29), resulting in splanchnic vasodilatation and subsequent increase in IAP. This 
relationship is cyclic in nature and if left undisturbed, results in a ‘vitious circle’ leading 
ultimately to ACS. Thus, while adenosine itself is a very potent anti-inflammatory molecule 
(33-35), in the development of IAH-ACS, elevated adenosine concentrations cause renal 
arterial dysfunction (38), ultimately causing collapse of kidney function manifested by 
decreased renin production and blood pressure and increased blood urea and creatinine 
concentrations (39-40). In this context, the renal failure resulting from increased adenosine 
concentrations is a main cause of multi-organ failure (41-42) and damage of vegetative 
splanchnic ganglia (43-44). The elevated serum IL-10 levels appear partly to be the direct 
consequence of adenosine stimulating monocyte secretion of IL-10 (34), but IL-10 can be 
produced also by other inflammatory cells. In the Figure 3 we propose a model describing 
the potential role of adenosine in the pathomechanism of IAH-ACS. 
Our observations show that the laboratory determination of serum adenosine and/or IL-10 
may be helpful for initial screening or grading of IAH as well as for monitoring progress in 
therapeutic reduction of IAP. As the determination of IL-10 by ELISA is an easily automated 
method, it may be preferred to the measurement of adenosine by HPLC, particularly, during 
follow-up of surgical, trauma or medical patients with high risk of IAH or ACS. 
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In conclusion, we report that plasma/serum concentrations of adenosine and IL-10 are 
strongly and linearly correlated to the values of IAP >15 mmHg (Grade II IAH) in surgical 
patients. Thus, monitoring of serum adenosine and IL-10 concentrations may offer 
significant insights into the progression and treatment of IAP, particularly, in patient 
populations at risk of IAH and ACS. The role of adenosine in the pathomechanism of IAH-
ACS offers a new insight into this severe clinical syndrome (45-46). 
 
 
(RR = Riva Rocci (blood tension), Crea = creatinine, MOF = multi organ failure) 
 
Fig. 3. The role of adenosine in the proposed model of the pathomechanism of ACS 
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6. Diagnostic methods 
Numerous investigations proved that only the physical examination of the abdomen to 
recognise ACS is inappropriate (11). Detection of ACS and elevated intra-abdominal 
pressure is based on standardized measurements of IAP. Practically IAP is detectable in 
every region of the abdomen (12,16,47,48). 
Direct technique: 
- during laparoscopy (laparo-insufflator) 
- with an intraperitoneal cateter and transducer 
- with a metal cannula lead into the intraperitoneal space and connected to a manometer 
lndirect technique: 
- pressure measurement of inferior caval vein 
- measurement throught nasogastric tube 
- measurement of vaginal pressure 
- measurement of rectal pressure 
- measurement of urinary bladder's pressure 
It seems that the most reliable and the less invasive method is the transvesical technique 
(7,8,13). It is based on the fact that IAP is equal with intravesical pressure. Filling the urinary 
bladder with 50 ml saline serum ensures that the pressure will be translocated to the 
catheter wich is clamped during the procedure. The pressure inside the catheter measurable 
by connecting a T-tube or inserting a sterile needle (Sugrue technique) (12). The T-tube is 
connected to a monitor via a transducer or to the system used to measure the central venous 
pressure (pressure of the liquid column). The intravesical technique's results correlated with 
the direct (laparoscopic insufflator) method. The intravesical way of measuring was more 
accurate than the gastric or rectal way which are very position depending. Animal-testing 
proved that the pressure of inferior caval vein is correlating with the vesical pressure but it 
is much more invasive and can be the source of serious complications - like other direct 
methods. Additionally urinary catheter is required in all critically ill patients. The 
intravesical method for measuring IAP was originally described by Kron (4), and then 
validated by Iberti and his team (8). It was simplificated by Sugrue and his team: a T-tube 
was inserted to the catheter. Since in this method it is unnecessary to prick the aperture, the 
number of infectious complications decreased. This method is simple but may be time 
consuming - because in case of critical patients approximately 7 minutes are needed for the 
procedure at least four times a day. Having intermittent character the standard IAP 
measuring is unable to give information about the length of IAH. To eliminate 
insufficiencies (like labour-intensive, fluctuating character) Balogh and his colleagues 
developed and validated the continuous abdominal pressure measurement (CIAPM) 
technique (11). Continuous intra-abdominal pressure measurement requires only a three-
way catheter and a transducer, and it is unnecessary to clamp the catheter and fill the 
urinary bladder („Balogh-Sugrue technique”). This method is used successfully to follow up 
critically ill patients in our department. 
7. Treatment 
To solve the problem of this serious clinical entity there are two opportunities: non-surgical 
(evacuate intraluminal contents and intra-abdominal space occupying lesions, improve 
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abdominal wall compliance, optimize fluid administration and systemic/regional perfusion) 
and surgical (early decompression) management.  
Non-surgical management (14-15) 
The treatment of ACS always means surgical decompression, but sometimes or if we have to 
treat only IAH we have the possibility for non-surgical way. The success is strongly depends 
on the etiology of the current IAH / ACS. 
The main fields of the conservative management are: 
- evacuate intraluminal contents: insert nasogastric and / or rectal tube 
     initiate gastro- / coloprokinetic agents 
     minimize enteral nutrition 
     administration of enemas 
     consider colonoscopic decompression 
     discontinue enteral nutrition 
- evacuate intra-abdominal space occupying lesions:  abdominal ultrasound to identify  
             abdominal CT to identify 
             percutaneous catheter drainage 
             consider surgical evacuation  
- improve abdominal wall compliance: ensure adequate sedation / analgesia 
     remove constrictive dressings 
     avoid prone position, head of bed > 20 degree  
     consider reverse Trendelenberg position 
     consider neuromuscular blockade 
- optimize fluid administration:  avoid excessive fluid resuscitation 
     aim for zero to negative fluid balance by day 3 
     resuscitate using hypertonic fluids, colloids 
     fluid removal through judicious diuresis 
     consider hemodialysis / ultrafiltration 
- optimize systemic / regional perfusion:  goal-directed fluid resuscitation 
              maintain APP (APP > 60 mmHg) 
              hemodynamic monitoring to guide resuscitation 
              vasoactive medications to keep APP > 60 mmHg 
If IAP > 25 mmHg (and/or APP < 50 mmHg) and new organ dysfunction is present, 
patient’s IAH / ACS is refractory to medical management. Strongly consider surgical 
abdominal decompression. 
During the non-surgical management the CIAPM is strongly recommended! 
Surgical management (14-15) 
The surgical management of the IAH / ACS always means decompressing laparotomy with 
temporary abdominal closure.  
If the patient has etiology for IAH / ACS it is very important to check the IAP continuously. 
When we have the criteria of ACS (see in the consensus definitions) we have to make the 
urgent decompression. 
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From now on it is important to continue with medical treatments and fluid resuscitation to 
reduce IAP and stabilize our patient. Having APP more than 60 mmHg and IAP < 12 mmHg 
consistently means that IAH has resolved. 
If we have APP > 60 mmHg and IAP > 12 mmHg we have to go on with the non-surgical 
way. But in case of APP < 60 mmHg we have to perform / revise decompression again. 
During the non-surgical management the CIAPM is strongly recommended! 
Reconstruction after open abdomen management 
After decompression it is necessary to consider the way and the time of closure. 
The main possibilities (13,16,49,50,51): 
- primer closure 
- primer skin or fascial closure (Towel Clip Closure, direct suture) 
- temporary abdominal closure (TAC) technique: let the abdomen open replacing it with 
tissue friendly mesh or other material temporarily (Bogota bag, VAC-Pac / vacuum-
assisted closure, Gore-Tex patch, Whitman patch, biological patches, skin graft) 
- covering the abdominal organs with omentum which may be epithelized in the future 
- staged abdominal closure (elective hernias) 
The closure is possible when the general condition is stable (24-48 hours) or after the 
definitive recovering (sometimes 6-12 months later). 
The aim is to prevent abdominal distension, though an enormous elective hernia will be 
generated. 
8. Special field: Pancreatitis and the ACS 
In the last few decades the intra-abdominal hypertension and the abdominal compartment 
syndrome has arrived to get a special attendence in non-traumatologic patients. One of 
these cases is the ACS caused by severe acut pancreatitis. By the recent publications the 
number of acute and chronic pancreatitis is increasing. On one hand it is due to evaluation 
of the radiological diagnostic techniques, on the other hand we have more possibility to 
treat the severe cases. In spite of the fact, the successfull management of severe acut 
pancreatitis still needs an interdiscipline cooperation.  
Clinical course 
The aim of this chapter is not describing the clinics, diagnosis and treatment of acute 
pancreatitis, it is done by the authors of other chapters. But to understand the relation 
between IAH / ACS and pancreatitis I would like to shortly summarise the leading findings 
in the clinical picture:  
The main symptom is the abdominal pain that usually starts in the gastric region but rapidly 
spreads to the complete abdomen. Often accompained with nausea, vomiting and paralytic 
ileus. Treating with minor analgesics often fails. In serious cases signs of shock like 
hypotension, tachycardia and cold sweat can be present. The paralytic ileus starts from the 
duodenum and jejunum and expand to the colon due to intensive fat necrosis and venous 
bowel congestion. Liberation of active pancreatic enzymes causes alterations in liver, 
kidneys and lungs and as the consequence of shock we face with acute renal failure.  
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A serious complication of pancreatitis is acute lung failure. The frequency depends on the 
severity of the basic disease.  
Patients with imminent and manifest severe cases must be under continuous observation in 
the intensive care unit. The circulatory parameters, blood pressure and pulse rate, palpation 
and auscultation of the abdomen, supervision of fluid intake and output, central venous 
pressure and laboratory values of haemoglobin and haematocrit, the number of leucocytes, 
amylase levels in the serum and urine and/or lipase in the serum, serum calcium, blood 
glucose daily profile, serum potassium, urea, creatinine in the serum, arterial pO2 pressure, 
acid-base-balance and sonography of the upper abdomen, the latter in 1-3 day intervals, are 
especially suitable for patient monitoring. 
Although the acute necrotizing inflammation (except biliary causes) can be controlled by 
conservative treatments in most cases, surgical intervention often becomes necessary under 
emergency conditions. 
The indication for early surgery applies upon failure of conservative treatment: the leading 
clinical symptoms during therapy inferred are: peritonitis, ileus, septic shock, MOF, 
incontrolable pain.  
Due to an increase in the intra-abdominal volume the diaphragm is pushed upward. 
Compression of the thoracic space results in a restrictive ventilatory disorder. (And we are 
facing with Abdominal Compartment Syndrome!!!) 
As the transverse colon is particulary affected and toxins from the large bowel can have 
adverse affects on the course of the disease.  
In these cases of the ACS urgent laparostomy is recommended. The laparotomy remains 
wide open and is only covered by a foil (Bogota Bag or VAC-Pac). This allows repeated 
peritoneal lavage and necrosectomy too. The prolonged inflammatory process in the 
abdomen and the risk of recurrent ACS favors the use of gradual closure or delayed 
reconstruction of the abdominal wall. The early recognition of the syndrome and the wide 
decompression are crucial factors of the treatment of this very serious clinical enthity (52). 
Although the above mentioned clinical findings of the severe acute pancreatitis are almost 
the same as we can see in patients suffering from ACS but do not confuse ACS with acute 
pancreatitis while it is only one of the possible causes of this serious symptoms. The two 
entities are very similar, this is the cause why the ACS is often late diagnosed and untreated 
which leads to early organ failure.  
The current estimate of the prevalence of IAH in severe acute pancreatitis is about 40%, with 
about 10% overall progressing to ACS associated with increased hospital mortality rates. In 
the majority of cases, the development of IAH is rapid. The agressive fluid resuscitation and 
the inflammatory process in the retroperitoneum leading to the development of visceral 
edema and pancreatic ascites within days or even hours from admission.  
The agressive fluid resuscitation is a „doble-edged weapon” : without strict control can 
induce the progress to ACS itself but it is proved that in the early phase the correct fluid 
therapy combined with prophylactic antibiotic treatment, surgical intervention, monitoring 
and management of organ dysfunctions, enteral nutrition and early endoscopic 
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spincterotomy in patients with common bile duct gallstone-induced pancreatitis have 
improved survival. 
Loosing patients in the early phase is frequently due to not recognised and not treated ACS.  
The presence of IAH can also be used as a predictor of the severity of acute pancreatitis, 
because by some clinical trials there is correlation with the increased IAP and severity of 
pancreatitis, mortality, peripancreatic infection rate, and need for surgical intervention (53). 
The true prevalence of IAH in patients with severe acute pancreatitis is not known. We can 
find numerous studies in the bibliography of the prevalence of IAH among the patients 
treated by severe acute pancreatitis. De Waele and his team described in their study that 
44% of the 41 study patients had IAP levels higher than 12 mmHg, and 4 patients (10%) had 
IAP levels higher than 25 mmHg with severe organ disfunction and undergoing surgical 
decompression (54). Keskinen treated 37 patients in the ICU for acute pancreatitis and 27% 
of the patients (n=10) had IAP levels higher than 25 mmHg (55). In a study of 297 patients 
from China presented that the overall incidence of IAH was 36% (56). 
Severe acute pancreatitis is one of the most common diseases associated with IAH in the 
ICU environment. 
Thus, it can be estimated that the overall prevalence of IAH in patients with severe acute 
pancreatitis is about 40%, and the frequency of ACS requiring surgical decompression is 
about 10% (53-56). 
In a study comparing patients with or without ACS (IAP > 25 mmHg) treated in the ICU for 
severe acute pancreatitis the hospital mortality rate for patients with ACS was 50% 
compared with 15% in patients without ACS (55). 
The following case reports from patientes treated in our department are to point out the 
importance of measurement of IAP: 
First patient:  
33-year-old man was taken to ICU with signs of acute pancreatitis after alcoholic abuse. 
Conservative treatment was started but on the second day the conditions of the man were 
getting worse. IAP measurement was started and we found IAP = 12 mmHg which rised to 
26 mmHg during the next 3 days and developed MOF. During the intervention we found 
the tipical clinical picture of acute necrotizing pancreatitis with retroperitoneal necrosis. 
Although the decompression with Bogota Bag insertion was performed we lost the patient 2 
days later. Concluding this case it is very important to pay attention to the early signs of IAP 
/ ACS and the timing of the decompression.  
Second patient:  
37-year-old woman was taken to our hospital after alimentary abuse and with consequent 
abdominal pain. Examinations proved acute pancreatitis. Despite the appropriate 
conservative therapy her condition worsened, IAP reached 20 mmHg, respiratory distress 
and oliguria developed. 
Laparotomy, lavage, drainage was performed. To prevent abdominal distension the 
abdomen was left open and organs were covered with a sterile urinary drainage bag (Bogota 
Bag). In the ICU 12 operations were performed during 108 nursing days. The IAP was 
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monitored permanently and when it reached the critical value necrectomy and lavage was 
performed. On the 116th nursing day she was sent home without complaints. 
Her abdomen was covered with epithelized omentum which wiIl be solved by a further 
operation (1-2). 
9. Discussion 
IAH and ACS are one of the major causes of organ failure and increased mortality (ACS 
with extremely high 38-71% mortality) among a wide variety of patient populations.  
The pathophysiology of IAH and ACS is based on the chain reaction of physiological 
processes generated by the increased abdominal pressure which affects almost every organ 
and it could be fatal without correct diagnosis and treatment. It was originally noticed in 
traumatological cases (gunshot and stab wounds, intra-abdominal haemorrhage) when the 
extreme abdominal distension was related with a rapidly worsening condition and ended in 
ARDS, MOF and toxic shock. The same process is taking place in general surgical patients in 
spite of the different etiology. The leading etiological factor among general surgical critically 
ill patients is the acute pancreatitis. The cause of this phenomenon is the extremely 
increased IAP. The diagnosis was supported by the improved methods of monitoring IAP 
because the physical examination of the abdomen is far from accurate with a sensitivity of 
only 40%. The gold standard of the IAP monitoring is the CIAPM ensures diagnosis of ACS 
and the appropriate indication of the operation. The treatment consists of adequate fluid 
resuscitation and surgical decompression. 
Intra-abdominal hypertension and abdominal compartment syndrome are frequent clinical 
findings among acute general surgical patients. Patients with comparable demographics and 
acute severity of illness are more likely to die if intra-abdominal hypertension or abdominal 
compartment syndrome is present. We conclude that the early recognition and surgical 
decompression is urgent. 
„We must study and learn from the past and, at the same time, proactively „invent” the 
future. The future of IAH and ACS is in our hands. It is time to pay attention.” (Cheatham, 
Ivatury, Malbrain, Sugrue) (53) 
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1. Introduction 
Acute pancreatitis is inflammation of the pancreas that occurs suddenly and usually 
resolves in a few days with treatment. Acute pancreatitis can be a life-threatening illness 
with severe complications. The most common cause of acute pancreatitis is the presence of 
small gallstones that cause inflammation of the pancreas as they pass through the common 
bile duct. Chronic heavy alcohol use is also a common cause. Acute pancreatitis can occur 
within hours or as long as 2 days after consuming alcohol. Other causes of acute pancreatitis 
include abdominal trauma, medications, infections, tumors, and genetic abnormalities of the 
pancreas. 
Pancreatic trauma is uncommon, accounting for only 0.2-6% of all injuries resulting from 
abdominal trauma, and is associated with a high mortality rate of 13.8-31% (Leppäniemi et 
al., 1988). The high mortality rate is due to the frequent occurrence of associated abdominal 
injuries. In addition, blunt abdominal trauma is considered to be the cause of one fifth of all 
cases of traumatic pancreatitis and it may result in contusion, parenchymal fracture, or 
ductal disruption (Portis et al., 1994). These injuries to the pancreas are typically caused by 
compression of the organ against the vertebral column, mostly in traffic related-accidents. 
Blunt trauma to the epigastrium is caused by steering wheels, handlebars, seatbelts, or 
directly. Other mechanisms of injury include sporting accidents, such as direct hits from a 
ball or a blunt blow. 
Therapeutic decisions for pancreatic trauma are based on the injury site and status of the 
pancreatic ductal system. When pancreatic ductal disruption exists or when duodenal injury 
cannot be ruled out, surgical exploration is usually required; however, surgery carries 
considerable morbidity and mortality risks. In this chapter, we discuss the management of 
pancreatic trauma and acute pancreatitis, including therapeutic endoscopy and surgical 
exploration.  
2. Amatomy and physiology 
The pancreas grows rapidly during a child’s first five years of life with a slower growth rate 
up to the age of 18 years of age (Spiegel et al., 1997). It is a large complex gland that lies 
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outside the walls of the alimentary tract parallel to the stomach at the level of the first and 
second lumbar vertebrae. It is surrounded anteriorly by the upper abdominal 
intraperitoneal organs and posteriorly by the thick paraspinal muscles. The lobules of the 
pancreas drain into the main pancreatic duct of Wirsungs which traverses the length of the 
gland and joins the common bile duct, emptying into the duodenum through the ampulla of 
Vater. The minor duct of Santorini usually branches off from the main pancreatic duct and 
also empties into the duodenum. The gland is not encapsulated; therefore, tears in 
pancreatic tissues permit pancreatic digestive enzymes to invade the peripancreatic tissue 
and leak into the peritoneal cavity.  
3. Pathogenesis 
The mechanism of blunt pancreatic trauma usually involves anterior compressive forces 
applied to the pancreas, which lies over the vertebral column. The pancreas is relatively 
fixed so that during blunt impact, the pancreas is not displaced and absorbs the full amount 
of force applied (Rawls, 2001).  
4. Classification 
Classically, according to Lucas’s classification of pancreatic injury, injuries without MPD 
disruption are designated Class I, while Class II or III injuries involve MPD disruption 
(Lucas, 1977). The Organ Injury Scaling Committee of the American Association for the 
Surgery of Trauma has proposed a pancreatic organ injury scale that is widely used and is 
based on the extent of parenchymal damage as well as the presence or absence of pancreatic 
duct injury (Moore et al., 1990). Minor contusions or superficial lacerations of the pancreas 
without duct involvement are classified as grade I injury. Grade II injuries are major 
contusions or lacerations without duct disruption. Distal transection of the pancreas or 
major parenchymal injuries with duct injuries is described as grade III. Grade IV injuries are 
proximal transections or any proximal parenchymal injuries involving the ampulla. Grade V 
injuries describe massive destructions of the pancreas head (Table 1).  
 
Table 1. Pancreatic injury severity scale (Moore et al., 1990) 
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5. Diagnosis 
5.1 Laboratory data 
It is generally reported that laboratory findings are relatively insensitive and non-specific in 
diagnosing pancreatic injury (Arkovitz et al., 1997; Bradley et al., 1998; Jobst et al., 1999). 
Serum amylase evaluation can suggest pancreatic injury; however, amylase levels have 
failed to predict or correlate with the degree of injury or disclose potential ductal disruption, 
especially when obtained in the early post-trauma period (Simon et al., 1994).  
Serum lipase is often based clinically in the setting of acute pancreatitis, but after blunt 
trauma, elevated serum lipase levels may be nonspecific and a poor indication of injury 
(Buechter et al., 1990). Because of their low sensitivity and specificity for pancreatic trauma, 
serum amylase and lipase have limited diagnostic value, but elevated levels may provide a 
clue to a severe injury requiring further investigation. 
5.2 Ultrasound 
An ultrasound examination will usually be performed to enable the diagnosis of free 
abdominal fluid or gross damage to the liver or spleen. The pancreas is not easily identified 
and examined to its full extent; therefore, pancreatic injuries, parenchymal or ductal, will 
frequently be missed. However, routine abdominal ultrasound examination in the 
emergency room will establish the diagnosis of an intra-abdominal injury and therefore 
establish the need for an urgent explorative laparotomy. To disclose main pancreatic duct 
injury in blunt and penetration pancreatic trauma, intraoperative ultrasonography has 
proven to be helpful (Hikida et al., 2004). 
5.3 Computed tomography 
When initially evaluating for injury, CT scanning is a simple, noninvasive means of 
evaluating the pancreas. New-generation helical CT scanners quickly enable an overview of 
abdominal injuries in severely traumatic patients. CT was reported to have 90% sensitivity 
in detecting pancreatic disruption (Teh et al., 2007). Furthermore, CT allows additional 
assessment of the severity and extent of pancreatic tissue damage and concomitant injuries 
(Bigattini et al. 1999).  
5.4 Magnetic resonance cholangiopancreatography  
Magnetic resonance cholangiopancreatography (MRCP) is another non-invasive diagnostic 
tool that allows the evaluation of pancreatic injuries with high sensitivity and specificity. 
Particularly in stable patients with suspected pancreatic injury, MRCP enables the non-
invasive detection or exclusion of pancreatic duct trauma and pancreatic specific 
complications. It may therefore provide information that can be used to guide management 
decisions in the further course of pancreatic trauma patients; however, its purely diagnostic 
nature and its inability to provide real-time visualization of ductal findings and 
extravasation are two of its disadvantages (Fulcher et al., 2000). Recently, secretin-
stimulated MRCP was also reported to be a safe, non-invasive test that can provide 
additional useful information about duct integrity and facilitate management (Gillams AR et 
al., 2006). 
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5.5 Endoscopic retrograde cholangiopancreatography 
Endoscopic retrograde cholangiopancreatography (ERCP) was documented to be a useful 
diagnostic tool, displaying sensitivity and specificity of 100% for pancreatic duct injury 
(Gougeon et al., 1976; Doctor et al., 1995). ERCP was also reported to be the definitive test 
for pancreatic duct injury, particularly, to demonstrate clearly the site of duct disruption and 
the grade of duct injury, whether the branch or main duct and partial or complete 
disruption of the main pancreatic duct MPD (Kim et al., 2001). 
Recently, ERCP has been shown not only to provide sufficient information for conclusive 
diagnosis but also to be an effective and safe non-operative treatment tool (Bendahan et al., 
1995; Huckfeldt et al., 1996; Kim et al., 2001; Cay et al., 2005; Houben et al., 2007). In certain 
cases of leakages of the pancreatic duct, transpapillary stent insertion might seal the injury 
and stabilize it in a way that eventually leads to resolution of the leakage  
6. Therapy 
Isolated pancreatic trauma is rare and usually results from direct trauma to the epigastrium, 
for example from the handle bars in bicycle accidents or in sports, typically in children or 
adolescents. Most patients with pancreatic lesions will present with multiple injuries, some of 
them hemodynamically unstable, and concomitant abdominal injuries; therefore, unstable 
patients may require initial damage control and correct assessment of the extent of pancreatic 
injury. On the other hand, in stable patients, ERCP plays an important role in the diagnosis, 
but also in the treatment of pancreatic duct injuries. Reports on the transpapillary stenting of 
duct lesions are very encouraging and justify the extensive use of ERCP (Canty et al., 2001).  
6.1 Case of endoscopic treatment  
A 17-year-old man was brought to the emergency department of our hospital with severe 
upper abdominal pain following a blow received in a rugby game. Emergency computed 
tomography (CT) revealed severe pancreatic neck injury. Forty-eight hours later, follow-up 
enhanced CT revealed that the pancreas was clearly lacerated and that the amount of peri- 
 
Fig. 1. Enhanced CT revealed an obvious laceration of the pancreas neck. (white arrow)  
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pancreatic fluid was increasing (Fig. 1); furthermore, serum amylase and elastase levels 
were elevated. ERP (endoscopic retrograde pancreatography) revealed that contrast 
medium in the main pancreatic duct (MPD) had leaked into the parenchyma, indicating 
MPD injury (Fig. 2). To prevent the traumatic pancreatitis from worsening, a stent was 
inserted endoscopically at a site distal to the injured portion of the MPD (Fig. 3). Thereafter, 
the patient’s complaint was markedly reduced, and his serum amylase levels returned to 
normal. In addition, the apparent pancreatic edema and peripheral fluid were decreased on 
CT (Okamoto et al., 2010).  
 
Fig. 2. Endoscopic pancreatography (ERP) revealed leakage of contrast medium.(white 
arrow)  
 
 
Fig. 3. Enhanced CT revealed the inserted pancreatic stent and disappearance of pancreas 
peripheral fluid.（white arrow)  
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6.2 Endoscopic pancreatic duct stent treatment  
Endoscopic transpapillary stent insertion by literature review is summarized in Table 2.  
 
n.d.: not determined, h: hour, d: day, m: month, L: lipase 
Table 2. Summary of reported pancreatic duct stent treatment cases 
This summary indicates that endoscopic transpapillary stent insertion is an effective 
technique for managing certain pancreatic traumatic injuries. A significant improvement in 
outcome was found for patients with stent therapy. Pancreatic stents are known to be 
associated with minor damage to the duct including ductal irregularity, stenosis, and side 
branch ectasia (Kozarek et al., 1991). These changes can occur even if the stent is patent, and 
they can persist or resolve after stent removal (Huckfeldt et al., 1996). A long-term study of 
a small group showed that 4 of 6 cases were complicated by ductal stricture, although stent 
therapy could avoid surgery in the acute trauma stage (Lin et al., 2006). Endo- and exocrine 
function were not examined. Further accumulated experiences are needed to clarify the 
significance of stent therapy.   
6.2.1 Case of surgical treatment 
A 34-year-old man was transferred to our hospital 18 hours after blunt abdominal trauma 
caused by impact against an automobile steering wheel. Emergent CT showed laceration of 
the pancreatic head and surrounding hematoma. Emergent laparotomy was carried out. 
Intraoperative pancreatography revealed injury of the proximal main pancreatic duct. 
Age Gender Trauma Initial S-Amy（IU/L CT findings Time to ERCP ERCP findings Disrupted portion Outcome References
1 22 M Stabbed injury n.d. (Emergent operation) 3d Duct disruption Proximal Recoverd Bendahan J., et al., 1995
2 27 F Car accident 127 Irregular order of the pancreas tail 3-4hr Extravasation of the contrast from MPD Neck (isthmus) Recovered Huckfeldt R, et al. 1996 
3 9 F Bike fall 436 Partial disruption of pancreatic parenchyma 1d Extravasation of the contrast from MPD Body Recovered Cantly T.G., et al., 2001
4 8 M Traffic accident 126 Disruption of the distal pancreas 1d Extravasation of the contrast from MPD Tail Recovered, mild MPD stricture Cantly T.G., et al., 2001
5 46 M n.d. 234 Head swelling 1d Extravasation from tail of MPD Head Recovered Kim HS, et al., 20001
6 35 M n.d. 390 Pancreas fracture 4d Intracapsular leakage from MPD n.d. Recovered, pseudocyst Kim HS, et al., 20001
7 40 F n.d. 742 Body swelling １d Intracapsular leakage from MPD Body Recovered, pseudocyst Kim HS, et al., 20001
8 60 M Car accident 536 Pancreas disruption and pseudocyst 5d Extravasation of the contrast from MPD Proximal Recovered Hashimoto A., et al., 2003
9 37 F Steering wheel 2467 Hematoma over pancreatic head 22d Stricture at the head with contrast extravasation Head Recovered, stent migration Lin B.C., et al.,2006
10 35 M Steering wheel 435 n.d. 19d Stricture at the head with contrast extravasation Head Recovered, MPD stricture Lin B.C., et al.,2006
11 36 M Steering wheel 417 Pancreatic neck laceration 8d Contrast extravasation at the body and tail Body Recovered, MPD stricture Lin B.C., et al.,2006
12 61 F Steering wheel 2270 Pancreatic body laceration 1d Contrast extravasation at the body with retroperiton Body Sepsis, Death Lin B.C., et al.,2006
13 18 M Steering wheel 366 Pancreatic body laceration 8h Contrast extravasation at the body Body Recovered, MPD stricture Lin B.C., et al.,2006
14 28 M Steering wheel 231 Pancreatic head laceration 16h Contrast extravasation at the head Head Recovered, mild MPD stricture Lin B.C., et al.,2006
15 8 M Handlebar n.d. n.d. 28d Incomplete disruption Body Recovered Houben C.H., et al., 2007
16 11 M Hit lamppost n.d. n.d. 4d Transection of MPD Neck Recovered Houben C.H., et al., 2007
17 10 F Handlebar n.d. n.d. 2d Incomplete disruption Body Recovered Houben C.H., et al., 2007
18 11 M Handlebar n.d. n.d. 2d Transection of MPD Neck Recovered Houben C.H., et al., 2007
19 11 F Fall from seesaw n.d. n.d. 2d Transection of MPD Body Recovered Houben C.H., et al., 2007
20 7 M Handlebar n.d. n.d. 9d Transection of MPD Neck Recovered Houben C.H., et al., 2007
21 10 M Handlebar n.d. n.d. 7d Transection of MPD Neck Recovered Houben C.H., et al., 2007
22 12 M Trivial fall n.d. n.d. 3d Transection of MPD Neck Recovered Houben C.H., et al., 2007
23 9 M Trivial fall n.d. n.d. 4d Transection of MPD Neck Recevered Houben C.H., et al., 2007
24 28 M Gun shot 406 Pancreatic injuruy involving the head, neck 1m Leakage of the contrast Head Recovered Rastogi M, et al., 2009
25 31 F Bicycle accident 406 Pancreatic edema 0d Disrupted unicinate branch Unicinate process Recovered Rogers S.J., et al., 2009
26 49 M Car accident L 7121 Pancreatic edema 0d Disrupted MPD Body Recovered Rogers S.J., et al., 2009
27 41 F Car accident L 480 Pancreatc edema 15d Disrupted unicinate branch Unicinate process Recovered Rogers S.J., et al., 2009
28 41 F Car accident 235 Distal pancreatic tear 10d Disrupted unicinate branch Unicinate process Recovered Rogers S.J., et al., 2009
29 18 F Skiing fall L 844 Peripancreatic edema, possible laceration 2d Transection of MPD Tail Recovered Rogers S.J., et al., 2009
30 54 M Gun shot L 583 IVC laceration, retroperitoneal fluid 1d Extravasation MPD Head Recovered Rogers S.J., et al., 2009
31 17 M Sport 437 Pancreas disruption and pseudocyst 2d Leakage from MPD Neck Recovered Okamoto H., et al., 2010
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Because stenosis of the main pancreatic duct was predicted as a complication, 
cholecystectomy, external drainage of the common bile duct, and external abdominal 
drainage were carried out. He was discharged with a pancreatic fistula 4 months 
postoperatively. Three months later, pancreatic juice output through the drainage tube 
decreased, and patient developed acute pancreatitis. CT revealed dilatation of the main 
pancreatic duct and atrophy of the pancreas distal to the site of injury (Fig. 4). A second 
operation was planed to perform to preserve pancreatic function after the patient's general 
condition improved. ERP demonstrated ductal stricture of the main pancreatic duct in the 
head of the pancreas and upstream dilatation of the pancreatic duct. A diagnosis of chronic 
obstructive pancreatitis was made, and in order to preserve the function of the distal 
pancreas, longitudinal pancreatojejunostomy with Roux-en-Y anastomosis was performed 
10 months after the initial operation. After the second operation, the patient's pancreatic 
function and pancreatic atrophy improved (Matsuda et al., 1999). 
 
Fig. 4. Enhanced CT revealed a laceration of pancreatic head (left, white arrow) and a 
hematoma near pancreas head (right, white arrow).  
6.2.2 Surgical treatment 
Isolated pancreatic injuries are rare and most patients will present with multiple injuries, 
some of them hemodynamically unstable, and concomitant abdominal injuries; therefore, 
unstable patients may require initial damage control and correct assessment of the extent of 
pancreatic injury. This usually allows delayed definitive treatment of complex injuries, 
especially of the head of the pancreas. With regard to treatment, external drainage alone has 
been proposed for grade I and II injuries, while surgical intervention, including distal 
pancreatectomy or pancreaticojejunostomy, is usually performed for grade III, IV, and V 
injuries. 
6.3 Nonoperative management 
Conservative management of pancreatic trauma in the absence of a ductal injury (grade I 
and II) is widely accepted and practiced as the majority are contusions that usually resolve 
spontaneously after conservative treatment (Rescorla et al., 1995; Keller et al., 1997; Meier et 
al., 2001; Canty et al., 2001). Nonoperative management of a pancreatic injury consists of 
bowel arrest, total parental nutrition, and serial imaging with either CT scans or ultrasound 
to follow injury resolution.  
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Octreotide, a synthetic somatostatin analogue that inhibits pancreatic secretions has been 
shown in adults to reduce the incidence of postsurgical pancreatitis after pancreatic surgery. 
The benefits of octreotide in pancreatic trauma are controversial, and in particular its role in 
pediatric trauma is still undefined (Amirara et al., 1994; Nwariaku et al., 1995; Mulligan et 
al., 1995; Cavallini et al., 2001), however, there are few reported cases of octreotide 
administration being effective for traumatic pancreatic injury (Morali et al.,1991; Shan et al., 
2002). Further accumulated evidence is required to prove this effect. 
7. Treatment algorithm 
We proposed an early treatment algorithm for endoscopic and surgical therapy, based on 
the presence or absence of a major pancreatic duct lesion. 
 
 
Fig. 4. Proposed early treatment algorithm for endoscopic and/or surgical therapy.  
 
Traumatic Pancreatitis - Endoscopic and Surgical Management 189 
7.1 Proximal duct injury 
Incomplete disruption of the MPD or complete disruption of the MPD without duct 
obstruction is the best candidate for the pancreatic duct stent therapy. Transductal 
pancreatic stent allows internal drainage of the pancreatic secretion and re-establishment of 
duct continuity (Bendahan et al., 1995; Huckfeldt et al., 1996; Cantly et al., 2001; Kim et al., 
2001; Lin et al., 2006; Houben et al., 2007; Rogers et al., 2009). 
Complete disruption of the MPD with duct obstruction increases the difficulty of stent 
placement beyond the fracture site. Disruption or complex injuries of the pancreatic head 
involving the ampulla, or devitalizing injuries of the pancreas head and duodenum usually 
are non-reconstructable injuries. In stable patients, pancreaticoduodenectomy is the best 
definite treatment for grade IV injuries. In unstable patients, exploration and placing of 
external drainage may be the best choice for damage control. Definitive treatment of the 
lesion can be achieved later, after the patient has been stabilized.  
7.2 Distal duct injury 
Distal pancreatic injury with duct involvement include major or stab wounds in the body or 
tail of the pancreas with an obvious duct injury or transection of more than half the width of 
the pancreas. If the clinical condition of the patient allows it, these grade III injuries are best 
treated by distal pancreatectomy even in emergency situations. In some cases, such as 
complete transection of the pancreatic body from the head, a distal pancreaticojejunostomy 
and closure of the proximal end of the pancreas rupture as in the Letton & Wilson 
procedure, may even become necessary if an organ-preserving approach is attempted 
(Letton et al., 1959). It has been documented that 19 patients were treated by distal 
pancreatectomy with splenectomy, 8 by pancreatectomy with preserving the spleen, and 2 
by placing a pancreatic duct stent in a series of 32 grade III patients (Lin et al., 2004). Major 
distal duct injuries have been managed mainly by surgical exploration.  
8. Complications and outcome 
The complication rate of any pancreatic injury is not only associated with concomitant 
injuries, but also with the severity of the pancreatic injury. As is widely accepted, the grade 
of pancreatic injury is an independent predictor of both pancreas-associated morbidity and 
mortality. Complications following pancreatic trauma include fistula, pancreatic abscess, 
pseudocyst formation, and sepsis. The American Association for the Surgery Trauma Organ 
Injury Score has been shown to predict the development of complications and mortality 
after pancreatic injury (Kao et al., 2003). 
Pancreatic abscesses have been treated interventionally by percutaneous drainage, but are 
frequently infected by multiple resistant bacteria, leading to sepsis. The treatment of 
pancreatic pseudocysts is interventional drainage and sealing, endoscopic gastrocystostomy, 
and operative enteric drainage. 
9. Conclusion 
Endoscopic transpapillary pancreatic duct stent is effective and safe management for 
pancreatic duct disruption, especially for proximal duct injury in selected patients. It may 
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avoid emergent surgery in the acute trauma stage; however, long-term ductal stricture 
should be carefully investigated during long-term follow-up. 
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1. Introduction 
Pancreatic ascites or internal pancreatic fistulae and pancreatic pleural effusion are rare 
complications of pancreatitis. This can occur in the clinical setting of an acute pancreatitis 
and more commonly as a complication of chronic pancreatitis1. This is an uncommon 
clinical condition; often the patients are sick and nutritionally compromised. Pancreatic 
ascites was first reported in the literature in 1953 when Smith described two cases of ascites 
associated with chronic pancreatitis2.  
2. Definition  
Exact definition to diagnose this condition is not clear in the literature. Pancreatic ascites 
/pleural effusion is characterised by accumulation of high amylase fluid in the peritoneal 
cavity/pleural cavity due to leakage of pancreatic juice from a disrupted pancreatic duct 
and a diagnosis is usually made once the aspirated fluid is high in protein (>3g/dl) and high 
in amylase (>1000 IU/L)3.   
3. Aetiology and pathogenesis  
Pancreatic ascites/pleural effusion can occur due to a) rupture of a pseudocyst into 
peritoneal cavity or to mediastinum and pleura or b) due to the disruption of a main 
pancreatic duct during the natural course of chronic pancreatitis3. Pancreatic leak occurs in 
3.5% of patients with chronic pancreatitis and 6% to 14% of patients with pancreatic 
pseudocyst 4, 5. The pathogenesis of the serous cavity effusion is different in acute and 
chronic pancreatitis setting. In acute pancreatitis, mostly in alcoholic pancreatitis, there is 
enough inflammatory reaction around the pancreas with neighbouring structures like 
stomach and transverse colon to form a pseudocyst. This can rupture into peritoneal cavity 
or mediastinum and to pleural cavity subsequently to produce ascites or pleural effusion 
respectively. Similar type of duct disruptions may also occur in acute setting in blunt 
abdominal trauma, biliary pancreatitis, and rupture of duplication cyst and rarely after 
pancreatic surgery or splenectomy1, 6.  
In the setting of chronic pancreatitis, leakage is seen in up to 80% of cases from a 
communicating pseudocyst due to ductal stricture and less commonly (20%) due to duct 
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disruption itself3, 7. This has also been described in the setting of tropical calcific pancreatitis 
as well from duct disruptions and leaking pseudocyst8. Once the amylase rich fluid enters 
serous cavity, since the enzymes are not activated it does not produce digestion, instead it 
produces irritation resulting in outpouring of albumin resulting in high-albumin ascites. 
This accumulation of amylase rich fluid is usually massive before it produces symptoms due 
to its pressure effects. The amylase in the fluid can get reabsorbed into the blood stream and 
produce elevation of serum amylase as well. It has been also reported in one series that 
pancreatic ascites or effusions may present with indolent symptoms and up to 42% of 
patients gave no history of pancreatic disease9. 
4. Diagnosis and evaluation  
Aim of the investigations in patients with pancreatic ascites are a). Overall assessment of 
patient’s general and nutritional status and b). To delineate the pancreatic ductal anatomy 
and to locate the possible site of leak. These patients should have a haemogram, serum 
protein, and albumin and amylase value and coagulation profile. Upper GI endoscopy to 
rule out peptic ulcer or periampullary malignant disease and ultrasonography should be 
done. The diagnosis is usually confirmed with ascitic fluid assay. Usually the ascitic/pleural 
fluid contains high protein >3g/dl and high amylase >1000 IU/ml. Ascitic fluid assay 
should also be done to rule out other differential diagnosis like cirrhosis of liver or 
disseminated malignancy.  
The localization of site of rupture or leak of main pancreatic duct is essential for planning 
therapy. Earlier, intraoperative pancreatography was the mainstay of localisation which is 
superseded largely by Endoscopic Retrograde Pancreatography (ERP) in recent years. 
However, these procedures are invasive and correct delineation of the duct anatomy and 
leak may not be feasible in all cases due to strictures or due to technical reasons. 
Demonstration of pancreatic duct leak by non invasive methods offer advantages like 
avoiding a sedation or anaesthesia, avoiding risk of introducing infection during injection 
of dye to the pancreatic duct. Non invasive investigations like CT scan helps in 
indentifying peripancreatic collections and details of the parenchyma of the pancreas. The 
details of pancreatic parenchyma, duct size, stones, strictures and psuedocysts are well 
displayed in a CT scan. The identification of site of leak from the pancreatic duct is 
possible in nearly half of the patients10. Magnetic Resonance Imaging (MRI) has also been 
reported to give good details of pancreatic parenchyma, details of the duct and details of 
the fistula11, 12. In MRP, high signal intensity of static or slowly flowing liquids is observed 
in T2 weighted images. Hence the pancreatic duct and the fistulous tract is displayed as 
high-signal intensity structure which helps in identifying the communication like 
pancreaticopleural fistula. The details of the pancreatic parenchyma and duct structural 
changes are also well displayed in MRI. Moreover, in MRI no contrast material is injected 
and there is no risk of infection in comparison with ERP. In a recent study13, the ability of 
helical CT scan and Magnetic Resonance Pancreatography (MRP) when performed alone 
in identifying the site of duct disruption were 50 and 67% respectively. When these two 
modalities were combined the exact site of rupture of duct was observed in 94% of cases. 
Hence, a combination of imaging modalities helps to improve the details of the duct 
disruption,the site of leak and the details of the pancreatic parenchyma which is essential 
in planning of therapy.  
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5. Management 
Management of these patients are challenging due to the compromised nutritional state, 
generalized weakness, diabetes mellitus and disease related factors like multiple strictures, 
large stones and inflammatory mass. All patients with a diagnosis of pancreatic ascites or 
pleural effusion should be assessed for their nutritional status. This is important as the 
morbidity and mortality of the various modes of treatment is related to the patient’s general 
condition. These patients may be managed by conservative approach, endoscopic therapy 
and by surgical therapy. This may be done in using an algorithm depending upon patient’s 
clinical condition8. (Table 1)  
Algorithmic approach to the management of Pancreatic ascites
Pancreatic Ascites
Assessment
CT scan ± MRI
ERCP
Control of ascites, pain
Poor nutrition
Nasojejunal feeds
Aspiration, Octreotide
Follow up
Failed 
Cannulation / stenting
Persistent
ascites, pain
Surgery
Pancreatic stenting
 
Table 1. Algorithmic approach to the management of pancreatic ascites. 
6. Conservative treatment 
Initial trial of conservative treatment is indicated in almost all patients. It was generally 
believed that there is high risk for mortality while the patients are on conservative therapy, 
which is due to poor nutritional management and assessment in the initial reports. Though 
an old series14 had reported high mortality with conservative therapy, the progress of the 
patient can be safely monitored on conservative therapy in current daily practice. The key 
steps in the conservative management of the pancreatic ascites or pleural effusion are a). 
Rest to the pancreas and to limit pancreatic exocrine stimulation by keeping the patients nil 
orally, b). Nutritional support by means of nasojejunal feeds or by Total Parenteral Nutrition 
(TPN), c). Use of drugs likes to decrease pancreatic secretion d). Drainage of fluid by 
aspiration, drainage of ascites or by tube thoracocentesis. So patients are kept nil per oral 
and nutritional support should be planned on case to case basis. There is no significant 
difference between enteral or parenteral feeds on pancreatic exocrine secretion clinically15. 
However, these patients are often nutritionally compromised and have nausea, anorexia and 
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poor tolerance to feeds due to exocrine insufficiency. Enteral nutritional support should be 
attempted whenever possible as it maintains mucosal integrity and prevents bacterial 
translocation. Nasojejunal feeds have a theoretic benefit as it prevents stimulation of 
pancreas and minimises fistula output. In patients who do not tolerate enteral feeds well or 
those with catabolic response TPN should be used either alone or along with enteral feeds.  
Serous cavities should be emptied to promote approximation of serosal surfaces by drainage 
of ascitic/pleural fluid. Repeated aspiration of ascites or drainage of the ascites with the 
tube near the pseudocyst helps to drain the fluid by a controlled fistula. Similarly, aspiration 
or tube drainage should be done according to be patient’s symptoms. Along with above 
measures, use of drugs with the aim to decrease the pancreatic exocrine secretion like 
somatostatin or octreotide also have a role in improving the pancreatic leak15-17. These drugs 
have been noted to decrease the fistula output (often within 24 hours of treatment) and 
accelerate the fistula closure. Depending upon the clinical situation a conservative therapy 
with above measures for 3-4 weeks helps in resolution of pancreatic leak in 25 – 60% of 
cases17,18. Patients with low sodium levels, albumin levels and those with a high fluid to 
serum protein levels had high chance for treatment failure18. Other agents attempted in 
closure of pancreatic leak are fibrin glue and nafamostat mesilate with variable results. 
Patients those who fails to respond to conservative measures or those patients who are 
symptomatic should undergo endotherapy or surgery.  
7. Endotherapy 
Endoscopic Retrograde Pancreatography (ERP) is the key step in planning of endoscopic 
treatment. ERP helps to delineate the anatomy of the duct, presence of strictures and site 
pancreatic leak (Figure 1). The principles of endotherapy include pancreatic sphincterotomy 
and placement of a transduodenal pancreatic stent across the site of ductal leak. This helps 
to obliterate the high-pressure gradient at the pancreatic sphincter, allowing preferential 
flow of pancreatic secretions along a low resistance path to the duodenum, thereby allowing 
the site of leak to heal. This has been reported in many series6, 8,13,19,20. It has been observed 
that a sphincterotomy and placement of stent close to the fistula, even if the stent could not 
be advance beyond the site of leak helps to heal the fistula or stabilizes patients clinical 
condition8. Other endoscopic approaches which are practised are endoscopic placement of 
nasopancreatic drainage21 and endosonography guided pancreatogastrostomy22. 
Nasopancreatic drainage alone has been used instead of placement of pancreatic duct 
stenting in treatment of pancreatic ascites22. The authors have reported nearly 90% of 
success in placement of nasopancreatic drain and disappearance of pseudocyst and ascites 
were observed on 4-6 weeks. Nasopancreatic drains allow repeated pancreatography to 
assess the progress of therapy and healing of the duct. This method provides the option of 
flushing of the drain to clear the blocks and allows removal of the drain once the duct 
disruption is healed. The disadvantages of this method are the discomfort to the patients 
due to the nasal tube and risk of accidental dislodgement.  
The success of endotherapy ranges from 50-90% depending upon the duct changes8, 19-21. 
Success of endoscopic treatment was based on three factors in this study a) ability to pass 
the stent across the site of disruption of the duct, b) absence of strictures and stones and c) 
ability to traverse the stricture. Those patients who had only partial relief of symptoms and 
those with failed endotherapy would require surgery.  
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Fig. 1. Endoscopic retrograde pancreatography showing leak of dye from tail duct. 
8. Surgery 
The surgical intervention is planned according to the ductal anatomy and site of leak (figure 
2). Aims of the surgery in patients with chronic pancreatitis with pancreatic ascites are to a) 
wide drainage of pancreatic duct, often with a Lateral Pancreatojejunostomy (LPJ) b) 
removal of pancreatic stones and ductal strictures and c) drainage of the cysts and external 
drainage of abscess. 
Patients with chronic pancreatitis with large duct (>7mm) should undergo wide drainage of 
pancreatic duct often with a lateral panctreatojejunostomy and removal of pancreatic stones 
and ductal strictures5, 7, 8. Specific repair of the site or disruption is often unnecessary; 
however the area of disruption should be included in the anastomosis. Similarly, a mature 
pseudocyst also can be incorporated in the anastomosis. In patients with normal sized duct, 
identification of the site of leak is very important. In those with distal leak, a distal 
pancreatectomy with or without splenectomy is a good option. Spleen preservation is often 
difficult in these patients due to dense adhesions and inflammatory process. If the 
inflammation and fibrosis is significant a medial to lateral approach in distal 
pancreatectomy may be used to avoid excessive bleeding.  
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Fig. 2.  Operative picture showing disruption of pancreatic duct in the body region with 
pancreatic stent in situ coming out through the site of disruption.  
In those with leak from the neck region Roux –en-Y anastomosis to the fistula site or 
pancreatogastrostomy has been described. In those patients with disconnected duct  
syndrome, often secondary to acute pancreatic necrosis, there is often a loss of tissue near 
the genu with fistula from either distal or proximal duct. A Roux-en-Y anastomosis to the 
distal duct and closure of the proximal duct or distal pancreatectomy with closure of 
proximal duct may be performed according to the clinical situation. In patients with long 
fistulous tract to skin, dissection of fistula and fistula-enterostomy has been reported with 
varying results23. Surgery for pancreatic ascites is often difficult due to the dense 
inflammatory process in the peripancreatic tissue, mesentery and due to the presence of 
pseudocysts and often identification of site of leak is difficult and cystojejunostomy to the 
leaking cyst is also an effective option24, 25. 
9. Conclusion 
Pancreatic ascites or pleural effusion are rare complications of acute or chronic pancreatitis 
wherein there is leakage of pancreatic juice to a serous cavity from a disrupted pancreatic 
duct or leaking pseudocyst. Preoperative workup should be aimed at the nutritional 
assessment of the patient and the pancreatic ductal imaging using CT scan or MRI. An 
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algorithmic approach may be adopted in managing this patients using conservative, 
endotherapy or surgical treatment according to the clinical scenario. A multidisciplinary 
approach of these modalities is essential for successful management of these patients. 
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1. Introduction  
Emphysematous (gas-forming) infections of the abdomen and pelvis 
Emphysematous (gas-forming) infections of the abdomen and pelvis represent potentially 
life-threatening conditions that require aggressive medical and often surgical 
management. The initial clinical manifestation of these entities may be insidious, but 
rapid progression to sepsis will occur in the absence of early therapeutic intervention. 
Conventional radiography and ultrasonography are often the initial imaging modalities 
used to evaluate patients with abdominopelvic complaints. However, when a differential 
diagnosis remains, or if further localization or confirmation of tentative findings is 
needed, computed tomography (CT) should be considered the imaging modality of 
choice. CT is both highly sensitive and specific in the detection of abnormal gas and well 
suited to reliable depiction of the anatomic location and extent of the gas. Of equal 
importance may be the capability of CT to help reliably identify benign sources of gas, 
because treatment (if any) varies dramatically depending on the source. Knowledge of the 
pathophysiologic characteristics, common predisposing conditions, and typical imaging 
features associated with gas-forming infections of the gall-bladder, stomach, pancreas, 
and genitourinary system will help make early diagnosis and successful treatment 
possible. In addition, such knowledge will aid in further diagnostic work-up, surveillance 
of potential complications, and evaluation of therapeutic response. The presence of gas 
within the parenchyma of solid organs or the walls of hollow viscera may be due to a 
variety of pathologic or benign entities. Besides infection with gas-forming bacteria, other 
possible sources include bland tissue infarction with necrosis, enteric fistula formation, 
and reflux from an adjacent hollow viscus. Gas should be differentiated from atmospheric 
air introduced at recent instrumentation or surgery. Gas associated with infection is 
generally thought to consist of carbon dioxide and nitrogen secondary to the fermentation 
of glucose by some species of bacteria. Poor glycolysis at the tissue level in diabetic 
patients results in increased glucose concentrations within the interstitial fluid. Other 
clinical factors that contribute to the increased production or slowed removal of gas 
include a depressed cell-mediated immune response, local tissue necrosis, and the 
presence of arteriosclerosis. The increased pH of bile associated with gallbladder 
inflammation and the focal tissue ischemia seen in gynecologic neoplasms are examples of 
specific underlying processes that help optimize bacterial culture media. In addition to 
broad-spectrum antimicrobial therapy and possible surgery, correction of associated 
underlying conditions such as urinary outflow obstruction, acid-base and electrolyte 
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imbalances, hypovolemia, and hyperglycemia is imperative. In the setting of gas-forming 
infections, clinical outcome will, in large part, depend on whether early diagnosis and 
treatment are achieved. The presence of comorbid conditions and equivocal physical 
examination findings may prevent rapid diagnosis or delay appropriate initial therapy. 
Consequently, appropriate radiologic imaging with prompt, accurate interpretation plays 
an important role in the diagnosis and management of these diseases. 
2. Main heading, emphysematous pancreatitis 
The most common causes of acute pancreatitis are the passage of gallstones and alcohol 
abuse. An overall mortality rate of 4% rapidly escalates to more than 50% when 
complications (eg, abscess formation, superinfection with gas-forming bacteria) occur. The 
infecting organisms are usually coliform bacteria and may reach the pancreatic bed by way 
of the bloodstream or lymphatic channels, a fistula from adjacent bowel, transmural passage 
from the transverse colon, or reflux of enteric organisms into the pancreatic duct or biliary 
tree via a patulous ampulla of Vater. Gas may be detected in up to 22% of pancreatic 
abscesses; however, its presence alone is not specific for the diagnosis of infection. Other 
sources of intraductal or parenchymal pancreatic gas include reflux from the duodenum 
following sphincterotomy, endoscopic instrumentation, enteric fistula (commonly involving 
the transverse colon), and end-organ infarction. Patients with emphysematous pancreatitis 
are usually debilitated and often have underlying immunocompromised conditions such as 
poorly controlled diabetes or chronic renal failure, atherosclerosis, tuberculosis, HIV 
infected individuals. 
2.1 Secondary heading 
Retrospective review of literature, and our one experience of treatment 8 patients with 
emphysematous pancreatitis in our department from 2003 to 2011. 
2.1.1 Tertiary heading, left justified 
Early radiographic detection of retroperitoneal gas is critical in the evaluation of 
superimposed emphysematous infection of the pancreas. Conventional abdominal 
radiography may demonstrate mottled gas overlying the midabdomen (Fig 1). 
This finding is not specific for pancreatitis because abscesses involving the lesser sac or 
perinephric space may also have this appearance. Diagnostic US is often of limited value in 
the evaluation of acute pancreatitis or its complications secondary to an adjacent air-filled 
small bowel loop from ileus. When identified, pancreatic gas will manifest as multiple 
irregular echogenic foci, often with posterior dirty acoustic shadowing. A significant volume 
of gas may limit the detection of adjacent fluid collections. CT is the modality of choice for 
detecting parenchymal gas as well as evaluating its extent and location (Fig 2, 3). 
Fluid collections or portal venous air are readily identified, and, although intravenously 
administered contrast material is not necessary for the visualization of air, it is useful for 
evaluating potential complications including parenchymal necrosis and abscess formation. 
The prognosis for emphysematous pancreatitis is grave, and successful treatment requires  
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Fig. 1. Emphysematous pancreatitis in a 66-year-old woman. Digital scout image from a CT 
scan demonstrates a mottled collection of gas bubbles in the midportion of the upper 
abdomen and extending into the left upper quadrant. 
 
Fig. 2. Emphysematous pancreatitis in a 66-year-old woman. Contrast-enhanced CT scans 
obtained at the same level as a show gas surrounding the body and tail of the pancreas 
(white arrows) and extending more cephalic within the anterior pararenal space. 
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Fig. 3. Contrast-enhanced CT scans in a 66-year-old woman with emphysematous 
pancreatitis. There are extensive inflammatory changes involving the surrounding fat (white 
arrows). 
aggressive management of the infection with systemic antimicrobial therapy and control of 
septic shock. Usually emphysematous pancreatitis occurs at the onset of the disease – first 
week of the illness, but some times it can manifest later on. There is at present a tendency to 
operate patients with infected necrosis as soon as the diagnosis is made, regardless of the 
clinical status. It is well known that pancreatic abscesses represent a distinct clinical entity 
and that they are treatable by nonoperative management, including percutaneous drainage. 
Similarly, selected patients with localized infected necrosis amenable to endoscopic, 
transgastric drainage can be managed with this interventional technique. There are some 
patients with retroperitoneal gas in the setting of severe acute pancreatitis who were treated 
with focused long-term (3–7 weeks) antibiotics; allegedly the infected necrosis resolved 
without any interventional drainage or necrosectomy. The emergence of a few cases 
treatable medically, though small in number, may be due in part to better intensive care and 
in part to improved antibiotic therapy. However, the lesson learnt from these cases is that 
some patients may improve without intervention. The above observations suggest the need 
to correlate clinical versus imaging and bacteriologic findings in acute pancreatitis with 
infected pancreatic necrosis. Not all patients with infected pancreatic necrosis may need 
intervention. 368 patients with severe acute necrotic pancreatitis were treated in our 
department from year 2003 to 2011, including 8 (2%) patients who had developed 
emphysematous pancreatitis. The data of these patients are presented in Table 1. 
The patient’s age averaged was 73,9 ± 4,8 years. All of them had manifestation of 
atherosclerosis (ischemic stroke, myocardial infarction, ischemic heart disease) four had 
metabolic syndromes such as hyperglycemia, one gastric and another one prostate cancer.  
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Parameter Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 
Age, years 72 66 74 67 79 80 80 73 
Sex female male male female male male male female 
Appache II 18 23 16 8 17 22 10 18 
CT evidence 
of necrosis 
degree 
30-50% 30-50% <30% <30% <30% >50% <30% 30-50% 
Necrosis 
localization head head head tail head tail head head 
Glucose 
during 
admission 
mmol/l 
12,5 10,2 7,0 11,3 6,9 11,7 6,0 5,8 
Comorbid 
illnesses IS IS MI ISH 
ISH;
CaV 
MI; 
CaP ISH 
IS; 
ISH 
Time of gas 
CT detection* 7 3 3 4 2 2 11 6 
Time of the 
operation** 15 4 3 - 3 3 13 7 
Type of the 
operation closed open open - open+G open open open 
Number of 
debridment 2 1 1  3 0 1 1 
Hospital 
stay, days 114 60 78 22 14 3 41 43 
Outcome recovery recovery recovery recovery dead dead recovery recovery 
Cultures of 
necrotic 
pancreas 
tissue 
E. coli E. coli;Pr E. coli - 
E. coli;
Bf Ef E. coli E. coli 
Table 1. Patients data treated in our department. IS - ischemic stroke; MI - myocardial 
infarction; ISH - ischemic heart disease; CaV - gastric cancer; CaP - prostate cancer; *Time of 
intrapancreatic gas CT detection, days from the onset of the disease; **Time of the operation, 
days from the onset of the disease; closed - closed lavage; open - open packing; G - 
gastrectomy; Pr - Providentia rettgeri; Bf-Bacteroides fragilis; Ef - Enterococcus faecalis;  
The trigger of the development of emphysematous pancreatitis in all cases was passage of 
gallstones. All of these patients had calculous cholecystitis and choledocholithiasis. Most of 
them CT scan showed pancreatic necrosis, retroperitoneal and intrapancreatic gas trapping 
in the first week of the disease. Necrosis with intrapancreatic gas trapping occurred more 
frequently in pancreatic head (six cases), less in pancreatic tail (two cases). Six patients, for 
whom vasopressor-noradrenaline doses were increased to 0,4 µg/kg/min to provide 
sustainable hemodynamics due to bacteremic shock, had been successfully treated by 
extensive pancreatic necrosectomy, open packing with debridement immediately after CT 
diagnosis of emphysematous pancreatitis. One female patient was treated with antibiotics 
(ciprofloxacin and metronidazole), oxygen therapy, fluid and electrolyte correction and 
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nasojejunal feeding for 9 days, followed by necrosectomy and continued lavage due to 
failure of organs. One patient at the same time had emphysematous pancreatitis and 
cholecystitis. All operated on patients had infected pancreatic necrosis which was confirmed 
bacteriologically. Escherichia coli infection was present in six patients, additionally 
Bacteroides fragilis, Providentia retgeri and Enterococcus faecalis were cultured 
respectively. Emphysematous pancreatitis requires urgent surgical management at the onset 
of disease due to multisystem organ failure and patient instability. Ordinarily early surgical 
interventions mortality rates are reported as at least 50%, and morbidity can approach 100%. 
Ideally, surgery should be delayed at the earliest of 3rd or 4’th week of illness until the 
necrosis has demarcated and organized. At that time, the necrosectomy is technically easier, 
and there is generally improved mortality and morbidity. However, we found that in cases 
of emphysematous pancreatitis, pancreatic necrosis is already demarcated and organized at 
the first week, which is enough to repeat one or two additional necrosectomies for the 
patient full recovery. The hospital stay was significantly shorter too. In comparison for the 
other our patients with open packing: an average of time of the operation from the onset of 
the disease was 29 days, overall hospital stay - 93 days and 4,2 additional necrosectomies for 
the patient full recovery. We also found that minimally invasive procedures in patients with 
emphysematous pancreatitis are not available, since fluid collections are absent. One patient 
(case 4) with overt inflammatory indices – C-reactive protein 177,7 mg/l, white blood cells 
16x109, febrile temperature 38,7 Co – on first presenting presenting, underwent conservative 
treatment regimen after radiological detection of emphysematous pancreatitis (fig.4.).  
 
Fig. 4. CT scan showing less than 30% pancreas tail necrosis with intrapancreatic and 
retroperitoneal gas. 
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This patient did not undergo a puncture for the bacteriological proof of infection based on 
the supposition of the possibility to confirm the radiological suspicion of infected pancreatic 
necrosis during the operation. Since no surgical interventions were performed on the non-
operated patient previously, there was no enteric fistula, and pancreatic necrosis was 
localized in the middle of parenchyma, we therefore considered clinical and CT data to be 
sufficient in this case for the proof of infection of pancreatic necrosis. Following successful 
conservative treatment, however, the patient avoided the operation, and, therefore, the 
causative agent of the infected pancreatic necrosis was not verified. CT follow-up for this 
female patient was performed in 8 weeks and in 3 months respectively showing complete 
intrapancreatic and retroperitoneal gas disappearing (fig. 5). 
 
Fig. 5. CT scan showing resolution of intrapancreatic and retroperitoneal gas after 8 weeks 
We suggest that the main factor determining such different outcomes of emphysematous 
pancreatitis in patients of similar age and with similar comorbidities and extend of the 
necrosis is the varying localization of necrosis in the pancreas. Necrosis in the pancreas head 
showing higher vascularization than the pancreatic tail is associated with a lower frequency 
of massive intoxication and organ failure necessitating surgical intervention. Other authors 
reported some cases of successful antibiotic treatment of infected pancreatic necrosis located 
in the pancreatic tail as well. In these cases, however, infected pancreatic necrosis was 
identified later on, not at the onset of the disease, and the number of the cases is too small to 
draw valid conclusions. 
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3. Conclusions 
Emphysematous pancreatitis is a potentially life-threatening condition. The initial clinical 
manifestation may be insidious, but rapid progression to sepsis will occur in the absence of 
early therapeutic intervention. Conventional radiography and ultrasonography are often the 
initial imaging modalities used to evaluate patients with abdominopelvic complaints. These 
modalities should be considered complementary, each with strengths and limitations. When 
a differential diagnosis re-mains, CT should be considered the imaging modality of choice. 
CT is both highly sensitive and specific in the detection of abnormal gas and well suited to 
reliable depiction of the anatomic location and extent of the gas. Therefore, with regard to 
emphysematous pancreatitis, appropriate radiologic evaluation combined with accurate 
interpretation of findings will help to ensure rapid diagnosis and optimal treatment 
planning. In addition, knowledge of the pathophysiologic characteristics and common 
predisposing conditions associated with gas-forming infections of the gallbladder, stomach, 
pancreas, and genitourinary system will aid in further diagnostic work-up, surveillance of 
potential complications, and evaluation of therapeutic response. The prognosis for 
emphysematous pancreatitis is grave, and successful treatment requires aggressive 
management of the infection with systemic antimicrobial therapy and control of septic 
shock. Early surgical debridement is usually performed, and recovery is typically 
prolonged. 
4. Acknowledgment  
Emphysematous pancreatitis is a rare and life-threatening necrotizing infection of the 
pancreas – 2% of all acute necrotic pancreatitis. CT is the modality of choice for detecting 
parenchymal gas as well as evaluating its extent and location. Ordinarily emphysematous 
pancreatitis requires urgent surgical management, which in most cases is successful, at the 
onset of disease due to multisystem organ failure and patient instability. In cases of 
emphysematous pancreatitis, pancreatic necrosis is already demarcated and organized at 
the first week, which is enough to repeat one or two additional necrosectomies for the 
patient full recovery. If the patient’s condition is stable, aggressive broad-spectrum 
antibiotic coverage, nutritional support, and routine correlation of clinical progression with 
radiological evaluation must be taken. As demonstrated by our experience, if the patient’s 
condition is stable, antibiotic treatment could be undertaken without any surgical 
intervention despite the evidence of pancreatic infection. General physical condition of the 
patient is an important factor for choosing a treatment rather than bacteriological or 
radiological findings of the infection. Aggressive broad-spectrum antibiotic coverage, 
nutritional support, and routine correlation of clinical progression with radiological 
evaluation were assets.  
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